Current use of existing antiviral drugs for COVID-19 [56].
\\n\\n
Released this past November, the list is based on data collected from the Web of Science and highlights some of the world’s most influential scientific minds by naming the researchers whose publications over the previous decade have included a high number of Highly Cited Papers placing them among the top 1% most-cited.
\\n\\nWe wish to congratulate all of the researchers named and especially our authors on this amazing accomplishment! We are happy and proud to share in their success!
Note: Edited in March 2021
\\n"}]',published:!0,mainMedia:{caption:"Highly Cited",originalUrl:"/media/original/117"}},components:[{type:"htmlEditorComponent",content:'IntechOpen is proud to announce that 191 of our authors have made the Clarivate™ Highly Cited Researchers List for 2020, ranking them among the top 1% most-cited.
\n\nThroughout the years, the list has named a total of 261 IntechOpen authors as Highly Cited. Of those researchers, 69 have been featured on the list multiple times.
\n\n\n\nReleased this past November, the list is based on data collected from the Web of Science and highlights some of the world’s most influential scientific minds by naming the researchers whose publications over the previous decade have included a high number of Highly Cited Papers placing them among the top 1% most-cited.
\n\nWe wish to congratulate all of the researchers named and especially our authors on this amazing accomplishment! We are happy and proud to share in their success!
Note: Edited in March 2021
\n'}],latestNews:[{slug:"intechopen-supports-asapbio-s-new-initiative-publish-your-reviews-20220729",title:"IntechOpen Supports ASAPbio’s New Initiative Publish Your Reviews"},{slug:"webinar-introduction-to-open-science-wednesday-18-may-1-pm-cest-20220518",title:"Webinar: Introduction to Open Science | Wednesday 18 May, 1 PM CEST"},{slug:"step-in-the-right-direction-intechopen-launches-a-portfolio-of-open-science-journals-20220414",title:"Step in the Right Direction: IntechOpen Launches a Portfolio of Open Science Journals"},{slug:"let-s-meet-at-london-book-fair-5-7-april-2022-olympia-london-20220321",title:"Let’s meet at London Book Fair, 5-7 April 2022, Olympia London"},{slug:"50-books-published-as-part-of-intechopen-and-knowledge-unlatched-ku-collaboration-20220316",title:"50 Books published as part of IntechOpen and Knowledge Unlatched (KU) Collaboration"},{slug:"intechopen-joins-the-united-nations-sustainable-development-goals-publishers-compact-20221702",title:"IntechOpen joins the United Nations Sustainable Development Goals Publishers Compact"},{slug:"intechopen-signs-exclusive-representation-agreement-with-lsr-libros-servicios-y-representaciones-s-a-de-c-v-20211123",title:"IntechOpen Signs Exclusive Representation Agreement with LSR Libros Servicios y Representaciones S.A. de C.V"},{slug:"intechopen-expands-partnership-with-research4life-20211110",title:"IntechOpen Expands Partnership with Research4Life"}]},book:{item:{type:"book",id:"7959",leadTitle:null,fullTitle:"Digestive System - Recent Advances",title:"Digestive System",subtitle:"Recent Advances",reviewType:"peer-reviewed",abstract:"The book focuses on the recent advances in the digestive system. It is composed of 3 sections: gastrointestinal duct, liver, and biliary system. There are 9 chapters: peptic ulcers; mid-gastrointestinal bleeding; gastrointestinal manifestations of IgA vasculitis; biomechanics of intestinal contractions; evaluation of serum sodium change after terlipressin in cirrhosis; history and background of biliary system; gallbladder carcinoma; ERCP for cholecysto-choledocholithiasis; and cystic artery variations and associated vascular complications in laparoscopic cholecystectomy. The knowledge presented in this book should be valuable for family physicians, internists, gastroenterologists, hepatologists, endoscopists, radiologists, and pathologists who are interested in digestive diseases to guide the clinical practice and management. This book should be also useful for patients and their relatives to better understand the digestive system.",isbn:"978-1-78985-140-3",printIsbn:"978-1-78985-139-7",pdfIsbn:"978-1-83968-390-9",doi:"10.5772/intechopen.77789",price:119,priceEur:129,priceUsd:155,slug:"digestive-system-recent-advances",numberOfPages:152,isOpenForSubmission:!1,isInWos:null,isInBkci:!1,hash:"13733cf2ed3652affb7832d133815bcd",bookSignature:"Xingshun Qi and Sam Koruth",publishedDate:"January 8th 2020",coverURL:"https://cdn.intechopen.com/books/images_new/7959.jpg",numberOfDownloads:8944,numberOfWosCitations:1,numberOfCrossrefCitations:1,numberOfCrossrefCitationsByBook:0,numberOfDimensionsCitations:13,numberOfDimensionsCitationsByBook:0,hasAltmetrics:0,numberOfTotalCitations:15,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"January 10th 2019",dateEndSecondStepPublish:"February 25th 2019",dateEndThirdStepPublish:"April 26th 2019",dateEndFourthStepPublish:"July 15th 2019",dateEndFifthStepPublish:"September 13th 2019",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6",editedByType:"Edited by",kuFlag:!1,featuredMarkup:null,editors:[{id:"197501",title:"Dr.",name:"Xingshun",middleName:null,surname:"Qi",slug:"xingshun-qi",fullName:"Xingshun Qi",profilePictureURL:"https://mts.intechopen.com/storage/users/197501/images/system/197501.png",biography:"Dr. Xingshun Qi is a deputy director at the Department of Gastroenterology, General Hospital of Northern Theater Command, China (formerly General Hospital of Shenyang Military Area). His major research interests are the management of liver cirrhosis, portal hypertension (especially portal vein thrombosis and Budd-Chiari syndrome), and hepatocellular carcinoma. He has edited eight English-language books and serves as an associate editor for BMC Gastroenterology, an associate editor for Frontiers in Medicine, an academic editor for Canadian Journal of Gastroenterology and Hepatology, an editorial board member of Therapeutic Advances in Gastroenterology, and an advisory editorial member of Advances in Therapy.",institutionString:"General Hospital of Northern Theater Command",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"6",totalChapterViews:"0",totalEditedBooks:"4",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:{id:"237315",title:"Dr.",name:"Sam",middleName:null,surname:"Koruth",slug:"sam-koruth",fullName:"Sam Koruth",profilePictureURL:"https://mts.intechopen.com/storage/users/237315/images/system/237315.jpeg",biography:"Dr. Sam Koruth\\'s educational qualifications include MBBS, MS (General Surgery), FMAS, and DMAS (Fellowship and diploma in Minimal Access Surgery). He has worked in the field of general surgery for over 6 years, and is currently practicing in Lourdes Hospital Kochi, Kerala, India where he has been trained under a reputed surgeon Dr. Santhosh John Abraham (Former President of Associations of Surgeons of India). In these years, Dr. Koruth has presented various papers at National and state level and has published many articles in the International forum. He also got the privilege of co- editing 2 chapters in the book “ Contemporary book of surgery”. Dr. Koruth won Best thesis of the year award, Best poster of the year award, 2nd best Research paper and best faculty video presentation in the year 2017 in the state forum. Additionally, he has won many awards in the national level. His best work has been on “Collagen 3 involvement in all types of Hernias” proving that its not just a primary disorder but a congenital defect, which has been accepted in the international journal.",institutionString:"Lourdes Hospital",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:null},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"181",title:"Gastroenterology",slug:"gastroenterology"}],chapters:[{id:"67428",title:"Peptic Ulcer Disease",doi:"10.5772/intechopen.86652",slug:"peptic-ulcer-disease",totalDownloads:1151,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"Peptic ulcer disease (PUD) is one of the commonest diseases seen throughout the world. There are various risk factors for the development of peptic ulcer disease, but the most important ones are Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs). Patients generally present with dyspepsia or peptic ulcer bleeding. Acid suppressant therapy, H. pylori eradication, and avoidance of nonsteroidal anti-inflammatory drugs are the cornerstones of treatment of peptic ulcer disease. Peptic ulcer bleeding could be life-threatening. It is managed by appropriate supportive care, intravenous proton pump inhibitor therapy, and endoscopic hemostasis. Transarterial embolization (TAE) and surgery are rarely required if endoscopic therapy fails.",signatures:"Monjur Ahmed",downloadPdfUrl:"/chapter/pdf-download/67428",previewPdfUrl:"/chapter/pdf-preview/67428",authors:[{id:"206355",title:"Associate Prof.",name:"Monjur",surname:"Ahmed",slug:"monjur-ahmed",fullName:"Monjur Ahmed"}],corrections:null},{id:"69303",title:"Mid-Gastrointestinal Bleeding",doi:"10.5772/intechopen.89337",slug:"mid-gastrointestinal-bleeding",totalDownloads:910,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"Mid-gastrointestinal bleeding constitutes a small proportion of all cases of gastrointestinal bleeding. It is more difficult to manage mid-gastrointestinal bleeding than upper or lower gastrointestinal bleeding. The etiology differs in younger and older age groups. The clinical presentation, investigations, and management are also different. Capsule endoscopy has improved the diagnostic accuracy to a great extent. Device-assisted enteroscopies (balloon-assisted enteroscopies and spiral enteroscopy) have both diagnostic and therapeutic potentials. Most of the time, patients present with obscure gastrointestinal bleeding which could be overt or occult. Another common presentation is iron deficiency anemia. A stepwise approach is essential to accurately diagnose and manage mid-gastrointestinal bleeding.",signatures:"Monjur Ahmed",downloadPdfUrl:"/chapter/pdf-download/69303",previewPdfUrl:"/chapter/pdf-preview/69303",authors:[{id:"206355",title:"Associate Prof.",name:"Monjur",surname:"Ahmed",slug:"monjur-ahmed",fullName:"Monjur Ahmed"}],corrections:null},{id:"67812",title:"Gastrointestinal Manifestations of IgA Vasculitis-Henoch-Schönlein Purpura",doi:"10.5772/intechopen.86966",slug:"gastrointestinal-manifestations-of-iga-vasculitis-henoch-sch-nlein-purpura",totalDownloads:1026,totalCrossrefCites:0,totalDimensionsCites:2,hasAltmetrics:0,abstract:"Immunoglobulin A vasculitis, formerly called Henoch-Schönlein purpura (HSP), is the most common systemic vasculitis in childhood. It is a small-vessel vasculitis mediated by type III hypersensitivity, manifested as rash accompanied by gastrointestinal (GI) symptoms, arthritis, and nephritis. The etiology of this disease (a leukocytoclastic vasculitis) is still uncertain, but immune complexes of IgA and unidentified antigens seem to have a central pathogenic role. Most often the diagnosis is established after the clinical examination; it is easy at first glance when the clinical presentation includes the classic tetrad of rash (nonthrombocytopenic palpable purpura), arthralgia/arthritis, abdominal pain, and renal manifestations but may be difficult when the gastrointestinal manifestations precede the skin purpuric rash. Gastrointestinal involvement is frequently seen and varies from mild symptoms to severe complications; sometimes the gastrointestinal symptoms (colicky abdominal pain, nausea, vomiting, diarrhea, gastrointestinal bleeding) are the first manifestations of the disease. Immunoglobulin A vasculitis is usually a self-limited disease with a benign course, and the treatment is often symptomatic; in severe cases corticosteroids are necessary.",signatures:"Camelia Cojocariu, Ana Maria Singeap, Stefan Chiriac, Catalin Sfarti, Irina Girleanu, Oana Petrea, Anca Trifan and Carol Stanciu",downloadPdfUrl:"/chapter/pdf-download/67812",previewPdfUrl:"/chapter/pdf-preview/67812",authors:[{id:"45442",title:"Dr.",name:"Anca",surname:"Trifan",slug:"anca-trifan",fullName:"Anca Trifan"},{id:"58426",title:"Prof.",name:"Carol",surname:"Stanciu",slug:"carol-stanciu",fullName:"Carol Stanciu"},{id:"202666",title:"Dr.",name:"Irina",surname:"Girleanu",slug:"irina-girleanu",fullName:"Irina Girleanu"},{id:"288391",title:"Associate Prof.",name:"Camelia",surname:"Cojocariu",slug:"camelia-cojocariu",fullName:"Camelia Cojocariu"},{id:"306764",title:"Dr.",name:"Ana Maria",surname:"Singeap",slug:"ana-maria-singeap",fullName:"Ana Maria Singeap"},{id:"306765",title:"Dr.",name:"Stefan",surname:"Chiriac",slug:"stefan-chiriac",fullName:"Stefan Chiriac"},{id:"306766",title:"Dr.",name:"Catalin",surname:"Sfarti",slug:"catalin-sfarti",fullName:"Catalin Sfarti"},{id:"306768",title:"Dr.",name:"Oana",surname:"Petrea",slug:"oana-petrea",fullName:"Oana Petrea"}],corrections:null},{id:"67678",title:"Biomechanics of the Small Intestinal Contractions",doi:"10.5772/intechopen.86539",slug:"biomechanics-of-the-small-intestinal-contractions",totalDownloads:1254,totalCrossrefCites:0,totalDimensionsCites:10,hasAltmetrics:0,abstract:"The small intestine is a part of the gastrointestinal segment comprising of the duodenum, jejunum, and ileum. They help to process the gastric contents for further digestion, which involves mixing with duodeno-biliary-pancreatic (DBP) secretions to facilitate the chemical digestion, and homogenization of the luminal contents through contractions of the circular and longitudinal smooth muscle fibers of the intestine. The contractions of these smooth muscle fibers develops the mechanical forces at the mucosal wall, which as a consequence, transfers its momentum to the underlying fluid to develop the fluid flows, suggesting relevance of mechanics in physiology. The resulting flows are what drive the digestion. Changes in contractility of wave shapes of circular and longitudinal smooth muscle contractions and fluid rheology are known to affect the digestive process through generation of various flow patterns that differ in luminal pressure, peak velocity, extent of shearing/ mixing, volume of mixing, and flow rate. Recent studies indicate that the digestive process can be very specific such as to cause lipid digestion through segmental contractions and transport by eliciting propagating contractions, suggesting that the intestine manages to digest a variety of food in an efficient manner by eliciting appropriate contractions.",signatures:"Ravi Kant Avvari",downloadPdfUrl:"/chapter/pdf-download/67678",previewPdfUrl:"/chapter/pdf-preview/67678",authors:[{id:"296837",title:"Dr.",name:"Ravi Kant",surname:"Avvari",slug:"ravi-kant-avvari",fullName:"Ravi Kant Avvari"}],corrections:null},{id:"69768",title:"Serum Sodium Concentration in Patients with Portal Hypertension and Acute Gastrointestinal Bleeding Treated with Terlipressin: A Retrospective Observational Study",doi:"10.5772/intechopen.89981",slug:"serum-sodium-concentration-in-patients-with-portal-hypertension-and-acute-gastrointestinal-bleeding-",totalDownloads:680,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"This retrospective observational study aimed to investigate the risk of serum sodium concentration in patients treated with terlipressin and attempted to explore the factors associated with serum sodium concentration. We included 17 patients with portal hypertension treated with terlipressin (Group 1), 7 with portal hypertension treated with somatostatin/octreotide (Group 2), 20 with acute non-variceal gastrointestinal bleeding treated with somatostatin/octreotide (Group 3), and 19 with acute pancreatitis treated with somatostatin/octreotide (Group 4). In all groups, serum sodium concentration at baseline was not significantly different from the lowest value during the infusion of terlipressin, somatostatin, or octreotide (Group 1: 136.95 ± 4.68 versus 135.52 ± 4.79, p = 0.426; Group 2: 139.64 ± 3.86 versus 138.41 ± 5.34, p = 0.813; Group 3: 138.02 ± 4.08 versus 137.69 ± 3.11, p = 0.630; Group 4: 135.96 ± 6.87 versus 134.60 ± 3.40, p = 0.098). The rate of serum sodium concentration reduction in Group 1 (8/17) was not significantly different from Group 2 (3/7, p = 1.000), Group 3 (11/20, p = 0.746), or Group 4 (14/19, p = 0.171). Age, sex, baseline MELD and Child-Pugh scores, cDDD value and duration of terlipressin, blood transfusion, and diuretics and paracentesis during terlipressin were not significantly associated with serum sodium concentration reduction in Group 1. In conclusion, serum sodium concentration is often reduced in patients treated with terlipressin. However, the association of sodium concentration reduction with terlipressin should be clarified.",signatures:"Xinmiao Zhou, Lichun Shao, Tingxue Song, Wenchun Bao, Xiaozhong Guo and Xingshun Qi",downloadPdfUrl:"/chapter/pdf-download/69768",previewPdfUrl:"/chapter/pdf-preview/69768",authors:[{id:"197501",title:"Dr.",name:"Xingshun",surname:"Qi",slug:"xingshun-qi",fullName:"Xingshun Qi"}],corrections:null},{id:"68799",title:"Prologue: Biliary System - History and Background",doi:"10.5772/intechopen.88400",slug:"prologue-biliary-system-history-and-background",totalDownloads:640,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Sam Koruth and Sooraj Sankar",downloadPdfUrl:"/chapter/pdf-download/68799",previewPdfUrl:"/chapter/pdf-preview/68799",authors:[{id:"237315",title:"Dr.",name:"Sam",surname:"Koruth",slug:"sam-koruth",fullName:"Sam Koruth"}],corrections:null},{id:"63683",title:"Gall Bladder Carcinoma: Clinical Presentations and Different Modalities of Treatment",doi:"10.5772/intechopen.81263",slug:"gall-bladder-carcinoma-clinical-presentations-and-different-modalities-of-treatment",totalDownloads:935,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"Gallbladder cancer (GBC) is the most common cancer of the biliary tract and has a particularly high incidence in Chile, Japan and northern India. The clinical presentation of GBC is often vague or delayed relative to pathologic progression, contributing to advanced staging and dismal prognosis at the time of diagnosis. In the diagnosis of GBC, differential diagnosis and determination of the local extension of tumor are important. For these purposes, imaging modalities such as endoscopic ultrasonography (EUS), CT, MRI and magnetic resonance cholangiopancreatography (MRCP) are useful. The treatment of localized GBC is based on surgery. Chemotherapy has been used extensively in advanced GBC, and we have gained some experience with gemcitabine-based combination (with cisplatin and oxaliplatin or with capecitabine) regimens.",signatures:"Wala Ben Kridis, Nabil Toumi, Jamel Daoud, Afef Khanfir and Mounir Frikha",downloadPdfUrl:"/chapter/pdf-download/63683",previewPdfUrl:"/chapter/pdf-preview/63683",authors:[{id:"241067",title:"Dr.",name:"Wala",surname:"Ben Kridis",slug:"wala-ben-kridis",fullName:"Wala Ben Kridis"},{id:"267757",title:"Prof.",name:"Nabil",surname:"Toumi",slug:"nabil-toumi",fullName:"Nabil Toumi"},{id:"267758",title:"Prof.",name:"Afef",surname:"Khanfir",slug:"afef-khanfir",fullName:"Afef Khanfir"},{id:"267759",title:"Prof.",name:"Mounir",surname:"Frikha",slug:"mounir-frikha",fullName:"Mounir Frikha"},{id:"270321",title:"Prof.",name:"Jamel",surname:"Daoud",slug:"jamel-daoud",fullName:"Jamel Daoud"}],corrections:null},{id:"65788",title:"Intraoperative ERCP for Management of Gallbladder and Common Bile Duct Stones",doi:"10.5772/intechopen.83352",slug:"intraoperative-ercp-for-management-of-gallbladder-and-common-bile-duct-stones",totalDownloads:1049,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:1,abstract:"It is not an uncommon scenario to have CBD stones in association with gallbladder stones. There is a general agreement in the surgical society that CBD stones should be removed. The classic option is to do open cholecystectomy and CBD exploration. With the emergence of minimally invasive surgery, namely laparoscopic cholecystectomy and ERCP, the therapist has better option to treat such patients such as preoperative ERCP, postoperative ERCP, and laparoscopic CBD exploration. The latest advance in that field is the use of ERCP at the time of laparoscopic cholecystectomy, i.e. intraoperative ERCP. This chapter with discuss the issue of minimally invasive management of cholecystocholedocholithiasis stressing on intraoperative ERCP.",signatures:"Ahmed Abdelraouf Elgeidie",downloadPdfUrl:"/chapter/pdf-download/65788",previewPdfUrl:"/chapter/pdf-preview/65788",authors:[{id:"262855",title:"Prof.",name:"Ahmed",surname:"Elgeidie",slug:"ahmed-elgeidie",fullName:"Ahmed Elgeidie"}],corrections:null},{id:"63779",title:"Cystic Artery Variations and Associated Vascular Complications in Laparoscopic Cholecystectomy",doi:"10.5772/intechopen.81200",slug:"cystic-artery-variations-and-associated-vascular-complications-in-laparoscopic-cholecystectomy",totalDownloads:1300,totalCrossrefCites:1,totalDimensionsCites:1,hasAltmetrics:0,abstract:"Substantial knowledge of the arterial supply and its anatomical variations of the gall bladder and liver are important in all the hepatobiliary surgical procedures. The arterial supply of gallbladder called cystic artery (CA) is a vital structure required to get ligated or clipped in the path of laparoscopic cholecystectomy. The possible concerns like intra-operative bleeding or adjoining accidental injuries will almost always be focused on the research consisting of dissection and clipping with cystic artery. Pseudoaneurysm of the cystic artery has additionally been belonging to the presence of acute cholecystitis or pancreatitis. An original supply of CA is usually assessed depending on the existence of hepatic artery variants. Laparoscopic cholecystectomy is really a recent and arduous noninvasive procedure and might even result in substantial unintended effects possibly iatrogenic or in the form of post-procedural complications. The perfect knowledge of anatomy in addition to feasible variation of cystic artery is mandatory. An efficient operative strategy and consciousness are probably the key components with all the results and marginal likelihood of complications, which often can be ultimately attainable. Within this chapter, we have attempted to explore some variations of cystic artery, complications and management.",signatures:"Pankaj Prasoon, Tomohiro Katada, Kohei Miura, Yuki Hirose, Jun Sakata and Toshifumi Wakai",downloadPdfUrl:"/chapter/pdf-download/63779",previewPdfUrl:"/chapter/pdf-preview/63779",authors:[{id:"79381",title:"Dr.",name:"Toshifumi",surname:"Wakai",slug:"toshifumi-wakai",fullName:"Toshifumi Wakai"},{id:"266766",title:"Dr.",name:"Pankaj",surname:"Prasoon",slug:"pankaj-prasoon",fullName:"Pankaj Prasoon"},{id:"266768",title:"Dr.",name:"Tomohiro",surname:"Katada",slug:"tomohiro-katada",fullName:"Tomohiro Katada"},{id:"266770",title:"Dr.",name:"Yuki",surname:"Hirose",slug:"yuki-hirose",fullName:"Yuki Hirose"},{id:"266772",title:"Prof.",name:"Jun",surname:"Sakata",slug:"jun-sakata",fullName:"Jun Sakata"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},subseries:null,tags:null},relatedBooks:[{type:"book",id:"6663",title:"Management of Chronic Liver Diseases",subtitle:"Recent Advances",isOpenForSubmission:!1,hash:"833ebcb9a2596f81deff0246ed7c9642",slug:"management-of-chronic-liver-diseases-recent-advances",bookSignature:"Xingshun Qi",coverURL:"https://cdn.intechopen.com/books/images_new/6663.jpg",editedByType:"Edited by",editors:[{id:"197501",title:"Dr.",name:"Xingshun",surname:"Qi",slug:"xingshun-qi",fullName:"Xingshun Qi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11321",title:"Anticoagulation",subtitle:"Current Perspectives",isOpenForSubmission:!1,hash:"141b615d62361de2af678b539f3061ed",slug:"anticoagulation-current-perspectives",bookSignature:"Xingshun Qi and Xiaozhong Guo",coverURL:"https://cdn.intechopen.com/books/images_new/11321.jpg",editedByType:"Edited by",editors:[{id:"197501",title:"Dr.",name:"Xingshun",surname:"Qi",slug:"xingshun-qi",fullName:"Xingshun Qi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10422",title:"Portal Hypertension",subtitle:"Recent Advances",isOpenForSubmission:!1,hash:"9ad8b9fc22c286639c6b0f4c2b275f7c",slug:"portal-hypertension-recent-advances",bookSignature:"Xingshun Qi",coverURL:"https://cdn.intechopen.com/books/images_new/10422.jpg",editedByType:"Edited by",editors:[{id:"197501",title:"Dr.",name:"Xingshun",surname:"Qi",slug:"xingshun-qi",fullName:"Xingshun Qi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6164",title:"Metagenomics for Gut Microbes",subtitle:null,isOpenForSubmission:!1,hash:"672dc229a6318cc2b7b7ef16b314e046",slug:"metagenomics-for-gut-microbes",bookSignature:"Ranjith N. Kumavath",coverURL:"https://cdn.intechopen.com/books/images_new/6164.jpg",editedByType:"Edited by",editors:[{id:"163692",title:"Dr.",name:"Ranjith",surname:"Kumavath",slug:"ranjith-kumavath",fullName:"Ranjith Kumavath"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7937",title:"Gastritis",subtitle:"New Approaches and Treatments",isOpenForSubmission:!1,hash:"de6520787ae127c8a78170e40caff3f7",slug:"gastritis-new-approaches-and-treatments",bookSignature:"Bruna Maria Roesler",coverURL:"https://cdn.intechopen.com/books/images_new/7937.jpg",editedByType:"Edited by",editors:[{id:"54995",title:"Dr.",name:"Bruna Maria",surname:"Roesler",slug:"bruna-maria-roesler",fullName:"Bruna Maria Roesler"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7103",title:"Constipation",subtitle:null,isOpenForSubmission:!1,hash:"0f5c714417d2c8a2e536ff6f78302cea",slug:"constipation",bookSignature:"Gyula Mózsik",coverURL:"https://cdn.intechopen.com/books/images_new/7103.jpg",editedByType:"Edited by",editors:[{id:"58390",title:"Dr.",name:"Gyula",surname:"Mozsik",slug:"gyula-mozsik",fullName:"Gyula Mozsik"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7863",title:"Pancreatitis",subtitle:null,isOpenForSubmission:!1,hash:"c8ee85f9459f901eba51628f45db7c80",slug:"pancreatitis",bookSignature:"Dmitry Victorovich Garbuzenko",coverURL:"https://cdn.intechopen.com/books/images_new/7863.jpg",editedByType:"Edited by",editors:[{id:"108808",title:"Prof.",name:"Dmitry",surname:"Garbuzenko",slug:"dmitry-garbuzenko",fullName:"Dmitry Garbuzenko"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6471",title:"Current Issues in the Diagnostics and Treatment of Acute Appendicitis",subtitle:null,isOpenForSubmission:!1,hash:"f5210117ff0a6e5c3863f1075ac38be5",slug:"current-issues-in-the-diagnostics-and-treatment-of-acute-appendicitis",bookSignature:"Dmitry Victorovich Garbuzenko",coverURL:"https://cdn.intechopen.com/books/images_new/6471.jpg",editedByType:"Edited by",editors:[{id:"108808",title:"Prof.",name:"Dmitry",surname:"Garbuzenko",slug:"dmitry-garbuzenko",fullName:"Dmitry Garbuzenko"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9078",title:"Biological Therapy for Inflammatory Bowel Disease",subtitle:null,isOpenForSubmission:!1,hash:"17e742f81cbce5608a67917a671d1386",slug:"biological-therapy-for-inflammatory-bowel-disease",bookSignature:"Raquel Franco Leal and Tristan Torriani",coverURL:"https://cdn.intechopen.com/books/images_new/9078.jpg",editedByType:"Edited by",editors:[{id:"226935",title:"Dr.",name:"Raquel Franco",surname:"Leal",slug:"raquel-franco-leal",fullName:"Raquel Franco Leal"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7104",title:"Gastroesophageal Reflux Disease",subtitle:"Theory and Research",isOpenForSubmission:!1,hash:"738f7a3225a21396cd5d58099b8b2d87",slug:"gastroesophageal-reflux-disease-theory-and-research",bookSignature:"Ali Ibrahim Yahya",coverURL:"https://cdn.intechopen.com/books/images_new/7104.jpg",editedByType:"Edited by",editors:[{id:"222438",title:"Prof.",name:"Ali Ibrahim",surname:"Yahya",slug:"ali-ibrahim-yahya",fullName:"Ali Ibrahim Yahya"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"79356",slug:"corrigendum-to-sexual-dysfunction-in-patients-with-systemic-sclerosis",title:"Corrigendum to: Sexual Dysfunction in Patients with Systemic Sclerosis",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/67322.pdf",downloadPdfUrl:"/chapter/pdf-download/67322",previewPdfUrl:"/chapter/pdf-preview/67322",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/67322",risUrl:"/chapter/ris/67322",chapter:{id:"66966",slug:"sexual-dysfunction-in-patients-with-systemic-sclerosis",signatures:"Barbora Heřmánková",dateSubmitted:"July 16th 2018",dateReviewed:"April 5th 2019",datePrePublished:"May 3rd 2019",datePublished:"September 18th 2019",book:{id:"8269",title:"New Insights into Systemic Sclerosis",subtitle:null,fullTitle:"New Insights into Systemic Sclerosis",slug:"new-insights-into-systemic-sclerosis",publishedDate:"September 18th 2019",bookSignature:"Michal Tomcik",coverURL:"https://cdn.intechopen.com/books/images_new/8269.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"193284",title:"Dr.",name:"Michal",middleName:null,surname:"Tomcik",slug:"michal-tomcik",fullName:"Michal Tomcik"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:null}},chapter:{id:"66966",slug:"sexual-dysfunction-in-patients-with-systemic-sclerosis",signatures:"Barbora Heřmánková",dateSubmitted:"July 16th 2018",dateReviewed:"April 5th 2019",datePrePublished:"May 3rd 2019",datePublished:"September 18th 2019",book:{id:"8269",title:"New Insights into Systemic Sclerosis",subtitle:null,fullTitle:"New Insights into Systemic Sclerosis",slug:"new-insights-into-systemic-sclerosis",publishedDate:"September 18th 2019",bookSignature:"Michal Tomcik",coverURL:"https://cdn.intechopen.com/books/images_new/8269.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"193284",title:"Dr.",name:"Michal",middleName:null,surname:"Tomcik",slug:"michal-tomcik",fullName:"Michal Tomcik"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:null},book:{id:"8269",title:"New Insights into Systemic Sclerosis",subtitle:null,fullTitle:"New Insights into Systemic Sclerosis",slug:"new-insights-into-systemic-sclerosis",publishedDate:"September 18th 2019",bookSignature:"Michal Tomcik",coverURL:"https://cdn.intechopen.com/books/images_new/8269.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"193284",title:"Dr.",name:"Michal",middleName:null,surname:"Tomcik",slug:"michal-tomcik",fullName:"Michal Tomcik"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"12156",leadTitle:null,title:"Legumes",subtitle:null,reviewType:"peer-reviewed",abstract:"This book will be a self-contained collection of scholarly papers targeting an audience of practicing researchers, academics, PhD students and other scientists. The contents of the book will be written by multiple authors and edited by experts in the field.",isbn:null,printIsbn:null,pdfIsbn:null,doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!0,isSalesforceBook:!1,isNomenclature:!1,hash:"a97becd6aa14a480ce28c05a3116f639",bookSignature:"",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/12156.jpg",keywords:null,numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"March 4th 2022",dateEndSecondStepPublish:"March 25th 2022",dateEndThirdStepPublish:"May 24th 2022",dateEndFourthStepPublish:"August 12th 2022",dateEndFifthStepPublish:"October 11th 2022",dateConfirmationOfParticipation:null,remainingDaysToSecondStep:"5 months",secondStepPassed:!0,areRegistrationsClosed:!0,currentStepOfPublishingProcess:1,editedByType:null,kuFlag:!1,biosketch:null,coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"5",title:"Agricultural and Biological Sciences",slug:"agricultural-and-biological-sciences"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:null},relatedBooks:[{type:"book",id:"6418",title:"Hyperspectral Imaging in Agriculture, Food and Environment",subtitle:null,isOpenForSubmission:!1,hash:"9005c36534a5dc065577a011aea13d4d",slug:"hyperspectral-imaging-in-agriculture-food-and-environment",bookSignature:"Alejandro Isabel Luna Maldonado, Humberto Rodríguez Fuentes and Juan Antonio Vidales Contreras",coverURL:"https://cdn.intechopen.com/books/images_new/6418.jpg",editedByType:"Edited by",editors:[{id:"105774",title:"Prof.",name:"Alejandro Isabel",surname:"Luna Maldonado",slug:"alejandro-isabel-luna-maldonado",fullName:"Alejandro Isabel Luna Maldonado"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10359",title:"Landraces",subtitle:"Traditional Variety and Natural Breed",isOpenForSubmission:!1,hash:"0600836fb2c422f7b624363d1e854f68",slug:"landraces-traditional-variety-and-natural-breed",bookSignature:"Amr Elkelish",coverURL:"https://cdn.intechopen.com/books/images_new/10359.jpg",editedByType:"Edited by",editors:[{id:"231337",title:"Dr.",name:"Amr",surname:"Elkelish",slug:"amr-elkelish",fullName:"Amr Elkelish"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2270",title:"Fourier Transform",subtitle:"Materials Analysis",isOpenForSubmission:!1,hash:"5e094b066da527193e878e160b4772af",slug:"fourier-transform-materials-analysis",bookSignature:"Salih Mohammed Salih",coverURL:"https://cdn.intechopen.com/books/images_new/2270.jpg",editedByType:"Edited by",editors:[{id:"111691",title:"Dr.Ing.",name:"Salih",surname:"Salih",slug:"salih-salih",fullName:"Salih Salih"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"117",title:"Artificial Neural Networks",subtitle:"Methodological Advances and Biomedical Applications",isOpenForSubmission:!1,hash:null,slug:"artificial-neural-networks-methodological-advances-and-biomedical-applications",bookSignature:"Kenji Suzuki",coverURL:"https://cdn.intechopen.com/books/images_new/117.jpg",editedByType:"Edited by",editors:[{id:"3095",title:"Prof.",name:"Kenji",surname:"Suzuki",slug:"kenji-suzuki",fullName:"Kenji Suzuki"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"872",title:"Organic Pollutants Ten Years After the Stockholm Convention",subtitle:"Environmental and Analytical Update",isOpenForSubmission:!1,hash:"f01dc7077e1d23f3d8f5454985cafa0a",slug:"organic-pollutants-ten-years-after-the-stockholm-convention-environmental-and-analytical-update",bookSignature:"Tomasz Puzyn and Aleksandra Mostrag-Szlichtyng",coverURL:"https://cdn.intechopen.com/books/images_new/872.jpg",editedByType:"Edited by",editors:[{id:"84887",title:"Dr.",name:"Tomasz",surname:"Puzyn",slug:"tomasz-puzyn",fullName:"Tomasz Puzyn"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"68908",title:"Advances in Surgical and Anesthetic Techniques for Cochlear Implantation",doi:"10.5772/intechopen.88380",slug:"advances-in-surgical-and-anesthetic-techniques-for-cochlear-implantation",body:'Cochlear implantation (CI) is the surgical implantation of an electrical device that can directly stimulate the auditory nerve through bypassing a nonfunctional inner ear. Through this device, speech and other sounds can be heard by severe to profound deaf people [1].
The first “true” CI was performed by William House and John Doyle on January 9, 1961; the surgery was performed through postauricular incision using mastoidectomy posterior tympanotomy approach (MPTA) to the middle ear. The electrode array was inserted then, after exposure of the round window (RW) membrane, into the scala tympani [2].
Interestingly, the surgical approach used and described by William house in 1961 became the classic or the standard approach for CI; for more than half a century, there was no major advancement or change in the surgical approach. However, there were different alternative approaches and some technical advancements, each of them having relative advantages and disadvantages.
The surgical technique of classic CI was described in detail by House [3]. The basic surgical steps are the following:
Postauricular incision is the originally described incision for CI, and also it is the most common used incision for CI [4] (Figure 1).
Minimal access postauricular incision.
A “U”-shaped anterior-based periosteal flap or Palva flap (Figure 2) is performed to expose both the mastoid bone and the planed site for drilling a well “seat or bed” for the receiver/stimulator (RS).
Palva flap in CI.
MPTA is performed using both the surgical microscope and otologic drill. Widening of the posterior tympanotomy in an inferior direction with removal of excess bone in front of the facial nerve is an essential step for good exposure of RW niche and membrane, taking care that RW membrane may be obscured by a false membrane (false RW membrane) that should be removed first by sharp instrument (Figure 3).
(a) Classic MPTA showing good visualization of the RW niche and false membrane that cover true RW membrane. (b) After removal of the false membrane, RW membrane is now well visualized.
In classic CI, fixation of the device is achieved mainly by drilling a custom-fit bony well “seat or bed” for accommodation of the thick part, the titanium case, of the RS of the selected implant. This well must be designed with the same configuration of the RS and should be deep enough so that the package rests in the well stably without the possibility of sliding or rocking and without protrusion outside the skull as a swelling [5].
The RW niche is lowered down by drilling the tegmen and pillars of the RW till good exposure of the RW membrane is achieved, and then cochleostomy is performed. In classic CI, cochleostomy is drilled as a separate opening inferior and slightly anterior to the RW membrane [6].
The device is brought up to the surgical field, and then the electrode is inserted into the cochlea either by using the fine-tipped micro forceps or by using the specific instruments manufactured for insertion of the selected electrode type.
The RS should be positioned in its drilled well “Seat or bed.” Its stability in the well should be ensured. Sewing the periosteum together over the implant is also important for further stabilization [7].
The distal end of the electrode array should be secured and fixed. This is performed routinely by sealing off the cochleostomy site through harvesting a small piece of fascia or pericranium and then applying it around the electrode array at the cochleostomy site. This sealing also prevents transmission of infection from the middle ear into the cochlea [6]. Also the electrode array is further stabilized by placing a loop of electrode cable against the tegmen mastoideum [8].
Intraoperative device monitoring is performed to confirm both electrical output of the device and electrical response of the patient at the same time. Intraoperative monitoring also provides objective data that can be used as a starting point for behavioral testing “psychophysics” [9].
First impedance telemetry, which confirms the integrity of the electrodes, is performed to all electrodes, and then the neural response of the patient can be tested by either measuring the electrical stapedial reflex thresholds (ESRT) or by measuring electrical compound action potential (ECAP), or neural response telemetry (NRT), which confirms stimulation of the auditory nerve. These electrical tests are essential to confirm the success of surgery; however, they are not a reliable predictor of postoperative performance [10].
The wound is closed in three layers: the periosteum, the subcutaneous layer, and the skin. Usually the dressing and pressure bandage are kept for 24 hours to reduce the possibility of a development of seroma or hematoma, then the wound is inspected, and another dressing is applied for another 5 days [5].
Surgical technique of cochlear implantation was described in detail by House [3]; this description remains the classic or the standard surgical technique for cochlear implantation. Up till the time of writing of these words, there is no significant change in the basic surgical principles of the classic or standard CI. However, some surgical modifications and technical innovations were advanced and advocated by some surgeons. The most important surgical advances on the classic CI, according to our point of view, are listed in this section and sorted according to the consequence of surgical steps of CI.
The first described incision for CI was small postauricular C-shaped incision as the device has a single channel and is small in size, and then after inventing the multichannel devices, which had larger RS, larger postauricular C-shaped incisions or interior-based U-shaped incision were used. Due to the drawback of these large incisions on the blood supply with high incidence of flap necrosis, postauricular incision became the standard again and remained the most commonly used incision [4]. It was first long with an upward extension “inverted J-shaped incision” and then gradually become shortened by time. Nowadays many CI centers use the minimal access postauricular incision (Figure 1), which is 3–4 cm in length and 1 cm behind the postauricular crease [11].
An extended endaural incision has been described as an alternative incision [12]. This incision aimed at making the skin incision away from the tension that may be caused by the body of the implant and the RS; however, skin breakdown at the external auditory canal (EAC) and wound infection have been reported as complications of this incision [11, 13, 14].
The surgical technique of endaural incision in CI should differ from the standard technique used for other otologic surgeries; the standard endaural incision entails incising the skin and periosteum in the same incision line at the incisura and the bony cartilaginous junction of the EAC. Endaural incision for cochlear implantation should be modified. The skin only is incised at the incisura and at the intercartilagi-nous gap between the conchal cartilage and EAC cartilages (Figure 4), then the skin and the SC tissues are dissected from the underlying pericranium, and then the pericranium is incised away from the site of skin incision. We think that through this modification, endaural incision can be used in CI with lower risk of wound infection or skin breakdown.
Modified endaural incision for CI. (a) Incision marking on the skin (note the transverse part of the incision is at the junction between the conchal cartilage and EAC cartilage) and (b) cutting the transverse part of the incision with scalpel.
Few modifications of the standard anterior-based periosteal flap “Palva flap” in CI were described; the aim of these modifications is to ensure both good exposure of the drilling areas (mastoid bone and RS well) and tight periosteal covering of the device at the same time. One of these modifications was described by Fouad et al. [15] in which the periosteum is elevated through two flaps: the first flap is a short anteriorly based periosteal flap that aims at exposure of the mastoid bone, and the second flap is an inferiorly based flap that aims at exposure of the RS bony well (Figure 5). Through this modification, the periosteum can cover the device completely without tension, and mastoid emissary vein disruption could be avoided [15].
Modified periosteal flap for CI. Two flaps are taken: (A) anteriorly based flap and (I) inferiorly based flap.
For more than half a century, the MPTA remains the gold standard approach for CI [16]. However, there is still need for “alternative” approach in certain situations. Also robotic CI is a new invention that can be used to reduce the need for excess bone drilling and to gain more rapid, safe, and direct access to the RW membrane.
MPTA is the classic standard approach for CI [17]. Many alternative approaches were described for CI. The most common are the suprameatal approach [18], the pericanal approach [19], transcanal (Veria) approach [20], and transattic approach [21].
These alternative approaches aim at avoiding the risk of facial nerve injury and decreasing the duration of the surgical procedure. According to El-Anwar et al., there is no significant difference between the reported overall complications rate using either the classic or alternative approaches for CI [22]. However, many authors discourage the non-mastoidectomy approaches for cochlear implantation for the following reasons: First, the angle between the electrode array and the trajectory line of the cochlea is more than 30°; this makes electrode insertion difficult with increasing possibility of intracochlear kinking of the electrode or intracochlear trauma [23]. Second, fixation of the electrode array into a tunnel or groove in the EAC is not suitable for children due to continuous EAC growth [19]. Third, alternative approaches have higher rate of revision cases on the long-term follow-up [11].
Most of the surgeons nowadays use the standard MPTA for CI; the nontraditional approaches for CI are used in extremely rare cases with difficult anatomical situations [22].
The beginning of the idea of “robotic cochlear implantation” was by thinking in using the navigation system in cochlear implantation through a computer-assisted CI surgery using the same classic posterior tympanotomy approach. This idea was first introduced and tried first on cadaver dissection in 2004 [24]; then in 2009, Majdani et al. [25] performed a cadaveric study of using a combination of industrial robot system and navigation system for building a “closed-loop feedback” control system for CI. Through this system they could make real-time feedback to track any movement or changes in the bone based on a preoperative temporal bone CT scan. Vital structures, such as the facial nerve, were defined and protected. The robot was able to drill only the targeted bone without violation of any critical structures [25].
After extensive work and experimental trials for inventing accurate combined robotic and image-guided system for CI [26, 27, 28], the minimally invasive robotic percutaneous cochlear implantation (PCI) became real [29].
PCI can modify the classic MPTA into drilling a predesigned small single straight bony tunnel starting from the mastoid cortex and targeting into the RW without risk of injury of the facial nerve, chorda tympani, external auditory canal, and tympanic membrane annulus [30].
According to the first reported case of robotic PCI [29], the procedure starts by preoperative imaging and accurate planning of the drilling pathway and identification of vital structures, before surgery. Then intraoperatively the drill path was assessed using imaging- and sensor-based data to confirm the proximity of the facial nerve. After making the bony tunnel with the robot, a small postauricular incision is made to elevate tympanomeatal flap to expose the RW membrane. The RW membrane is opened through anterior tympanotomy after elevation of the tympanomeatal flap, and then the electrode array, passing through the drilled tunnel, was inserted manually under microscope visualization [29].
It is a minimal invasive surgery with small wound, short duration, and minimal bone drilling which can cause noise and thermal effect on the cochlea.
It has high accuracy rates; the geometric accuracy was measured, in experimental studies, equal to 0.15 ± 0.08 mm at the depth of the cochlea.
It preserves the mastoid air cells, which has physiological role in middle ear ventilation.
Expensive.
Its safety and accuracy in vivo are still under clinical trials.
The trends in manufacturing recent CI devices is toward making the RS as thin as possible, so that recent devices are thinner and need drilling a shallower bony well for RS. For example, the thickness of the RS of the CI532® (Cochlear Corp) is 3.9 mm, while the thickness of the RS of the older generation of the same company such as CI124RE® is 6.9 mm. Drilling a bony well with depth equal to 3 mm is usually enough to accommodate most of recent implants.
Some surgeons advocate the tight “temporalis pocket” technique in fixating the body of the implant; this technique entails elevation of small tight periosteal pocket that can just lodge the device tightly without the need of drilling a well for the RS [31]. Although slim devices can be fixed easier with tight temporalis pocket technique, still most of surgeons prefer drilling a well for stabilization of the RS [16].
Other methods for RS fixation:
Tie-down sutures that were passed through monocortically drilled holes on each side of the R/S [32].
Using polypropylene mesh over the R/S and securing the mesh with titanium screws [33].
Cementing the R/S with ionomeric bone cement [34].
Some CI devices, such as the Neuro Zti® (Oticon Corp), are manufactured with two titanium screws that can be fixed during surgery without the need for drilling a bony well.
Insertion of the electrode into the scala tympani is the goal of standard cochlear implantation. To achieve this goal, there are three possible approaches to the scala tympani, each one having advantage and disadvantage:
Traditional cochleostomy technique: in which there is a separate opening just inferior and slightly anterior to the RW membrane; it should be crated after good visualization of the RW membrane and lowering down the RW niche. The main advantages of this approach are avoiding the hook region of the basal turn, providing more effective sealing of both cochleostomy and RW by fibrous tissue, and providing appropriate angle of electrode insertion away from the osseous spiral lamina [5, 16], However, this approach entails more bone drilling on the cochlea that may expose the neuro-sensitive structures of the cochlea to traumatic and thermal effect of the drill [35].
RW approach: in which the RW membrane is opened, better by using a sharp needle. This approach is the least traumatic approach; however, electrode insertion may be difficult, and electrode may be hanged in the hook region by a projecting crista fenestra, which will need further drilling to allow electrode insertion.
Extended RW approach: in which the round window membrane is opened and then the anterior-inferior margin of the RW is drilled till good visualization of the scala tympani is achieved. Through this approach, the hook region is avoided, electrode array insertion will be in the same trajectory line of the scala tympani, and trauma to the osseous spiral lamina will be avoided.
The “best” type of cochleostomy is still a controversial issue; however, according to the meta-analysis conducted by Santa Maria et al., hearing preservation rates were higher in cochleostomy than in RW approach [36]. Whatever the surgical approach used for cochleostomy, the key point for successful scala tympani insertion with minimal trauma is good access and visualization of the whole round window membrane.
However, the RW visibility through the surgical microscope through MPTA is variable. St Thomas’ Hospital introduced a classification for the visibility of the RW during CI as follows: type I, the RW membrane is entirely exposed; type IIa, more than 50% but less than 100% of the RW membrane is exposed; type IIb, the exposure of RW membrane is less than 50% but more than 0%; and type III, the RW membrane could not be identified. Most of the adult cases (76%) were type I, 17% was type IIa and IIb, while 7% was type III [37].
Otoendoscopy can be used, instead of surgical microscope, to solve the problem of “difficult RW.” Marchioni et al. [38] has described the surgical technique of endoscopic CI. They used 3 mm rigid otoscope through the EAC, after elevation of an intact tympanomeatal flap, without incising the EAC skin, and then endoscopic cochleostomy is performed through the RW membrane. However, they did not use MPTA for electrode insertion; instead of that, they used pericanal approach by drilling a bony grove in the posterior wall of EAC [38].
However, due to the advantages of the standard MPTA, the use of endoscope in CI became mainly limited to help the surgeons in accurate identification of the RW membrane and precise electrode placement; also this technique appears to be particularly useful for malformed or abnormal cochlea [39, 40, 41].
According to the method of insertion of the CI electrode array, there are three main types of CI electrode arrays that vary in the design and the method of the insertion:
The lateral wall (LW) electrode: Such as the K electrode of the Nucleus® (Cochlear Corp, Lane Cove, Australia), all MED-EL electrodes (MED-EL Corp, Innsbruck, Austria), and the HiFocus™ 1 J Electrode (Advanced Bionics Corp, Sylmar, CA). The lateral wall electrode, with exception of the 1 J electrode, is usually inserted by using micro forceps with or without the guide of claw instrument. The 1 J Electrode is better to be inserted with its specific pre-loaded metal tube connecting to its specific applicator.
The midscalar (MS) electrode: such as Mid-Scala Electrode of HiFocus™ (Advanced Bionics Corp,). This type of electrode is usually inserted through a specific applicator using the off-stylet technique (that was originally described for the Contour Advance electrode® (Cochlear Corp) [42].
The perimodiolar (PM) electrode: such as HiFocus Helix™ electrode (Advanced Bionics Corp) and the Contour® electrode (Cochlear Corp). Both of these electrodes have a stylet that is removed during insertion by the off-stylet technique. The recent CI532® (Cochlear Corp) is a PM slim electrode (0.7 mm); during insertion the electrode is loaded in its sheath, the stopper is kept at the cochleostomy opening, and then the electrode array is slowly advanced out of the electrode sheath. The electrode sheath was then removed, after seeing the three white markers at the cochleostomy site [43].
Each of the three types of electrode array has advantages and disadvantages. In general, the LW electrodes are usually slimmer and are assumed to have less traumatic effect on the cochlea during insertion, but they are usually rest away from the spiral ganglia which are the target of the electrodes’ stimulatory impulses. The PM electrodes can hug the modiolus and became very close to the spiral ganglia; but because of the need of stylet, they are usually more stiff and thick, except the new PM electrode generations such as CI532® (Cochlear Corp), so that PM electrodes usually have more traumatic potentials on the cochlea during insertion. The MS electrodes are assumed to have the advantages of both LW and PM electrodes, but they can also have the disadvantages of both of them [44, 45, 46].
Proper electrode insertion is achieved by both making full insertion, which entails inserting all active electrodes into the scala tympani, and by making appropriate depth of insertion. Regarding the depth of insertion, Yukawa et al. [47] reported that the better predictor of the outcome for the depth of electrode insertion is the angular depth rather than the intracochlear length of the electrode or even the number of active electrodes that is used in speech processing. It is expected that LW electrodes, especially the long types as FlexSoft™ (MED-EL Corp), can demonstrate greater angular insertion depth, more than 360°, while the PM or MS electrodes are usually designed to encircle the first basal turn making angular insertion depth nearly equal to 360° [48]. Insertion depth at 360°, or less than one cochlear turn, is usually associated with poor speech outcome; however, above 360°, there is no association between the depth of insertion and the speech outcome [49, 50]. Deep insertion is assumed to have the advantage of extending the electrical stimulation into the apical region that is responsible for low-frequency sounds; this provides better place pitch match which may improve the outcomes of CI especially in the music perception [51]. However, deep insertion is usually associated with increasing the risk of intracochlear trauma [45].
In conclusion, the best design for “ideal” CI electrode is a matter of debate; there is no “best” CI electrode for all CI cases.
Fixation of the implant entails both fixation of the RS, the main body of the implant, and fixation of the electrode array. Fixation of the RS was mentioned before, but whatever is the technique used, the periosteum should be tightened and sewed over the implant during this step [7].
Fixation of the electrode array should be in both its proximal and distal ends; the proximal end is fixed simply by either drilling a deep groove or trough starting from the RS bony well at the site of exit of the electrode to the mastoid cavity [52]. This trough could be drilled deeper. As it reaches the mastoid cavity at the sino-dural angle, the bone at this area is thick, so the trough can be modified in this area into incomplete tunnel with a bony ledge. The electrode could be secured in this tunnel even after electrode insertion (Figure 6).
The electrode is secured at the sino-dural angle before entering the mastoidectomy cavity, by an incomplete tunnel with a bony ledge.
The distal end of electrode array is fixed routinely by both inserting fascial plug around the electrode at the cochleostomy site and also by placing a loop of electrode cable against the tegmen mastoideum. Other surgical techniques that can be used, in addition, for electrode fixation at its distal end are:
Using a titanium clip to attach the electrode array to the incus bar [53].
The “split-bridge” technique [54], in which a channel is made through the incus bar and the lead wedged in it.
Making a small inferiorly based bone grove in the posterior tympanotomy into which the electrode array can be squeezed for fixation [55]. The groove is made with 1 mm diamond burr between the facial nerve and the chorda tympani nerve (Figure 7).
A groove in the lower end of the posterior tympanotomy for accommodation and stabilization of the electrode after insertion.
The use of the Internet for monitoring of CI devices from remote locations is a recent advance in CI programming. In a study by Shapiro et al. [56] remote intraoperative CI device monitoring was compared to in situ monitoring. The results showed that there is a significant reduction of the audiologist’s time with remote testing than in situ testing. This represents a significant reduction in time required for testing and consequently the cost. This can be achieved by only Internet connection and a telephone [57].
Toner et al. [58] reported a case series of cochlear implantation under local anesthesia; however, using local anesthesia in CI was not widely used till the last 10 years [59, 60, 61, 62, 63], especially after the introduction and widespread usage of dexmedetomidine as a sedative drug for cases of CS-LA. Dexmedetomidine can make “cooperative sedation,” in which the patient remains arousable and cooperative without causing delirium and unnecessary movements associated with delirium [63].
CI under CS-LA achieved comparable results with general anesthesia (GA) regarding perioperative comorbidities and achieved better results than GA regarding patient satisfaction in elderly patient [63].
CS-LA is not only indicated in patients who are unfit for GA, but also it is generally preferred than GA in elderly patients. CI under CS-LA has the following advantages in elderly patients [63]:
CS-LA was associated with decreased drug costs, surgery time, and anesthesia time.
Length of stay was significantly shorter in patients undergoing CI under CS-LA.
Patient satisfaction was superior with CS-LA.
Perioperative morbidity was higher, but not significant, with GA than CS-LA.
GA in elderly patient carries the risk of unexpected cognitive consequences after surgery.
According to Shabashev et al. [63], the patient receives dexmedetomidine as the main sedative drug, in addition to fentanyl, midazolam, lidocaine, and propofol, depending on the necessary level of sedation and analgesia. In addition, 8–10 mL of 2% lidocaine with 1:100,000 epinephrine was used as a local infiltration anesthesia. In some instances, when patients experienced additional pain upon exposing the middle ear mucosa, gelfoam pledges soaked in the same local anesthetic solution were applied directly to the middle ear mucosa for 2 minutes before continuing the manipulation. Supplemental oxygen less than 29% was administered via nasal cannula or face mask. Surgical drape was applied around the operative site, but the face was left completely uncovered to facilitate direct communication with the patient during the procedure [63].
All the previously described refinements and advances in both surgical techniques and electrode design aim at increasing the performance of the electrode within the cochlea and decreasing the traumatic effect of the electrode on the residual neuro-sensitive structures in the cochlea; this can preserve the residual function of these structures aiming at hearing preservation. Through these surgical refinements, nontraumatic “soft” CI surgery can achieve the target of hearing preservation.
In addition to the previously described technical refinements, there are many surgical considerations that should be respected during performing nontraumatic “soft” CI surgery. The most important surgical considerations are:
Minimal bone drilling during cochleostomy and avoidance of entrance of bone dusts into cochlear lumen [35].
Careful dealing with the endosteum during cochleostomy by incising it sharply using a sharp needle [64].
Scala tympani electrode insertion and avoidance of injury of the osseous spiral lamina and basilar membrane [65].
Preservation of the perilymph in scala tympani by avoiding suction of the perilymph during cochleostomy [16].
Smooth and slow electrode insertion [36].
In case of using long electrode, avoid excess pressure on electrode during insertion that may cause intracochlear trauma [45].
Electrode fixation and stabilization [7].
Sealing of the cochleostomy with soft tissue seal to avoid perilymph leakage [36].
Corticosteroid can be administrated during CI surgery aiming at hearing preservation [65]. Perioperative corticosteroids can be used either systemic, intratympanic, or intracochlear. Systemic steroid can be used either intravenously during the surgery or orally after the surgery [64]. Postoperative oral corticosteroid improved hearing preservation rates according to the systematic review conducted by Santa et al. [36].
Intratympanic steroid has been described through either applying a gelfoam soaked with methylprednisolone 125 mg/ml over RW membrane for 30 minutes before cochleostomy [66] or by filling the middle ear by dexamethasone 4 mg/ml before electrode insertion [67].
Intracochlear corticosteroid has been described through either using intracochlear injection of triamcinolone acetonide solution in addition to hyaluronic acid [68] or through silicone-based dexamethasone-eluted cochlear implant [69].
Experimental animal study on corticosteroid-eluted cochlear implant devices showed significant hearing preservation rates and histopathologic evidence of lower inflammatory response to the electrode [70, 71, 72]. However, until nowadays, many authors still discourage the use of intracochlear or intratympanic corticosteroids during CI surgery [16].
In addition to corticosteroid, other drugs can be administrated through drug-eluted CI device. There are many ongoing experimental trials on intracochlear application of neurotrophins and antiapoptotic drugs through drug-eluted CI device [72].
CI surgery was introduced first as the only solution for hearing loss in profound deaf subjects. The US Food and Drug Administration first approved CI for adults with postlingual profound bilateral sensorineural hearing loss in 1985 and children in 1990. Nowadays, with the refinement of the surgical techniques and the advances of electrode design, CI candidacy guidelines have been expanded to include adults and children with residual hearing in the implanted ear [73].
This expansion in CI candidacy criteria was based on the strong evidence of two hypotheses: the first is the ability of CI surgery to preserve the residual hearing, and the second is the beneficial effect and the better speech outcomes of CI surgery in ears with residual hearing.
Systematic review studies were conducted on the effect of CI surgical techniques on hearing preservations [36, 65, 74]; all of these studies gathered that nontraumatic “soft” CI surgery can preserve hearing. Gantz et al. conducted a multicenter study on the outcome of CI surgery on 87 ears with residual hearing. At initial activation, 90% of the subjects maintained a functional low-frequency pure-tone average; this percentage was reduced to 80% after 12 months [75].
Regarding the benefit of CI in ears with residual hearing, a systematic review study was conducted on the outcome of CI in children with residual hearing; this study demonstrated that the better the preoperative residual hearing, the better the postoperative speech perception outcomes [76].
More than half a century passed since the first cochlear implantation surgery; throughout this long period, the main advances happened in cochlear implantation were the manufacture of the implant itself, surgical technique showing a lot of refinement rather than changes, and also the possibility of surgery nowadays to be performed under local anesthesia. The ongoing advances in cochlear implants and refinements of the surgical techniques have improved the outcomes of cochlear implantation and allowed for hearing preservation in case of preoperative residual hearing.
Roland Jr., J.T. had major role in this work; he helped me as a mentor, and also he provided me with four figures of his own work (Figures 1,2,5, and 6).
The authors declare no conflict of interest.
CI | cochlear implantation |
MPTA | mastoidectomy posterior tympanotomy approach |
RW | round window |
CS-LA | conscious sedation with local anesthesia |
GA | general anesthesia |
RS | receiver/stimulator |
ESRT | electrical stapedial reflex thresholds |
ECAP | electrical compound action potential |
NRT | neural response telemetry |
PCI | percutaneous cochlear implantation |
EAC | external auditory canal |
LW | lateral wall |
MS | midscalar |
PM | perimodiolar |
Coronaviruses (CoVs) belong to the subfamily Orthocoronavirinae in the family of Coronaviridae. In this family, there are four types of viruses: α-coronavirus, β-coronavirus, γ-coronavirus, δ-coronavirus [1]. The CoV genome is an enveloped, positive-sense, and single-stranded RNA, and it has the largest genome of known RNA viruses. It is known that α- and β-CoV types cause infections in mammals as δ- and γ-CoVs infect birds [2]. Severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) belonging to β-CoVs are the most aggressive strains of coronaviruses and cause viral pneumonia outbreaks [3, 4]. SARS-CoV disease is a kind of pneumonia and caused by novel CoV whose genome structure was more than 82% identical to those of SARS-CoV, named coronavirus disease 2019 (COVID-19) [5, 6]. SARS-Cov-2 is a beta gene virus genetically very close to bat-CoVRaTG13, and bat-SL-CoVZC45 Covs can cause severe illness. As the COVID-19 outbreak turned into a global threat, the World Health Organization (WHO) announced it as a global pandemic on 12 March 2020. The COVID-19 pandemic has changed the scenario of the entire world. COVID-19 outbreak started in Wuhan, China, has globally spread to 219 countries and territories [7]. Currently, there are few vaccines for COVID-19. Their acceptance and efficacy are an issue of debate across the whole world. Therefore, there is an urgent need to find drugs or vaccines for the treatment of COVID-19 infections effectively. However, there are some studies related to the use of known drugs such as remdesivir and chloroquine that have proved efficacy on COVID-19 infection. We summarize some antiviral drugs as therapeutic options for the treatment of COVID-19 [8].
COVID-19 mainly attacks the respiratory-tract-associated organs. Additionally, the virus has shown impact various to other organs or systems such as the gastrointestinal system, nervous system, etc. [9]. The most common symptoms in COVID-19 patients are fever, dry cough, loss of taste, lethargy, shortness of breath, dyspnea, chest pain, fatigue, myalgia, whereas headache, dizziness, abdominal pain, diarrhea, nausea, and vomiting are less commonly observed [10, 11]. Anosmia is also one of the most critical symptoms in COVID-19 patients [12]. COVID-19 is more contagious than other coronaviruses, and its transmission rate is higher than the closely related strain, SARS-CoV-10 [13]. Currently, new variants of COVID-19 are reported from different regions of the world. Coronavirus interacts with cell surface receptors such as angiotensin-converting enzyme-2 (ACE-2) and neuropilin to gain entry inside the cell. The receptor-binding domain of viral spike protein is essential in SARS-CoV-2 entry into the host cell via surface ACE-2 [14]. Recently, another cell receptor Neuropilin-1 was found to be involved in SARS-CoV-2 entry. After binding to the receptor, the conformational change in the spike protein leads to virus fusion with the host cell membrane. The virus may transfer the RNA directly inside the cells or may proceed through the endosomal pathway [15]. Upon translation of viral RNA, the viral replicase polyprotein PP1a and PP1ab are produced and cleaved into small products by viral endopeptidase [16]. RNA-dependent RNA polymerase (RdRp) produces subgenomic RNAs by discontinuous transcription [16, 17]. This further gets translated into respective viral proteins. After processing through the endoplasmic reticulum (ER), ER-Golgi intermediate compartment (ERGIC), and Golgi complex, the viral RNA and proteins are assembled into virions. These virions are transported through vesicles and exocytosed for transmission. These steps of the viral life cycle are beneficial virus inhibition targets for different drugs. The coronaviruses are ribonucleic acid (RNA) viruses, which have a positive single-strand RNA [14, 18]. When SARS-CoV-2 enters the body and comes in contact with the host cell membrane, some changes occur in the structure of the virus. The human TMPRSS2 protein alters the conformation of the spike glycoprotein in the virus. Two substantial protease enzymes, 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLPro), have essential roles in its viral replication process after it enters the host cell via ACE2 receptors [19]. The expression of several genes, such as AHCYL2, ZNF385B, etc., appears to have a strong correlation with the expression of ACE2 and TMPRSS2 protein receptors in human healthy and normal lung cells [20].
However, repurposing drugs could prove to be beneficial tactics for finding COVID-19 treatment, including cost-effectiveness, elimination of some clinical trial steps, faster on-field availability, combining the drugs with other possible drugs, and the invention of information about the mechanisms of the existing drug. Researchers were able to develop the possible COVID-19 medications using information from previous CoVs therapies, genetic sequences, and protein modeling studies. Antimalarials, antivirals, antibiotics, and corticosteroids are among the most often studied medications, and they have been repurposed based on their ability to neutralize viruses, reduce lung inflammation, or alleviate other illness symptoms. Chloroquine (CQ), hydroxychloroquine (HCQ), and azithromycin (AZM) are the most often utilized antiviral drugs against COVID-19, since they have already demonstrated reasonable antiviral efficacy against SARS-CoV, MERS-CoV, and SARS-CoV-2. Anti-HIV medications lopinavir/ritonavir (LPV/RTV) are being studied for COVID-19 since they were successful in previous CoV epidemics. Furthermore, the anti-Ebola medicine remdesivir (RDV) was evaluated for COVID-19 and garnered further attention.
Similarly, favipiravir (FPV), ribavirin (RBV), umifenovir (UFV), and oseltamivir (OTV) have broad-spectrum antiviral activities and clinically tested against COVID-19. The effective uses of HCQ, RDV, LPV/RTV, or LPV/RTV in combination with Interferon (IFN) β-1a against COVID-19 [21], all these drugs had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay in hospitalized patients. So far, to treat severe and critical COVID-19, only corticosteroids have proven effective [21]. Other drugs, such as Angiotensin-Converting-Enzyme inhibitors (ACEi), have also been used to treat COVID-19. However, no clear correlation was reported between mortality rate and ACEi drugs in hypertension patients with COVID-19 [22]. Due to the possibility of secondary infection in these patients, antibiotics have been used as various protocols [23].
Umifenovir (UFV) may interact with SARS-CoV-2 surface glycoproteins and lipids and obstruct the interaction with the entry receptor ACE-2. Antibodies against SARS-CoV-2 may prevent the virus from entering the body and causing illness. Chloroquine (CQ), hydroxychloroquine (HCQ), and azithromycin (AZM) can raise endosomal pH, making viral entrance and RNA release more difficult. CQ, HCQ, and AZM all have immunomodulatory properties. RDV, FPV, and RBV are nucleoside inhibitors that impede RNA replication and reduce RNA-dependent RNA polymerase activity. Fraternization of LPV with viral protease may change proteolysis. OTV may interact with components involved in exocytosis, preventing the virus from leaving the cell. Antibodies against cytokine receptors and corticosteroids have been shown to have anti-inflammatory properties in the face of excessive immune responses. Drugs such as CQ are wide-spectrum inhibitors of viral cell entry, and RDV is a wide-spectrum RNA polymerase inhibitor. SARS-CoV-2 infection concurrently triggers the host immune system and an inflammatory cascade response (cytokine storm). These are being targeted in the treatment of COVID-19 patients [23].
So far, no fully effective drug has been discovered against this virus. The antiviral drugs, usually nucleoside analogs or intracellular proteases, block the virus by preventing its entry into the cell or by interfering with its replication inside the cell. Protease inhibitors target certain proteases, whereas fusion inhibitors block the fusion phase of viral entrance. Transcription inhibitors impede viral replication by inhibiting RNA-dependent RNA polymerase during the reverse transcription process. Nucleoside reverse transcriptases are some of the transcriptase inhibitors. M2 channel protein is a target for certain antivirals. In this chapter, we have provided information about repurposed drugs that are used against COVID-19, the mechanism of activity, therapeutic regimens, pharmacokinetics, and drug-drug interactions [7, 8].
The rationale major biochemical events and components in the replication cycle of coronavirus are considered as targets for currently developed drugs. These include the spike protein, proteolytic enzymes, and RNA-dependent RNA polymerase [24]. SARS-CoV-2 is transmitted mainly via respiratory droplets. The virus enters the host cells through two pathways, either via endosomes or plasma membrane fusion. In both mechanisms, the viral S protein mediates attachment to the membrane of the host cell and engages ACE2 as the entry receptor [25]. A host protease termed transmembrane serine protease 2 (TMPRSS2) activates the connection between S protein and ACE-2 [26]. S protein is used by the virus to destroy antibodies and make it simpler for it to attach to host receptors [27]. Beta-coronaviruses generally employ hemagglutinin-esterase (HE) to bind to sialic acid on the glycoprotein surface, despite the fact that the fusion machinery of SARS-CoV-2 remains unknown [28]. Fusion inhibitors might be used to prevent these fusion stages.
The envelope is peeled off when fusion is complete, and the SARS-CoV-2 genome, together with its nucleocapsid, penetrates the cytoplasm of the host cell. Its genome comprises the open reading frames 1a and 1b (ORF1a and ORF1b) genes, which create two polyproteins (pp) named pp1a and pp1b, which aid in the viral translation process by hijacking host ribosomes [29]. Main protease (Mpro) and papain-like protease (Ppro) break these polyproteins to create multiple non-structural proteins [30]. Aside from Mpro and Ppro, SARS-CoV-2 has 3C-like cysteine protease (3CLPro), which has a 96% resemblance to SARS-CoV. These proteases are essential for viral replication and transcription, and protease inhibitors inhibiting these proteases are potential antivirals for SARS-CoV-2. The promising clinical outcomes for COVID-19 patients should be obtained by using alpha-interferon, chloroquine phosphate, arabinol, remdesivir, lopinavir/ritonavir, and anti-inflammatory drugs [31, 32, 33, 34]. Moreover, clinical trials with these drugs should be performed on COVID-19 patients to prove their efficacy and safety as proposed for tocilizumab (Figure 1) [35].
Schematic diagram of the life cycle of SARS-CoV-2.
Highest sequence similarity (~96%) was observed for the bat Coronavirus. So, it has been speculated that COVID-19 was transmitted from bats to humans. The intermediary animal host could be a pangolin or dog. COVID-19 illness is spread via intimate contact with an infected individual, as well as minute respiratory droplets emitted during coughing, sneezing, or talking [36]. Small droplets of saliva or sputum emitted from the mouth might carry large amounts of viruses that can linger in the air for lengthy periods of time and function as infection carriers. Even when a person is not in direct physical touch with the infected individual, inhaling these minute droplets causes viral infection to move from the sick to the healthy. The virus enters the human body via the eyes, nose, and mouth and spreads by encountering the virus on infected surfaces and then touching these bodily areas [37]. Environmental factors such as temperature and humidity influence viral propagation across infected surfaces [38]. The binding of homotrimer spike protein (S) on the virus’s surface to ACE2 on the host’s cell membrane facilitates SARS-CoV-2 entry into host cells [16]. The host cell receptor’s credit is a critical predictor of the virus’s tissue tropism and pathogenicity. The life cycle of SARS-CoV-2 is similar to the SARS-CoV and MERS-CoV [39]. Different strategies have been adopted to fight COVID-19.
COVID-19 diagnosis is a crucial step in tracking the virus and understanding its spread. This aids in the prevention of transmission as well as adequate patient care. COVID-19 is diagnosed in the first instance by observing signs and symptoms such as first loss of smell or taste or both, cough, mild to high fever, myalgia or weariness, and so on [40]. In addition, some people experience gastrointestinal problems such as vomiting, diarrhea, and nausea [41]. However, variations in the development of symptoms ranging from asymptomatic to severe instances, such as septic shock, metabolic acidosis, coagulation malfunction, and acute respiratory pneumonia-like syndrome, have been recorded often [17]. These indications and symptoms should only be used as a starting point for additional testing, not as a diagnostic tool. The recognition of symptoms in clinical conditions is the most important factor in diagnosis. Swabs are used to obtain pathological samples from the upper and lower respiratory areas (throat, oropharyngeal, nasopharyngeal, broncho-alveolar fluid, and sputum). The virus is still absent in the blood and urine of infected people, hence they are not regarded valid clinical specimens. The interlink between the temporal surge of viral load and its bio-distribution in different tissues of the body has a critical implication on the accuracy of various tests for diagnosis, according to reports of inconsistency in RTPCR test results for CoV-SARS-2 in various tissues [42] and temporal variation of test results from the same tissues [43]. SARS-spike CoV-2’s surface glycoprotein binds to the ACE2 receptor and then enters the host cell. Viral particles release their DNA after entering the host cell, which is then translated into protein, and additional viral particles are created, which are then released to infect the next cells. Many assays (molecular and immunological assays) or tools have been used for the diagnosis of COVID-19 and many more are currently in development.
SARS-Cov-2 infections currently have no vaccinations or antiviral therapies available [44]. Because developing safe and stable vaccines takes time and the pandemic is still going on, it’s critical to test and discover current medications that are already effective against SARS and MERS to determine whether they can be effectively applied to SARSCov-2. Various preclinical studies on other CoVs genetically very close to SARS-Cov-2 suggested that promising clinical outcomes for COVID-19 patients should be obtained by using several drugs including alpha-interferon, chloroquine phosphate, arabinol, remdesivir, lopinavir/ritonavir, and anti-inflammatory drugs. In a large-scale drug screening, nelfinavir has potent antiviral activity against SARS-Cov-2 [45]. Besides, praziquantel, pitavastatin, and perampanel might be effective against SARS-CoV-2. The outbreak of COVID-19 infection is related to the unavailability of specific drugs to combat this viral infection. Despite the challenges related to COVID-19 therapy, there are still several approaches being undertaken that show significant outcomes [5]. Discuss the positive impacts of some of the clinically used drugs for the COVID-19. Some drugs are in clinical trials, and some have shown significant promise in COVID-19 patients [46]. To find the solutions for COVID-19, great efforts have been made and are continued to develop vaccines, small-molecule drugs, or monoclonal antibodies that can prevent the infection [47]. In addition to drugs under clinical trials, some vaccines are expected to play a significant role in controlling the COVID-19 pandemic (Figure 2).
Common inhibitory action of antiviral drugs.
In 2009, Gilead Sciences, Inc. (USA) developed an antiviral drug called Remdesivir (RDV) to treat hepatitis B [48]. It did not indicate a desirable act against hepatitis. However, it is effective against other viruses, such as the Nipah virus, hepatitis C, and Marburg [49]. RDV is a broad-spectrum antiviral nucleoside analog, and now it is used as a treatment option for COVID-19 [50]. It is the class of polymerase inhibitors and showed activity against different RNA viruses, including SARS-CoV, MERS-CoV, Lassa fever virus, Junin virus, respiratory syncytial virus, Nipah virus, Hendra viruses, filoviruses, and Ebola viruses. RDV is a prodrug of its parent adenosine triphosphate analog, (2R,3R,4S,5R)-2-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile (GS-441524), and has similarity to the adenine nucleic acid structurally. Both of these drugs are metabolized into the active component as nucleoside triphosphate (GS-443902) after ingestion and show antiviral activity against SARS-CoV [51]. RDV targets the viral genome replication process by acting as an RdRp inhibitor [52], RDV was used to block the RNA-dependent RNA polymerase of SARS-CoV-2. On metabolization of RDV into active nucleoside triphosphate (NTP), which competes with ATP for incorporation into nascent RNA strands, premature RNA synthesis occurs, resulting in RNA strand termination and cessation of growth [51]. RDV when tested through in vitro studies using the Vero E6 cells showed an EC50 value of 1.76 μM that showed its activity against SARS-CoV-2 [53]. Intravenous remdesivir treatment showed significant improvement for COVID-19. RDV and chloroquine are highly effective in the control of SARS-CoV-2 infection. In severe COVID-19 treated with RDV, improvements in the clinical finding were observed in 68% of patients [54]. However, in October 2020, the WHO removed it from the list of effective drugs in the treatment procedure of COVID-19 patients because it failed in the first trials for the treatment of COVID-19 [42]. There are still controversies regarding the results, no benefit in COVID-19 treatment using RDV; whereas, the company claims it as a promising drug for the same. After penetrating the cell, RDV as a prodrug (GS-5734) and like Favipiravir, binds to the triphosphate group under esterase, kinase, and phosphatase enzymatic reactions. These enzymes modify the structure of RDV and convert it to the active form, RDV-triphosphate (RDV-TP or GS-441524) [55]. After virus entry into the cell cytoplasm, this prodrug gets activated and loses its ability to diffuse to the intercellular space [53]. However, the primary mechanism of action of RDV against SARS-CoV-2 is unclear, and more research is necessary to understand it [56]. In an in vitro study, the combination of RDV and chloroquine (antimalarial drug) effectively inhibited SARS-CoV-2 growth in Vero E6 cells [19]. RDV is used to treat COVID-19 cases.
The combined use of RDV and IFN-β created a higher antiviral activity compared with the lopinavir/ritonavir-IFN-β combination against the MERS-CoV virus. Additionally, RDV could be better pulmonary function, cause fall lung viral loads and severe lung pathology in mice; on the contrary, lopinavir/ritonavir-IFN-β could not [57]. In two clinical studies, the use of RDV has been carried out against severe or mild respiratory infections caused by COVID-19. Recently, RDV for emergency use to treat COVID-19, including five antiviral drugs, ribavirin, RDV, sofosbuvir, galidesivir, and tenofovir, was conducted against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp); these drugs showed promising results against COVID-19. Prominent adverse reactions were an acute respiratory failure, decreased glomerular filtration rate, lymphocytopenia, pyrexia, hyperglycemia, increased anemia, increased creatine, and liver transaminases. RDV given in combination with baricitinib (Janus kinase inhibitor used to hinder intracellular signaling of cytokines) was effective compared with RDV alone in terms of reducing recovery time additionally speeding improvement. RDV’s parent nucleotide GS-441524 is superior and less toxic than its prodrug form and has shown efficacy [58].
Favipiravir (Avigan or T705) is a synthetic antiviral agent that was first marketed as an anti-influenza drug in Japan. It is a derivative of pyrazine carboxamide (6-fluoro-3-hydroxy-2-pyrazine carboxamide) [59]. Due to its similarity to the purine (guanine) nucleotide, it is a type of RNA-dependent RNA-polymerase (RdRp) inhibitor. RdRp uses Favipiravir-RTP in the synthesis of mRNA strands, which can consequently stop viral protein synthesis via suppressing the translation process. Activated Favipiravir-RTP could suppress the SARS-CoV-2 RdRp enzyme and inhibit viral mRNA elongation and protein synthesis [60]. Favipiravir acts against RNA viruses by working on viral genetic copying to prevent its reproduction. A phase 3 clinical trial was involved for the treatment of COVID-19 disease using Favipiravir. For the first day, take 1800 mg twice a day, then 600 mg three times a day from the second day onward for a total of 14 days. Normalization of pyrexia, respiratory rate, and cough alleviation for at least 72 h are the key objectives [61]. The precursor of this drug known as T1105 has anti-influenza effects [62]. Drug excretion is through renal elimination and is mainly impacted by aldehyde oxidase and xanthine oxidase [62]. Favipiravir is a prodrug that is phosphorylated upon its entry into the cell and converted to an active antiviral form, favipiravir ibufuranosyl-5′-triphosphate (T-705-RTP). Favipiravir was first prescribed in Wuhan, to treat patients with SARS-CoV-2 infection. In June 2020, it was approved for mild-to-moderate COVID-19 cases in India. Favipiravir has been consumed to cure distinct viral diseases. Favipiravir was effective against some RNA viruses, such as yellow fever virus, Lisa virus, West Nile virus, Bunyavirus, arenavirus, flavivirus, filoviruses, and Ebola virus [63]. The exact mechanism of action is not clear against SARS-CoV-2. Favipiravir is considered a potential drug for COVID-19 and is currently used for COVID-19 treatment in Japan and Indonesia. Besides, its anti-influenza virus action, it stops the replication of RNA viruses such as flavi-, alpha-, filo-, bunya-, arena-, noroviruses [64]. Favipiravir showed a more powerful antiviral activity than lopinavir/ritonavir. Adverse reactions are not observed in a favipiravir therapy group. Compared with the lopinavir/ritonavir group, it had considerably fewer adverse effects. In a Japanese study, FPV was also shown to control inflammatory mediators and pneumonia progression in COVID-19 patients [65]. Severe or critical COVID-19 patients showed improvements after treating with FPV and FPV also led to improved lung histology [66].
Lopinavir is an antiviral drug belonging to the family of protease inhibitors. It is commonly used to treat Acquired Immunodeficiency Syndrome (AIDS) and prevent HIV from spreading inside the body. Lopinavir/ritonavir (LPV/RTV) is used in combination with other antiretroviral drugs for the treatment of HIV-1 infection. In the coronavirus pandemic, when no definitive drug was proposed to treat patients, it was used in combination with Ritonavir. This LPV/RTV is branded as Kaletra. Lopinavir has a relatively short half-life in the blood and is affected by the cytochrome p450 enzyme, while Ritonavir is a protease inhibitor and reduces the Lopinavir metabolism by suppressing the function of cytochrome p450. The half-life of Lopinavir is improved, and its circulation period is increased. LPV/RTV acts as a protease inhibitor drug and inhibits the action of 3-CLpro, a chymotrypsin-like protease enzyme, that plays a vital role in the processing and interferes with the process of viral replication and its release from host cells [67, 68, 69]. LPV/RTV use is related to diverse side effects, mainly in the gastrointestinal tract. Diarrhea, impaired hepatic cell function, and pancreatitis are some of these crucial side effects.
The use of lopinavir as an emergency drug in China increased the eosinophil count among COVID-19 patients [70]. In an in silico study, LPV/RTV used as HIV protease inhibitors inhibited the main protease (MPro) of SARS-CoV-2 [71]. The LPV/RTV is being used as an emergency treatment for COVID-19 patients in some countries [72]. LPV/RTV alone or in combination with interferon (INF)-β, an inflammation regulator, has been listed by WHO as options for “solidarity” clinical trial for COVID-19. COVID-19 might benefit from LPV/RTV since it reduces viral load and improves clinical symptoms. Lung damage was also significantly reduced when LPV/RTV and umifenovir were used together [73]. A research found that while LPV/RTV therapy was associated with a better result, it did not significantly speed up the clinical progression of severe COVID-19 infection. Although the efficacy of lopinavir for COVID-19 has yet to be determined, LPV/RTV has been employed in the treatment of COVID-19 patients [57]. Now, LPV/RTV and IFN-β1b are in phase 2 for the MERS therapy. Despite the positive findings, in a recent study performed on patients with SARS-CoV-2 infection, the LPV/RTV did not provide clinical improvement compared with standard care processes [72]. Findings of LPV/RTV clinical efficacy remain limited and primarily anecdotal cases. LPV/RTV in the therapy of COVID-19 is needed as current results contradict. LPV/RTV can ameliorate the outcome of MERS-CoV infection [74]. Moreover, LPV/RTV is assumed as a therapeutic option for COVID-19 pneumonia [72]. Thus, more well-designed clinical studies are necessary to identify their efficacy as therapeutic agents for COVID-19.
Novaferon has potential as an antiviral drug against COVID-19. It is a synthesized protein consisting of 167 amino acids, designed on the technical basis of DNA shuffling technology. The antiviral effects of novaferon are shown alone and in combination with lopinavir/ritonavir (LPV/RTV) for COVID-19 treatment. Novaferon inhibited the viral replication in infected cells (EC50 = 1.02 ng/ml) and protected healthy cells from SARS-CoV-2 infection (EC50 = 0.1 ng/ml). Both novaferon and novaferon plus LPV/RTV groups had significantly higher SARS-CoV-2 clearance rates on day 6 than the LPV/RTV group [8].
Ribavirin (Virazole) is an antiviral drug belonging to the nucleoside analogues, (1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide). It is a synthetic nucleoside analog with a guanosine-like structure. Ribavirin disrupts viral DNA and RNA replication, thereby inhibiting virus proliferation in the cell. Although Ribavirin’s primary mechanism of action is suppressing the virus replication, and can also interfere with viral RNA capping, which depends on the presence of natural guanosine in the RNA structure. The natural guanosine in the viral RNA structure prevents the breakdown of RNA strands. Ribavirin reduces the guanosine synthesis in the cell by inhibiting the activity of the inosine monophosphate dehydrogenase enzyme, which negatively impacts virus replication [75]. Although Virazole does not entirely inhibit viral RNA synthesis, the synthesis of the viral genetic material is severely impaired. It results in significant and persistent mutations in viral RNA, which reduce the viability of the virus in host cells [76]. Besides, the presence of Ribavirin in the patient’s body can reduce viral immune evasion and boost immune maintenance [77]. It is the first broad-spectrum antiviral drug against DNA and RNA viruses [75]. It is used clinically to treat HIV and hepatitis C virus (HCV) patients.
Ribavirin, which has been studied for its antiviral effectiveness against SARS-CoV-2, is used to inhibit viral RNA production and viral mRNA capping with a broad range of antiviral activity. It’s a prodrug that, when metabolized, looks like purine RNA nucleotide, which prevents viral multiplication by interfering with RNA metabolism. It was discovered in a comparison study of SARS-CoV-2 patients treated with lopinavir/ritonavir (LPV/RTV) and ribavirin combination treatment [77]. Ribavirin is one of the medications used to treat COVID-19 in conjunction with either IFN alpha or LPV/RTV [46]. Using ribavirin in combination with sofosbuvir and remdesivir, docking and modeling studies revealed that ribavirin is a viable candidate medication for COVID-19 therapy [78]. Ribavirin and sofosbuvir are currently part of the therapeutic regimen to treat COVID-19 in some countries.
Ribavirin inhibits the function of inosine monophosphate dehydrogenase, which affects the formation of guanosine triphosphate (GTP), preventing RNA and DNA viral replication. During the SARS outbreak in Hong Kong, ribavirin was utilized. With or without steroids, it was occasionally chosen. The combination of ribavirin and interferon-β, which appears to inhibit SARS-CoV replication, has shown significant efficacy in the inhibition of SARS-CoV [79]. The ribavirin triple antiviral treatment was safe and superior compared with lopinavir-ritonavir combined therapy.
The drug showed antiviral efficacy against canine distemper virus, hepatitis C virus, Enterovirus, Chikungunya virus, and Semliki Forest virus, orthopoxvirus, influenza virus, flavi- and paramyxoviruses [80]. A study observed reduced replication of the MERS-CoV in rhesus macaques upon treatment with IFN-α2b and RBV [81]. RBV in combination with LPV/RTV was used in SARS-CoV and MERS-CoV trials [82]. In the case of SARS-CoV-2 infection, an in vitro study showed the EC50 of RBV as 109.50 uM [31]. A study included RBV along with LPV/RTV and IFN-α in the treatment of hospitalized COVID-19 patients. When compared with those that only received LPV-RTV, the triple treatment was found to be effective in reducing illness symptoms and viral shedding. The RBV dosage was 400 mg bid for 14 days, paired with 400 mg/100 mg of LPV/RTV + IFN-β. A research examined the effectiveness of antivirals sofosbuvir/daclatasvir and RBV in the treatment of COVID-19 patients. COVID-19 patients treated with RBV had a greater death rate (33%) than those treated with sofosbuvir/daclatasvir. A cohort study comparing RBV vs. supportive therapy stated that RBV did not help in reducing the mortality rate in COVID-19 patients [83].
It is an antiviral widely used to treat the influenza virus. Arbidol can prevent SARS-CoV-2 infection
Darunavir, an anti-HIV drug, is recommended for COVID-19 treatment in Italy. It is used in a combined regimen along with cytochrome P-450 inhibitors such as ritonavir or cobicistat and confirmed their replication inhibitory effect against SARS-CoV-2. A clinical trial assessed the effectiveness of darunavir combination with other antivirals and hydroxychloroquine for COVID-19 patients. A combination of darunavir and cobicistat is also being tested [93]. PREZCOBIX®, a fixed-dose combination of darunavir and cobicistat, is also used to treat COVID-19. COVID-19 infection was recently discovered in HIV-positive individuals who were already taking darunavir, raising questions about the effectiveness of this HIV protease inhibitor. The darunavir might not be effective in preventing SARS-CoV-2 infection at the dosage of 800 mg [94]. Darunavir is a second generation of HIV-1 protease inhibitors used to prevent SARS-CoV-2 infection in vitro [17] by inhibiting viral replication at 300 μM, and this inhibition efficiency was 280-fold compared with the untreated groups. Darunavir boosted with ritonavir or cobicistat is used in HIV/AIDS treatment. The efficacy of darunavir or ritonavir is enhanced by cytochrome p450 (CYP3A) inhibition [95]. Cell experiments with darunavir showed that the drug inhibited viral replication of COVID-19 in vitro. The lopinavir/ritonavir used in the treatment of HIV/AIDS has more efficacy and tolerability than darunavir, its use in COVID-19 is limited.
Oseltamivir (Tamiflu) is an antiviral agent that is used for patients with influenza A and B. It is a protease inhibitor, which specifically inhibits the neuraminidase enzyme in the influenza virus. This enzyme has a key role in the binding of the influenza virus to the cell membrane and spread throughout the body. Therefore, Oseltamivir, by targeting neuraminidase, prevents the spread of the influenza virus and its progression inside the body [96]. This drug was used in the treatment of COVID-19 infection, which showed an appropriate effect on patients [41]. Oseltamivir has been applied in concomitant regimens with other drugs such as Hydroxychloroquine or Favipiravirs [97]. In addition to treating influenza A and B patients, this drug may also be used in severe cases. For the treatment of flu patients, Tamiflu is prescribed in a 75 mg dosage twice a day and once a day as prophylaxis. The main side effects of this drug can be nausea and headache [98]. Neuraminidase inhibitors seem beneficial for COVID-19 patients and can reduce their ventilator requirements [99]. The precise mechanism of action of Oseltamivir against COVID-19 infection is still unclear. Oseltamivir is a synthetic derivative prodrug of ethyl ester [100]. It acts as a neuraminidase inhibitor against the influenza virus and is also effective for various avian influenza virus strains [101]. An in vitro oseltamivir study on H5N1 influenza showed that the IC50 was 0.1–4.9 nM [102]. In vivo study involving H5N1 infection required a longer course and higher dosage of Oseltamivir. The COVID-19 originated in China during flu season, and hence earlier, many patients received oseltamivir treatment until the causative agent SARSCoV-2 was discovered. Some current clinical trials have used oseltamivir in combination with other major therapeutic drugs [31, 41].
Sofosbuvir is an antiviral drug and RdRp inhibitor that exerts its effect by suppressing RdRp enzyme activity. A combination of Sofosbuvir with Ledipasvir is used for treating patients with genotype 1 of HCV67. Because of the similarity in the transcription and replication mechanism of the SARS-CoV-2 with HCV in host cells, physicians speculate that this drug may help treat COVID-19 patients [103]. This drug disrupts the activity of RdRp by acting like free nucleotides that are essential for viral mRNA synthesis [104]. Sofosbuvir is a potential option for COVID-19 treatment [105], and extensive clinical studies should be performed to verify the effectiveness of this drug.
Danoprevir, an HCV N53 protease inhibitor, is authorized in China for the treatment of noncirrhotic genotype 1b chronic hepatitis C in combination with other medications. In China, only two clinical studies of danoprevir coupled with ritonavir in the treatment of SARS-CoV-2 infection were completed [8].
In a computer simulation, atazanavir bonded more firmly to the active site of SARS-CoV-2 MPro than lopinavir, and atazanavir suppressed SARS-CoV-2 replication in a test tube. A prior trial on HIV-positive individuals found that combining atazanavir with ritonavir enhanced glucose uptake and lipid parameters while also lowering fasting glucose levels more efficiently than lopinavir-ritonavir. The atazanavir might be an alternative for lopinavir when combined with ritonavir for COVID-19 treatment. This antiviral drug is an option for COVID-19 treatment [8].
SARS-CoV-2 penetrates host cells by receptor-mediated endocytosis, just as other viruses. AP2-related protein kinase 1 controls the process of endocytosis (AAK1). As a result, disrupting AAK1 will prevent not just viral entrance but also intracellular viral assembly. Baricitinib is a Janus kinase (JAK) inhibitor that has a high affinity for AAK1 and can inhibit it. SARS-CoV-2 infection can be treated with baricitinib, which inhibits both viral entry and the inflammatory response [106]. JAK inhibitors such as ruxolitinib and fedratinib, which are linked to baricitinib, decreased clathrin-mediated endocytosis at higher dosages, suggesting that they may not be effective at acceptable concentrations in lowering viral infectivity. Neutropenia, lymphocytopenia, and viral reactivation have all been linked to the use of baricitinib for therapeutic purposes. Because individuals infected with SARSCoV-2 had a lower absolute lymphocyte count, baricitinib may increase the risk of co-infection [107].
Blocking virus-host fusion is a promising target for the novel antiviral agents that inhibit the Abl kinase pathway [41]. In a study, imatinib, an Abl kinase inhibitor, was observed to block the replication of SARS and MERS viruses by blocking viral fusion in 2016 [108]. COVID-19 utilized the SARS-coronavirus receptor ACE2 as well as the cellular protease TMPRSS2 to get access to target cells; therefore, TMPRSS2, transmembrane serine protease 2, inhibiting medicines such imatinib might be evaluated as COVID-19 disease treatment alternatives [37].
Another possible medicine that targets the fusion stage in viruses is camostat mesylate, a serine protease inhibitor. SARS-CoV-2 enters target host cells via ACE-2 receptors and/or TMPRSS2 receptors, with camostat mesylate acting as a TMPRSS2 inhibitor. It inhibits the virus’s cellular entrance by downregulating the production of the SARS-CoV-2 spike (S) protein, which prevents surface fusion. SARS-CoV infection in human bronchial epithelial cells was inhibited by camostat mesylate [109]. In vitro testing revealed that camostat mesylate and E-64d (a cysteine protease inhibitor) effectively blocked SARS-CoV-2 TMPRSS2 binding. Clinical studies are now underway to compare the efficacy of hydroxychloroquine and camostat mesylate vs. hydroxychloroquine alone. Another serine protease inhibitor, nafamostat mesylate, was shown to be 15 times more effective in preventing the SARS-CoV-2 virus from infecting host cells. As a result, nafamostat mesylate can be regarded a preferable option to camostat mesylate due to its more robust antiviral activity and acceptable safety profile [37]. Disseminated intravascular coagulation is also treated with nafamostat mesylate (DIC). It will aid in the management of DIC, as seen by increased fibrinolysis in COVID-19 patients [110].
In an in vitro research utilizing Vero E6 cells, nitazoxanide and its active component, tizoxanide, showed promise against MERS CoV and SARS CoV-2, with EC50 values of 0.92 and 2.12 μM, respectively [111]. In addition to coronaviruses, it exhibited action against norovirus, rotavirus, parainfluenza, respiratory syncytial virus, and influenza virus. This antiviral efficacy is due to the fact that the action mechanism is based on interfering with the virus’s host-regulated reproduction pathways rather than the virus’s particular pathways [112]. Nitazoxanide stimulates innate antiviral systems through amplification of cytoplasmic RNA sensing and type 1 IFN pathways. Nitazoxanide increases the expression of certain host systems that interfere with viral infection, allowing viruses to evade the host’s cellular defenses [113]. The nitazoxanide used against influenza viruses blocks the maturation of viral hemagglutinin at the post-translational stage [112]. Even if the findings aren’t promising, this medicine is used to treat some acute respiratory infections such as influenza. Although the in vitro activity of nitazoxanide against SARS-CoV-2 is promising, additional research is needed to understand its function in the management of COVID-19 (Figure 3).
Chemical structure of antiviral drugs.
Other various antiviral agents have been utilized to determine their impacts against SARS-CoV-2. Galidesivir is a nucleoside analog and a protease inhibitor [114]. This drug mechanism on COVID-19 is hypothesized to be similar to other antivirals, although its exact action mechanism is unknown. Another antiviral agent for COVID-19 is Tenofovir, which is known as an anti-influenza drug. It is an antiretroviral agent that targets DNA polymerase and inhibits virus replication [115, 116]. The action mechanism of this substance against COVID-19 requires further studies.
A fusion inhibitor is a group of antivirals that inhibit the fusion process during viral entry into the host cells. Some drugs are available with umifenovir and camostat mesylate representing antiviral activity against SARS-CoV-2 [117].
Some protease inhibitors such as lopinavir, darunavir, and atazanavir are used against COVID-19 [118]. In a computational study, drugs such as carfilzomib, valrubicin, eravacycline, lopinavir, and elbasvir inhibited the main protease in SARS-CoV-2. Further studies are required to confirm the efficacy of these drugs. Saquinavir and other protease inhibitors such as indinavir, amprenavir, and nelfinavir might also show the same effects against COVID-19 like protease inhibitors, due to resemblance between the structures. In a computer simulation, saquinavir and indinavir were found to suppress 3CLPro activity in SARS-CoV-2 [119]. In vitro inhibition of SARS-CoV-2 was shown to be inhibited by saquinavir, indinavir, amprenavir, and nelfinavir, with nelfinavir demonstrating the greatest suppression when compared with the others. In Singapore, saquinavir has been used to treat COVID-19 patients. Two other medications, raltegravir and paritaprevir, were shown to have the ability to block 3CLPro activity in SARS-CoV-2 in a computational investigation (Tables 1 and 2) [120].
Class | Drugs | Application | Emergency use for COVID-19 |
---|---|---|---|
Fusion inhibitor | Umifenovir (Arbidol) | Influenza | Singapore, China |
Protease Inhibitor | Lopinavir | HIV | USA, Japan, Singapore, Italy, China, IPC (Lopinavir-Ritonavir fix dose) |
Darunavir | HIV-1 | Italy (Darunavir-Ritonavir fix dose) | |
Atazanavir | HIV-1 | Singapore | |
Saquinavir | HIV-1 | Singapore | |
Nucleoside reverse transcriptase inhibitor | Emtricitabine | HIV-1 | Singapore (Emtricitabine-Tenofovir fix dose) |
Azvudine | HIV-1 | Singapore | |
Nucleotide reverse transcriptase inhibitor | Remdesivir | Ebola | WHO, IPC, USA, Singapore, Italy |
Favipiravir | (Avigan) Influenza | Singapore, Japan, Indonesia | |
Ribavirin | HCV | Singapore, IPC | |
Sofosbuvir | HCV | Singapore | |
Neuraminidase inhibitor (Virus release inhibitor) | Oseltamivir (Tamiflu) | Influenza A & B | IPC, Singapore, Indonesia |
Current use of existing antiviral drugs for COVID-19 [56].
International Pulmonologists’ Consensus includes the USA, India, Iran, China, Italy, Great Britain, EUA, Colombia, Egypt, Singapore, Romania, Ireland, Malaysia, Saudi Arabia, Sudan, Greece, and Bolivia.
Group | Drugs | Mechanism of action |
---|---|---|
Viral RNA polymerase inhibitors | Remdesivir (GS-5734) | RdRp inhibitor, prodrug, the analog of adenosine nucleotide |
Favipiravir | RdRp inhibitor, prodrug, the analog of guanosine nucleotide | |
Viral protein synthesis inhibitors | Ritonavir/Lopinavir | Inhibitor of protease |
Inhibitors of viral entry | Hydroxychloroquine Chloroquine | Increase in endosomal pH needed for the virus/cell fusion. Interfere with cellular receptor glycosylation of SARS CoV (ACE-2) |
Immunomodulators | Nitazoxanide | Interfere with host regulated pathways of virus replication, amplification of type 1 IFN pathways, and cytoplasmic RNA sensing |
Ivermectin | Inhibition of importin 1 heterodimer to inhibit the nuclear import of host and viral proteins |
Mechanism of action of antiviral drugs used for the treatment of COVID-19.
Another technique for combating SARS-CoV-2 infection is to inhibit RdRp and impede viral replication by targeting the reverse transcription process. Nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase translocation inhibitors are a few examples of possible inhibitors (NRTTIs).
Other NtRTIs with comparable structural properties to remdesivir or ribavirin, such as adefovir, tenofovir alafenamide, tenofovir disoproxil, abacavir, ganciclovir, and didanosine, exhibit antiviral effectiveness against SARS-CoV-2. NRTIs (lamivudine, stavudine, zidovudine, emtricitabine, zalcitabine, and azvudine) and NNRTIs (efavirenz, nevirapine, delavirdine, and rilpivirine) may also have antiviral activity against SARS-CoV-2 [56].
Oseltamivir is a neuraminidase inhibitor used in preventing influenza Neuraminidase inhibitor drugs such as oseltamivir, zanamivir, and peramivir are antiviral drugs that inhibit the viral neuraminidase enzyme and are recommended for influenza and to block the release of viral particles out of host cells. Neuraminidase inhibitors are also used as empirical treatment in MERS-CoV infection [121, 122]. However, a combination of oseltamivir with ganciclovir and lopinavir/ritonavir is used to treat COVID-19 patients [40]. A computational study also supported synergistic effects of oseltamivir-lopinavir-ritonavir combination against SARS-CoV-2 [123]. Oseltamivir is used with ceftriaxone and terbutaline to treat COVID-19 [124]. A study showed that the CT scan of the lungs of a COVID-19 patient showed significant improvement after a three-day course of oseltamivir [19]. Oseltamivir has been used either with or without antibiotics and corticosteroids against COVID-19. In a clinical trial, oseltamivir is tested with chloroquine and favipiravir [93, 125].
Nowadays, the rising SARS-CoV-2 turned into a global threat. COVID-19 targets lung cells by connecting to ACE2 protein. This protein is largely produced in some tissues such as the bile duct, liver, gastrointestinal organs, esophagus, testis, and kidney as well as lung tissue. Thus, COVID-19 may damage these organs and tissues. With the global threatening caused by COVID-19, efficient therapy against COVID-19 is quickly necessary. Nevertheless, the development of new drugs for this disease is still a huge problem for people in the world, and we have none formally approved drugs against COVID-19 now. It is very crucial to cut off the extending of this virus owing to epidemic avoidance and checking techniques. We need to develop novel drugs and to find new therapy methods to prevent this outbreak and to treat COVID-19. The extent of the current pandemic, along with other factors, such as the lack of time to develop novel and effective agents against COVID-19, the high mortality rate, possible mutations in its genetic material and severe economic shocks to societies highlight the value of testing antiviral drugs present in our drug arsenal. Some drugs that have already started with repositioning may be effective against COVId-19 as well. It is essential to address the drug-drug interaction of the drugs in COVID-19 patients with comorbidities. We hope that the continuing studies may provide solutions for the prevention and therapy against the COVID-19.
Despite the fact that specific antiviral medications for COVID-19 have yet to be identified or authorized by the FDA, the usage of some currently existing antiviral agents that target various phases in COVID-19’s life cycle might be an alternate therapeutic strategy for combating the pandemic. Fusion inhibitors, protease inhibitors, and transcription inhibitors are just a few of the interesting antiviral medication classes to investigate. Apart from antiviral medicines, various interesting techniques to treating COVID-19 are being employed, such as convalescent plasma, which has been found to reduce viral load and patient morbidity. The effects of interferon (IFN)-α/β and IL-6R inhibitor1 have also been encouraging [126, 127, 128]. The introduction of several new technologies is likely to yield good benefits. The safety of patients should be prioritized while evaluating new SARS-CoV-2 vaccinations. Nanotechnology offers an effective new route for diagnostics and treatment techniques. The more distinctive nanoparticles operate as excellent antiviral medication delivery vehicles, increasing the procedure’s effectiveness. Finding appropriate diagnostic and therapeutic strategies for the fast and efficient care of severe COVID-19 patients is urgently needed [129, 130]. Different research on different CoV-induced diseases shows that using α-interferon, chloroquine phosphate, arabinol, remdesivir, lopinavir/ritonavir, and anti-inflammatory medications might result in encouraging clinical results for SARS-Cov-2 patients. Tocilizumab should be used as a therapy approach for severe COVID-19 pneumonia to achieve favorable results. Furthermore, further clinical studies with appropriate medications should be conducted on SARS-CoV-2 patients to demonstrate effectiveness and safety.
We are thankful to the Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, 21955, Saudi Arabia, and Glocal School of Pharmacy, Glocal University, Mirzapur Pole, 247121, Saharanpur, Uttar Pradesh, India for providing necessary facilities.
The authors declare no conflicts of interest.
3CLpro | 3-chymotrypsin-like protease |
AAK1 | AP2-associated protein kinase 1 |
ACE2 | angiotensin-converting enzyme 2 |
ACEi | angiotensin-converting-enzyme inhibitors |
ADR | acute respiratory distress syndrome |
AIDS | acquired immunodeficiency syndrome |
Cm | maximum concentration |
CMV | cytomegalovirus |
COVID-19 | coronavirus disease 2019 |
DCGI | drug controller general of India |
DR | drug repurposing |
E | envelope protein |
ER | endoplasmic reticulum |
ERGIC | endoplasmic reticulum-Golgi apparatus compartment |
EVD | Ebola virus disease |
HA | hemagglutinin envelope glycoprotein |
HAV | hepatitis A virus |
HCMV | human cytomegalovirus |
HCV | hepatitis-C virus |
HE | hemagglutinin esterase |
HSV | herpes simplex virus |
ICU | intensive care unit |
INF-β | interferon |
Kb | kilo base pairs |
M | membrane protein |
MERS | Middle-East Respiratory Syndrome |
Mpro | main protease |
N | nucleocapsid |
NNRTI | non-nucleoside reverse-transcriptase inhibitors |
NRTTI | nucleoside reverse transcriptase translocation inhibitors |
NtRTI | nucleotide reverse-transcriptase inhibitor |
PLPro | Papain-like protease |
qRT-PCR | quantitative real-time polymerase chain reaction |
R0 | reproductive number |
RdRp | RNA-dependent RNA polymerase |
RNA | ribonucleic acid |
RVFV | Rift Valley fever virus |
S(P) | Spike protein |
S | glycoprotein spike |
SARS | severe acute respiratory syndrome |
SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
SPs | spike proteins |
TMPRSS2 | transmembrane serine protease 2 |
US FDA | United States Food and Drug Administration |
WHO | World Health Organization |
As this section deals with legal issues pertaining to the rights of individual Authors and IntechOpen, for the avoidance of doubt, each category of publication is dealt with separately. Consequently, much of the information, for example definition of terms used, is repeated to ensure that there can be no misunderstanding of the policies that apply to each category.
",metaTitle:"Copyright Policy",metaDescription:"Copyright is the term used to describe the rights related to the publication and distribution of original works. Most importantly from a publisher's perspective, copyright governs how authors, publishers and the general public can use, publish and distribute publications.",metaKeywords:null,canonicalURL:"/page/copyright-policy",contentRaw:'[{"type":"htmlEditorComponent","content":"Copyright is the term used to describe the rights related to the publication and distribution of original Works. Most importantly from a publisher's perspective, copyright governs how Authors, publishers and the general public can use, publish, and distribute publications.
\\n\\nIntechOpen only publishes manuscripts for which it has publishing rights. This is governed by a publication agreement between the Author and IntechOpen. This agreement is accepted by the Author when the manuscript is submitted and deals with both the rights of the publisher and Author, as well as any obligations concerning a particular manuscript. However, in accepting this agreement, Authors continue to retain significant rights to use and share their publications.
\\n\\nHOW COPYRIGHT WORKS WITH OPEN ACCESS LICENSES?
\\n\\nAgreement samples are listed here for the convenience of prospective Authors:
\\n\\nDEFINITIONS
\\n\\nThe following definitions apply in this Copyright Policy:
\\n\\nAuthor - in order to be identified as an Author, three criteria must be met: (i) Substantial contribution to the conception or design of the Work, or the acquisition, analysis, or interpretation of data for the Work; (ii) Participation in drafting or revising the Work; (iii) Approval of the final version of the Work to be published.
\\n\\nWork - a Chapter, including Conference Papers, a Scientific Article and any and all text, graphics, images and/or other materials forming part of or accompanying the Chapter/Conference Paper.
\\n\\nMonograph/Compacts - a full manuscript usually written by a single Author, including any and all text, graphics, images and/or other materials.
\\n\\nCompilation - a collection of Works distributed in a Book that IntechOpen has selected, and for which the coordination of the preparation, arrangement and publication has been the responsibility of IntechOpen. Any Work included is accepted in its entirety in unmodified form and is published with one or more other contributions, each constituting a separate and independent Work, but which together are assembled into a collective whole.
\\n\\nScientific Journal – Periodical publication intended to further the progress of science.
\\n\\nJournal Article/Scientific Article – Publication based on empirical evidence. It can support a hypothesis with original research, describe existing research or comment on current trends in a specific field.
\\n\\nIntechOpen - Registered publisher with office at 5 Princes Gate Court, London, SW7 2QJ - UNITED KINGDOM
\\n\\nIntechOpen platform - IntechOpen website www.intechopen.com whose main purpose is to host Monographs in the format of Book Chapters, Long Form Monographs, Compacts, Conference Proceedings, Scientific Journals and Videos.
\\n\\nVideo Lecture – an audiovisual recording of a lecture or a speech given by a Lecturer, recorded, edited, owned and published by IntechOpen.
\\n\\nTERMS
\\n\\nAll Works published on the IntechOpen platform and in print are licensed under a Creative Commons Attribution 3.0 Unported and Creative Commons 4.0 International License, a license which allows for the broadest possible reuse of published material.
\\n\\nCopyright on the individual Works belongs to the specific Author, subject to an agreement with IntechOpen. The Creative Common license is granted to all others to:
\\n\\nAnd for any purpose, provided the following conditions are met:
\\n\\nAll Works are published under the CC BY 3.0 and CC BY 4.0 license. However, please note that book Chapters may fall under a different CC license, depending on their publication date as indicated in the table below:
\\n\\n\\n\\n
LICENSE | \\n\\t\\t\\tUSED FROM - | \\n\\t\\t\\tUP TO - | \\n\\t\\t
\\n\\t\\t\\t Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0) \\n\\t\\t\\t | \\n\\t\\t\\t1 July 2005 (2005-07-01) | \\n\\t\\t\\t3 October 2011 (2011-10-03) | \\n\\t\\t
\\n\\t\\t\\t Creative Commons Attribution 3.0 Unported (CC BY 3.0) \\n\\t\\t\\t | \\n\\t\\t\\t5 October 2011 (2011-10-05) | \\n\\t\\t\\tCurrently | \\n\\t\\t
\\n\\t\\t\\t Creative Commons 4.0 International (CC BY 4.0) – for Journal Articles \\n\\t\\t\\t | \\n\\t\\t\\t15 March 2022 | \\n\\t\\t\\tCurrently | \\n\\t\\t
The CC BY 3.0 and CC BY 4.0 license permits Works to be freely shared in any medium or format, as well as the reuse and adaptation of the original contents of Works (e.g. figures and tables created by the Authors), as long as the source Work is cited and its Authors are acknowledged in the following manner:
\\n\\nContent reuse:
\\n\\n© {year} {authors' full names}. Originally published in {short citation} under {license version} license. Available from: {DOI}
\\n\\nContent adaptation & reuse:
\\n\\n© {year} {authors' full names}. Adapted from {short citation}; originally published under {license version} license. Available from: {DOI}
\\n\\nReposting & sharing:
\\n\\nOriginally published in {full citation}. Available from: {DOI}
\\n\\nRepublishing – More about Attribution Policy can be found here.
\\n\\nThe same principles apply to Works published under the CC BY-NC-SA 3.0 license, with the caveats that (1) the content may not be used for commercial purposes, and (2) derivative works building on this content must be distributed under the same license. The restrictions contained in these license terms may, however, be waived by the copyright holder(s). Users wishing to circumvent any of the license terms are required to obtain explicit permission to do so from the copyright holder(s).
\\n\\nDISCLAIMER: Neither the CC BY 3.0 license, CC BY 4.0, nor any other license IntechOpen currently uses or has used before, applies to figures and tables reproduced from other works, as they may be subject to different terms of reuse. In such cases, if the copyright holder is not noted in the source of a figure or table, it is the responsibility of the User to investigate and determine the exact copyright status of any information utilised. Users requiring assistance in that regard are welcome to send an inquiry to permissions@intechopen.com.
\\n\\nAll rights to Books and Journals and all other compilations published on the IntechOpen platform and in print are reserved by IntechOpen.
\\n\\nThe copyright to Books, Journals and other compilations is subject to separate copyright from those that exist in the included Works.
\\n\\nAll Long Form Monographs/Compacts are licensed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license granted to all others.
\\n\\nCopyright to the individual Works (Chapters) belongs to their specific Authors, subject to an agreement with IntechOpen and the Creative Common license granted to all others to:
\\n\\nUnder the following terms:
\\n\\nThere must be an Attribution, giving appropriate credit, provision of a link to the license, and indication if any changes were made.
\\n\\nNonCommercial - The use of the material for commercial purposes is prohibited. Commercial rights are reserved to IntechOpen or its licensees.
\\n\\nNo additional restrictions that apply legal terms or technological measures that restrict others from doing anything the license permits are allowed.
\\n\\nThe CC BY-NC 4.0 license permits Works to be freely shared in any medium or format, as well as reuse and adaptation of the original contents of Works (e.g. figures and tables created by the Authors), as long as it is not used for commercial purposes. The source Work must be cited and its Authors acknowledged in the following manner:
\\n\\nContent reuse:
\\n\\n© {year} {authors' full names}. Originally published in {short citation} under {license version} license. Available from: {DOI}
\\n\\nContent adaptation & reuse:
\\n\\n© {year} {authors' full names}. Adapted from {short citation}; originally published under {license version} license. Available from: {DOI}
\\n\\nReposting & sharing:
\\n\\nOriginally published in {full citation}. Available from: {DOI}
\\n\\nAll Book cover design elements, as well as Video image graphics are subject to copyright by IntechOpen.
\\n\\nEvery reproduction of a front cover image must be accompanied by an appropriate Copyright Notice displayed adjacent to the image. The exact Copyright Notice depends on who the Author of a particular cover image is. Users wishing to reproduce cover images should contact permissions@intechopen.com.
\\n\\nAll Video Lectures under IntechOpen's production are subject to copyright and are property of IntechOpen, unless defined otherwise, and are licensed under the Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This grants all others the right to:
\\n\\nShare — copy and redistribute the material in any medium or format
\\n\\nUnder the following terms:
\\n\\nUsers wishing to repost and share the Video Lectures are welcome to do so as long as they acknowledge the source in the following manner:
\\n\\n© {year} IntechOpen. Published under CC BY-NC-ND 4.0 license. Available from: {DOI}
\\n\\nUsers wishing to reuse, modify, or adapt the Video Lectures in a way not permitted by the license are welcome to contact us at permissions@intechopen.com to discuss waiving particular license terms.
\\n\\nAll software used on the IntechOpen platform, any used during the publishing process, and the copyright in the code constituting such software, is the property of IntechOpen or its software suppliers. As such, it may not be downloaded or copied without permission.
\\n\\nUnless otherwise indicated, all IntechOpen websites are the property of IntechOpen.
\\n\\nAll content included on IntechOpen Websites not forming part of contributed materials (such as text, images, logos, graphics, design elements, videos, sounds, pictures, trademarks, etc.), are subject to copyright and are property of, or licensed to, IntechOpen. Any other use, including the reproduction, modification, distribution, transmission, republication, display, or performance of the content on this site is strictly prohibited.
\\n\\nPolicy last updated: 2016-06-08
\\n"}]'},components:[{type:"htmlEditorComponent",content:'Copyright is the term used to describe the rights related to the publication and distribution of original Works. Most importantly from a publisher's perspective, copyright governs how Authors, publishers and the general public can use, publish, and distribute publications.
\n\nIntechOpen only publishes manuscripts for which it has publishing rights. This is governed by a publication agreement between the Author and IntechOpen. This agreement is accepted by the Author when the manuscript is submitted and deals with both the rights of the publisher and Author, as well as any obligations concerning a particular manuscript. However, in accepting this agreement, Authors continue to retain significant rights to use and share their publications.
\n\nHOW COPYRIGHT WORKS WITH OPEN ACCESS LICENSES?
\n\nAgreement samples are listed here for the convenience of prospective Authors:
\n\nDEFINITIONS
\n\nThe following definitions apply in this Copyright Policy:
\n\nAuthor - in order to be identified as an Author, three criteria must be met: (i) Substantial contribution to the conception or design of the Work, or the acquisition, analysis, or interpretation of data for the Work; (ii) Participation in drafting or revising the Work; (iii) Approval of the final version of the Work to be published.
\n\nWork - a Chapter, including Conference Papers, a Scientific Article and any and all text, graphics, images and/or other materials forming part of or accompanying the Chapter/Conference Paper.
\n\nMonograph/Compacts - a full manuscript usually written by a single Author, including any and all text, graphics, images and/or other materials.
\n\nCompilation - a collection of Works distributed in a Book that IntechOpen has selected, and for which the coordination of the preparation, arrangement and publication has been the responsibility of IntechOpen. Any Work included is accepted in its entirety in unmodified form and is published with one or more other contributions, each constituting a separate and independent Work, but which together are assembled into a collective whole.
\n\nScientific Journal – Periodical publication intended to further the progress of science.
\n\nJournal Article/Scientific Article – Publication based on empirical evidence. It can support a hypothesis with original research, describe existing research or comment on current trends in a specific field.
\n\nIntechOpen - Registered publisher with office at 5 Princes Gate Court, London, SW7 2QJ - UNITED KINGDOM
\n\nIntechOpen platform - IntechOpen website www.intechopen.com whose main purpose is to host Monographs in the format of Book Chapters, Long Form Monographs, Compacts, Conference Proceedings, Scientific Journals and Videos.
\n\nVideo Lecture – an audiovisual recording of a lecture or a speech given by a Lecturer, recorded, edited, owned and published by IntechOpen.
\n\nTERMS
\n\nAll Works published on the IntechOpen platform and in print are licensed under a Creative Commons Attribution 3.0 Unported and Creative Commons 4.0 International License, a license which allows for the broadest possible reuse of published material.
\n\nCopyright on the individual Works belongs to the specific Author, subject to an agreement with IntechOpen. The Creative Common license is granted to all others to:
\n\nAnd for any purpose, provided the following conditions are met:
\n\nAll Works are published under the CC BY 3.0 and CC BY 4.0 license. However, please note that book Chapters may fall under a different CC license, depending on their publication date as indicated in the table below:
\n\n\n\n
LICENSE | \n\t\t\tUSED FROM - | \n\t\t\tUP TO - | \n\t\t
\n\t\t\t Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0) \n\t\t\t | \n\t\t\t1 July 2005 (2005-07-01) | \n\t\t\t3 October 2011 (2011-10-03) | \n\t\t
\n\t\t\t Creative Commons Attribution 3.0 Unported (CC BY 3.0) \n\t\t\t | \n\t\t\t5 October 2011 (2011-10-05) | \n\t\t\tCurrently | \n\t\t
\n\t\t\t Creative Commons 4.0 International (CC BY 4.0) – for Journal Articles \n\t\t\t | \n\t\t\t15 March 2022 | \n\t\t\tCurrently | \n\t\t
The CC BY 3.0 and CC BY 4.0 license permits Works to be freely shared in any medium or format, as well as the reuse and adaptation of the original contents of Works (e.g. figures and tables created by the Authors), as long as the source Work is cited and its Authors are acknowledged in the following manner:
\n\nContent reuse:
\n\n© {year} {authors' full names}. Originally published in {short citation} under {license version} license. Available from: {DOI}
\n\nContent adaptation & reuse:
\n\n© {year} {authors' full names}. Adapted from {short citation}; originally published under {license version} license. Available from: {DOI}
\n\nReposting & sharing:
\n\nOriginally published in {full citation}. Available from: {DOI}
\n\nRepublishing – More about Attribution Policy can be found here.
\n\nThe same principles apply to Works published under the CC BY-NC-SA 3.0 license, with the caveats that (1) the content may not be used for commercial purposes, and (2) derivative works building on this content must be distributed under the same license. The restrictions contained in these license terms may, however, be waived by the copyright holder(s). Users wishing to circumvent any of the license terms are required to obtain explicit permission to do so from the copyright holder(s).
\n\nDISCLAIMER: Neither the CC BY 3.0 license, CC BY 4.0, nor any other license IntechOpen currently uses or has used before, applies to figures and tables reproduced from other works, as they may be subject to different terms of reuse. In such cases, if the copyright holder is not noted in the source of a figure or table, it is the responsibility of the User to investigate and determine the exact copyright status of any information utilised. Users requiring assistance in that regard are welcome to send an inquiry to permissions@intechopen.com.
\n\nAll rights to Books and Journals and all other compilations published on the IntechOpen platform and in print are reserved by IntechOpen.
\n\nThe copyright to Books, Journals and other compilations is subject to separate copyright from those that exist in the included Works.
\n\nAll Long Form Monographs/Compacts are licensed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license granted to all others.
\n\nCopyright to the individual Works (Chapters) belongs to their specific Authors, subject to an agreement with IntechOpen and the Creative Common license granted to all others to:
\n\nUnder the following terms:
\n\nThere must be an Attribution, giving appropriate credit, provision of a link to the license, and indication if any changes were made.
\n\nNonCommercial - The use of the material for commercial purposes is prohibited. Commercial rights are reserved to IntechOpen or its licensees.
\n\nNo additional restrictions that apply legal terms or technological measures that restrict others from doing anything the license permits are allowed.
\n\nThe CC BY-NC 4.0 license permits Works to be freely shared in any medium or format, as well as reuse and adaptation of the original contents of Works (e.g. figures and tables created by the Authors), as long as it is not used for commercial purposes. The source Work must be cited and its Authors acknowledged in the following manner:
\n\nContent reuse:
\n\n© {year} {authors' full names}. Originally published in {short citation} under {license version} license. Available from: {DOI}
\n\nContent adaptation & reuse:
\n\n© {year} {authors' full names}. Adapted from {short citation}; originally published under {license version} license. Available from: {DOI}
\n\nReposting & sharing:
\n\nOriginally published in {full citation}. Available from: {DOI}
\n\nAll Book cover design elements, as well as Video image graphics are subject to copyright by IntechOpen.
\n\nEvery reproduction of a front cover image must be accompanied by an appropriate Copyright Notice displayed adjacent to the image. The exact Copyright Notice depends on who the Author of a particular cover image is. Users wishing to reproduce cover images should contact permissions@intechopen.com.
\n\nAll Video Lectures under IntechOpen's production are subject to copyright and are property of IntechOpen, unless defined otherwise, and are licensed under the Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This grants all others the right to:
\n\nShare — copy and redistribute the material in any medium or format
\n\nUnder the following terms:
\n\nUsers wishing to repost and share the Video Lectures are welcome to do so as long as they acknowledge the source in the following manner:
\n\n© {year} IntechOpen. Published under CC BY-NC-ND 4.0 license. Available from: {DOI}
\n\nUsers wishing to reuse, modify, or adapt the Video Lectures in a way not permitted by the license are welcome to contact us at permissions@intechopen.com to discuss waiving particular license terms.
\n\nAll software used on the IntechOpen platform, any used during the publishing process, and the copyright in the code constituting such software, is the property of IntechOpen or its software suppliers. As such, it may not be downloaded or copied without permission.
\n\nUnless otherwise indicated, all IntechOpen websites are the property of IntechOpen.
\n\nAll content included on IntechOpen Websites not forming part of contributed materials (such as text, images, logos, graphics, design elements, videos, sounds, pictures, trademarks, etc.), are subject to copyright and are property of, or licensed to, IntechOpen. Any other use, including the reproduction, modification, distribution, transmission, republication, display, or performance of the content on this site is strictly prohibited.
\n\nPolicy last updated: 2016-06-08
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{},profiles:[{id:"396",title:"Dr.",name:"Vedran",middleName:null,surname:"Kordic",slug:"vedran-kordic",fullName:"Vedran Kordic",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/396/images/7281_n.png",biography:"After obtaining his Master's degree in Mechanical Engineering he continued his education at the Vienna University of Technology where he obtained his PhD degree in 2004. He worked as a researcher at the Automation and Control Institute, Faculty of Electrical Engineering, Vienna University of Technology until 2008. His studies in robotics lead him not only to a PhD degree but also inspired him to co-found and build the International Journal of Advanced Robotic Systems - world's first Open Access journal in the field of robotics.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"441",title:"Ph.D.",name:"Jaekyu",middleName:null,surname:"Park",slug:"jaekyu-park",fullName:"Jaekyu Park",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/441/images/1881_n.jpg",biography:null,institutionString:null,institution:{name:"LG Corporation (South Korea)",country:{name:"Korea, South"}}},{id:"465",title:"Dr.",name:"Christian",middleName:null,surname:"Martens",slug:"christian-martens",fullName:"Christian Martens",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Rheinmetall (Germany)",country:{name:"Germany"}}},{id:"479",title:"Dr.",name:"Valentina",middleName:null,surname:"Colla",slug:"valentina-colla",fullName:"Valentina Colla",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/479/images/358_n.jpg",biography:null,institutionString:null,institution:{name:"Sant'Anna School of Advanced Studies",country:{name:"Italy"}}},{id:"494",title:"PhD",name:"Loris",middleName:null,surname:"Nanni",slug:"loris-nanni",fullName:"Loris Nanni",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/494/images/system/494.jpg",biography:"Loris Nanni received his Master Degree cum laude on June-2002 from the University of Bologna, and the April 26th 2006 he received his Ph.D. in Computer Engineering at DEIS, University of Bologna. On September, 29th 2006 he has won a post PhD fellowship from the university of Bologna (from October 2006 to October 2008), at the competitive examination he was ranked first in the industrial engineering area. He extensively served as referee for several international journals. He is author/coauthor of more than 100 research papers. He has been involved in some projects supported by MURST and European Community. His research interests include pattern recognition, bioinformatics, and biometric systems (fingerprint classification and recognition, signature verification, face recognition).",institutionString:null,institution:null},{id:"496",title:"Dr.",name:"Carlos",middleName:null,surname:"Leon",slug:"carlos-leon",fullName:"Carlos Leon",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Seville",country:{name:"Spain"}}},{id:"512",title:"Dr.",name:"Dayang",middleName:null,surname:"Jawawi",slug:"dayang-jawawi",fullName:"Dayang Jawawi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Technology Malaysia",country:{name:"Malaysia"}}},{id:"528",title:"Dr.",name:"Kresimir",middleName:null,surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/528/images/system/528.jpg",biography:"K. Delac received his B.Sc.E.E. degree in 2003 and is currentlypursuing a Ph.D. degree at the University of Zagreb, Faculty of Electrical Engineering andComputing. His current research interests are digital image analysis, pattern recognition andbiometrics.",institutionString:null,institution:{name:"University of Zagreb",country:{name:"Croatia"}}},{id:"557",title:"Dr.",name:"Andon",middleName:"Venelinov",surname:"Topalov",slug:"andon-topalov",fullName:"Andon Topalov",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/557/images/1927_n.jpg",biography:"Dr. Andon V. Topalov received the MSc degree in Control Engineering from the Faculty of Information Systems, Technologies, and Automation at Moscow State University of Civil Engineering (MGGU) in 1979. He then received his PhD degree in Control Engineering from the Department of Automation and Remote Control at Moscow State Mining University (MGSU), Moscow, in 1984. From 1985 to 1986, he was a Research Fellow in the Research Institute for Electronic Equipment, ZZU AD, Plovdiv, Bulgaria. In 1986, he joined the Department of Control Systems, Technical University of Sofia at the Plovdiv campus, where he is presently a Full Professor. He has held long-term visiting Professor/Scholar positions at various institutions in South Korea, Turkey, Mexico, Greece, Belgium, UK, and Germany. And he has coauthored one book and authored or coauthored more than 80 research papers in conference proceedings and journals. His current research interests are in the fields of intelligent control and robotics.",institutionString:null,institution:{name:"Technical University of Sofia",country:{name:"Bulgaria"}}},{id:"585",title:"Prof.",name:"Munir",middleName:null,surname:"Merdan",slug:"munir-merdan",fullName:"Munir Merdan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/585/images/system/585.jpg",biography:"Munir Merdan received the M.Sc. degree in mechanical engineering from the Technical University of Sarajevo, Bosnia and Herzegovina, in 2001, and the Ph.D. degree in electrical engineering from the Vienna University of Technology, Vienna, Austria, in 2009.Since 2005, he has been at the Automation and Control Institute, Vienna University of Technology, where he is currently a Senior Researcher. His research interests include the application of agent technology for achieving agile control in the manufacturing environment.",institutionString:null,institution:null},{id:"605",title:"Prof",name:"Dil",middleName:null,surname:"Hussain",slug:"dil-hussain",fullName:"Dil Hussain",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/605/images/system/605.jpg",biography:"Dr. Dil Muhammad Akbar Hussain is a professor of Electronics Engineering & Computer Science at the Department of Energy Technology, Aalborg University Denmark. Professor Akbar has a Master degree in Digital Electronics from Govt. College University, Lahore Pakistan and a P-hD degree in Control Engineering from the School of Engineering and Applied Sciences, University of Sussex United Kingdom. Aalborg University has Two Satellite Campuses, one in Copenhagen (Aalborg University Copenhagen) and the other in Esbjerg (Aalborg University Esbjerg).\n· He is a member of prestigious IEEE (Institute of Electrical and Electronics Engineers), and IAENG (International Association of Engineers) organizations. \n· He is the chief Editor of the Journal of Software Engineering.\n· He is the member of the Editorial Board of International Journal of Computer Science and Software Technology (IJCSST) and International Journal of Computer Engineering and Information Technology. \n· He is also the Editor of Communication in Computer and Information Science CCIS-20 by Springer.\n· Reviewer For Many Conferences\nHe is the lead person in making collaboration agreements between Aalborg University and many universities of Pakistan, for which the MOU’s (Memorandum of Understanding) have been signed.\nProfessor Akbar is working in Academia since 1990, he started his career as a Lab demonstrator/TA at the University of Sussex. After finishing his P. hD degree in 1992, he served in the Industry as a Scientific Officer and continued his academic career as a visiting scholar for a number of educational institutions. In 1996 he joined National University of Science & Technology Pakistan (NUST) as an Associate Professor; NUST is one of the top few universities in Pakistan. In 1999 he joined an International Company Lineo Inc, Canada as Manager Compiler Group, where he headed the group for developing Compiler Tool Chain and Porting of Operating Systems for the BLACKfin processor. The processor development was a joint venture by Intel and Analog Devices. In 2002 Lineo Inc., was taken over by another company, so he joined Aalborg University Denmark as an Assistant Professor.\nProfessor Akbar has truly a multi-disciplined career and he continued his legacy and making progress in many areas of his interests both in teaching and research. He has contributed in stochastic estimation of control area especially, in the Multiple Target Tracking and Interactive Multiple Model (IMM) research, Ball & Beam Control Problem, Robotics, Levitation Control. He has contributed in developing Algorithms for Fingerprint Matching, Computer Vision and Face Recognition. He has been supervising Pattern Recognition, Formal Languages and Distributed Processing projects for several years. He has reviewed many books on Management, Computer Science. Currently, he is an active and permanent reviewer for many international conferences and symposia and the program committee member for many international conferences.\nIn teaching he has taught the core computer science subjects like, Digital Design, Real Time Embedded System Programming, Operating Systems, Software Engineering, Data Structures, Databases, Compiler Construction. In the Engineering side, Digital Signal Processing, Computer Architecture, Electronics Devices, Digital Filtering and Engineering Management.\nApart from his Academic Interest and activities he loves sport especially, Cricket, Football, Snooker and Squash. He plays cricket for Esbjerg city in the second division team as an opener wicket keeper batsman. He is a very good player of squash but has not played squash since his arrival in Denmark.",institutionString:null,institution:null},{id:"611",title:"Prof.",name:"T",middleName:null,surname:"Nagarajan",slug:"t-nagarajan",fullName:"T Nagarajan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universiti Teknologi Petronas",country:{name:"Malaysia"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:13389},{group:"region",caption:"Middle and South America",value:2,count:11661},{group:"region",caption:"Africa",value:3,count:4168},{group:"region",caption:"Asia",value:4,count:22334},{group:"region",caption:"Australia and Oceania",value:5,count:2019},{group:"region",caption:"Europe",value:6,count:33642}],offset:12,limit:12,total:135275},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{topicId:"23"},books:[{type:"book",id:"11433",title:"Human Migration in the Last Three Centuries",subtitle:null,isOpenForSubmission:!0,hash:"9836df9e82aa9f82e3852a60204909a8",slug:null,bookSignature:"Dr. Ingrid Muenstermann",coverURL:"https://cdn.intechopen.com/books/images_new/11433.jpg",editedByType:null,editors:[{id:"77112",title:"Dr.",name:"Ingrid",surname:"Muenstermann",slug:"ingrid-muenstermann",fullName:"Ingrid Muenstermann"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11438",title:"Fake News in the Era of Global Crises",subtitle:null,isOpenForSubmission:!0,hash:"5f61f975031e13ee705d8b5853f1aa58",slug:null,bookSignature:"Dr. David Eller",coverURL:"https://cdn.intechopen.com/books/images_new/11438.jpg",editedByType:null,editors:[{id:"476616",title:"Dr.",name:"Jack",surname:"Eller",slug:"jack-eller",fullName:"Jack Eller"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11473",title:"Social Inequality - Structure and Social Processes",subtitle:null,isOpenForSubmission:!0,hash:"cefab077e403fd1695fb2946e7914942",slug:null,bookSignature:"Ph.D. Yaroslava Robles-Bykbaev",coverURL:"https://cdn.intechopen.com/books/images_new/11473.jpg",editedByType:null,editors:[{id:"313341",title:"Ph.D.",name:"Yaroslava",surname:"Robles-Bykbaev",slug:"yaroslava-robles-bykbaev",fullName:"Yaroslava Robles-Bykbaev"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11474",title:"Quality of Life Interventions - Magnitude of Effect and Transferability",subtitle:null,isOpenForSubmission:!0,hash:"5a6bcdaf5ee144d043bcdab893ff9e1c",slug:null,bookSignature:"Ph.D. Sage Arbor and Dr. Tafline C. Arbor",coverURL:"https://cdn.intechopen.com/books/images_new/11474.jpg",editedByType:null,editors:[{id:"245319",title:"Ph.D.",name:"Sage",surname:"Arbor",slug:"sage-arbor",fullName:"Sage Arbor"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11769",title:"Multiculturalism and Interculturalism",subtitle:null,isOpenForSubmission:!0,hash:"6c4bda24f278d74f943f2155f13f4d73",slug:null,bookSignature:"Dr. Muhammad Mohiuddin, Dr. Tareque Aziz and Dr. Sreenivasan Jayashree",coverURL:"https://cdn.intechopen.com/books/images_new/11769.jpg",editedByType:null,editors:[{id:"418514",title:"Dr.",name:"Muhammad",surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11773",title:"Archaeology - Challenges and Updates",subtitle:null,isOpenForSubmission:!0,hash:"17d91462fa926279f65164ac0d5641cd",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/11773.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11778",title:"Correctional Facilities and Correctional Treatment - International Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"a933550a6966a04e4677a4c0aea8f5b2",slug:null,bookSignature:"Prof. Rui Abrunhosa Gonçalves",coverURL:"https://cdn.intechopen.com/books/images_new/11778.jpg",editedByType:null,editors:[{id:"198691",title:"Prof.",name:"Rui",surname:"Abrunhosa Gonçalves",slug:"rui-abrunhosa-goncalves",fullName:"Rui Abrunhosa Gonçalves"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11780",title:"Volunteering",subtitle:null,isOpenForSubmission:!0,hash:"008a5fc8005ea6b9228cfe39f9521abe",slug:null,bookSignature:"Ph.D. Diann Kelly",coverURL:"https://cdn.intechopen.com/books/images_new/11780.jpg",editedByType:null,editors:[{id:"325207",title:"Ph.D.",name:"Diann",surname:"Cameron Kelly",slug:"diann-cameron-kelly",fullName:"Diann Cameron Kelly"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12115",title:"European Politics",subtitle:null,isOpenForSubmission:!0,hash:"274a7fe06bb1c3cf128bf7ad081c7c12",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12115.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12116",title:"Youth and Youth Work",subtitle:null,isOpenForSubmission:!0,hash:"5fcd245b25b23db90b3fd0430d61e168",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12116.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12117",title:"Terrorism",subtitle:null,isOpenForSubmission:!0,hash:"6e88a48205eb81b8374e9e8efac25f6e",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12117.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12119",title:"Multilingualism",subtitle:null,isOpenForSubmission:!0,hash:"eea6bdfe13e423a793fe42c262e0ae64",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12119.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:26},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:7},{group:"topic",caption:"Business, Management and Economics",value:7,count:4},{group:"topic",caption:"Chemistry",value:8,count:16},{group:"topic",caption:"Computer and Information Science",value:9,count:18},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:8},{group:"topic",caption:"Engineering",value:11,count:41},{group:"topic",caption:"Environmental Sciences",value:12,count:5},{group:"topic",caption:"Immunology and Microbiology",value:13,count:8},{group:"topic",caption:"Materials Science",value:14,count:16},{group:"topic",caption:"Mathematics",value:15,count:9},{group:"topic",caption:"Medicine",value:16,count:66},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:2},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:7},{group:"topic",caption:"Physics",value:20,count:6},{group:"topic",caption:"Psychology",value:21,count:5},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:8},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:30},popularBooks:{featuredBooks:[{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10796",title:"Extracellular Vesicles",subtitle:"Role in Diseases, Pathogenesis and Therapy",isOpenForSubmission:!1,hash:"eb5407fcf93baff7bca3fae5640153a2",slug:"extracellular-vesicles-role-in-diseases-pathogenesis-and-therapy",bookSignature:"Manash K. Paul",coverURL:"https://cdn.intechopen.com/books/images_new/10796.jpg",editors:[{id:"319365",title:"Assistant Prof.",name:"Manash K.",middleName:null,surname:"Paul",slug:"manash-k.-paul",fullName:"Manash K. Paul"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"95",title:"Applications and Experiences of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"4bcb22b1eee68210a977a97d5a0f363a",slug:"applications-and-experiences-of-quality-control",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",editors:[{id:"22230",title:"Prof.",name:"Ognyan",middleName:null,surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3560",title:"Advances in Landscape Architecture",subtitle:null,isOpenForSubmission:!1,hash:"a20614517ec5f7e91188fe8e42832138",slug:"advances-in-landscape-architecture",bookSignature:"Murat Özyavuz",coverURL:"https://cdn.intechopen.com/books/images_new/3560.jpg",editors:[{id:"93073",title:"Dr.",name:"Murat",middleName:null,surname:"Ozyavuz",slug:"murat-ozyavuz",fullName:"Murat Ozyavuz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10739",title:"Global Decline of Insects",subtitle:null,isOpenForSubmission:!1,hash:"543783652b9092962a8fa4bed38eeb17",slug:"global-decline-of-insects",bookSignature:"Hamadttu Abdel Farag El-Shafie",coverURL:"https://cdn.intechopen.com/books/images_new/10739.jpg",editors:[{id:"192142",title:"Dr.",name:"Hamadttu",middleName:null,surname:"Abdel Farag El-Shafie",slug:"hamadttu-abdel-farag-el-shafie",fullName:"Hamadttu Abdel Farag El-Shafie"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10911",title:"Higher Education",subtitle:"New Approaches to Accreditation, Digitalization, and Globalization in the Age of Covid",isOpenForSubmission:!1,hash:"223a02337498e535e967174c1f648fbc",slug:"higher-education-new-approaches-to-accreditation-digitalization-and-globalization-in-the-age-of-covid",bookSignature:"Lee Waller and Sharon Waller",coverURL:"https://cdn.intechopen.com/books/images_new/10911.jpg",editors:[{id:"263301",title:"Dr.",name:"Lee",middleName:null,surname:"Waller",slug:"lee-waller",fullName:"Lee Waller"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3737",title:"MATLAB",subtitle:"Modelling, Programming and Simulations",isOpenForSubmission:!1,hash:null,slug:"matlab-modelling-programming-and-simulations",bookSignature:"Emilson Pereira Leite",coverURL:"https://cdn.intechopen.com/books/images_new/3737.jpg",editors:[{id:"12051",title:"Prof.",name:"Emilson",middleName:null,surname:"Pereira Leite",slug:"emilson-pereira-leite",fullName:"Emilson Pereira Leite"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"1770",title:"Gel Electrophoresis",subtitle:"Principles and Basics",isOpenForSubmission:!1,hash:"279701f6c802cf02deef45103e0611ff",slug:"gel-electrophoresis-principles-and-basics",bookSignature:"Sameh Magdeldin",coverURL:"https://cdn.intechopen.com/books/images_new/1770.jpg",editors:[{id:"123648",title:"Dr.",name:"Sameh",middleName:null,surname:"Magdeldin",slug:"sameh-magdeldin",fullName:"Sameh Magdeldin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4797},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",publishedDate:"July 27th 2022",numberOfDownloads:7175,editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",publishedDate:"July 27th 2022",numberOfDownloads:1981,editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10796",title:"Extracellular Vesicles",subtitle:"Role in Diseases, Pathogenesis and Therapy",isOpenForSubmission:!1,hash:"eb5407fcf93baff7bca3fae5640153a2",slug:"extracellular-vesicles-role-in-diseases-pathogenesis-and-therapy",bookSignature:"Manash K. Paul",coverURL:"https://cdn.intechopen.com/books/images_new/10796.jpg",publishedDate:"July 20th 2022",numberOfDownloads:2308,editors:[{id:"319365",title:"Assistant Prof.",name:"Manash K.",middleName:null,surname:"Paul",slug:"manash-k.-paul",fullName:"Manash K. Paul"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",publishedDate:"July 27th 2022",numberOfDownloads:1473,editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"95",title:"Applications and Experiences of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"4bcb22b1eee68210a977a97d5a0f363a",slug:"applications-and-experiences-of-quality-control",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",publishedDate:"April 26th 2011",numberOfDownloads:318571,editors:[{id:"22230",title:"Prof.",name:"Ognyan",middleName:null,surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",publishedDate:"September 26th 2012",numberOfDownloads:271836,editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3560",title:"Advances in Landscape Architecture",subtitle:null,isOpenForSubmission:!1,hash:"a20614517ec5f7e91188fe8e42832138",slug:"advances-in-landscape-architecture",bookSignature:"Murat Özyavuz",coverURL:"https://cdn.intechopen.com/books/images_new/3560.jpg",publishedDate:"July 1st 2013",numberOfDownloads:243450,editors:[{id:"93073",title:"Dr.",name:"Murat",middleName:null,surname:"Ozyavuz",slug:"murat-ozyavuz",fullName:"Murat Ozyavuz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10739",title:"Global Decline of Insects",subtitle:null,isOpenForSubmission:!1,hash:"543783652b9092962a8fa4bed38eeb17",slug:"global-decline-of-insects",bookSignature:"Hamadttu Abdel Farag El-Shafie",coverURL:"https://cdn.intechopen.com/books/images_new/10739.jpg",publishedDate:"July 20th 2022",numberOfDownloads:1582,editors:[{id:"192142",title:"Dr.",name:"Hamadttu",middleName:null,surname:"Abdel Farag El-Shafie",slug:"hamadttu-abdel-farag-el-shafie",fullName:"Hamadttu Abdel Farag El-Shafie"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10911",title:"Higher Education",subtitle:"New Approaches to Accreditation, Digitalization, and Globalization in the Age of Covid",isOpenForSubmission:!1,hash:"223a02337498e535e967174c1f648fbc",slug:"higher-education-new-approaches-to-accreditation-digitalization-and-globalization-in-the-age-of-covid",bookSignature:"Lee Waller and Sharon Waller",coverURL:"https://cdn.intechopen.com/books/images_new/10911.jpg",publishedDate:"July 13th 2022",numberOfDownloads:2082,editors:[{id:"263301",title:"Dr.",name:"Lee",middleName:null,surname:"Waller",slug:"lee-waller",fullName:"Lee Waller"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",publishedDate:"October 17th 2012",numberOfDownloads:256294,editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11328",title:"Botulinum Toxin",subtitle:"Recent Topics and Applications",isOpenForSubmission:!1,hash:"7dd05a316001cef143e209eda51387a7",slug:"botulinum-toxin-recent-topics-and-applications",bookSignature:"Suna Sabuncuoglu",coverURL:"https://cdn.intechopen.com/books/images_new/11328.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"270856",title:"Associate Prof.",name:"Suna",middleName:null,surname:"Sabuncuoglu",slug:"suna-sabuncuoglu",fullName:"Suna Sabuncuoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11085",title:"Polycystic Ovary Syndrome",subtitle:"Functional Investigation and Clinical Application",isOpenForSubmission:!1,hash:"3066dd3ff29e1fac072fd60b08d4d3e7",slug:"polycystic-ovary-syndrome-functional-investigation-and-clinical-application",bookSignature:"Zhengchao Wang",coverURL:"https://cdn.intechopen.com/books/images_new/11085.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"204883",title:"Dr.",name:"Zhengchao",middleName:null,surname:"Wang",slug:"zhengchao-wang",fullName:"Zhengchao Wang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10833",title:"Tumor Angiogenesis and Modulators",subtitle:null,isOpenForSubmission:!1,hash:"f29b575c46128b2da061ef7f9bd1070b",slug:"tumor-angiogenesis-and-modulators",bookSignature:"Ke Xu",coverURL:"https://cdn.intechopen.com/books/images_new/10833.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"59529",title:"Dr.",name:"Ke",middleName:null,surname:"Xu",slug:"ke-xu",fullName:"Ke Xu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11356",title:"Molecular Cloning",subtitle:null,isOpenForSubmission:!1,hash:"671c629dd86e97f0fb467b9e70e92296",slug:"molecular-cloning",bookSignature:"Sadık Dincer, Hatice Aysun Mercimek Takcı and Melis Sumengen Ozdenef",coverURL:"https://cdn.intechopen.com/books/images_new/11356.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"188141",title:"Prof.",name:"Sadik",middleName:null,surname:"Dincer",slug:"sadik-dincer",fullName:"Sadik Dincer"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10669",title:"Corrosion",subtitle:"Fundamentals and Protection Mechanisms",isOpenForSubmission:!1,hash:"4a76d54f8a40fc2e7002a8d13fd617c1",slug:"corrosion-fundamentals-and-protection-mechanisms",bookSignature:"Fahmina Zafar, Anujit Ghosal and Eram Sharmin",coverURL:"https://cdn.intechopen.com/books/images_new/10669.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"89672",title:"Dr.",name:"Fahmina",middleName:null,surname:"Zafar",slug:"fahmina-zafar",fullName:"Fahmina Zafar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10677",title:"Advanced Topics of Topology",subtitle:null,isOpenForSubmission:!1,hash:"bf964c52f9e653fac20a7fcab58070e5",slug:"advanced-topics-of-topology",bookSignature:"Francisco Bulnes",coverURL:"https://cdn.intechopen.com/books/images_new/10677.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"92918",title:"Dr.",name:"Francisco",middleName:null,surname:"Bulnes",slug:"francisco-bulnes",fullName:"Francisco Bulnes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11195",title:"Recent Advances in Biometrics",subtitle:null,isOpenForSubmission:!1,hash:"2d32e33e0f499cb5241734bb75dd2a83",slug:"recent-advances-in-biometrics",bookSignature:"Muhammad Sarfraz",coverURL:"https://cdn.intechopen.com/books/images_new/11195.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"215610",title:"Prof.",name:"Muhammad",middleName:null,surname:"Sarfraz",slug:"muhammad-sarfraz",fullName:"Muhammad Sarfraz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"367",title:"Pathology",slug:"agricultural-and-biological-sciences-plant-biology-pathology",parent:{id:"41",title:"Plant Biology",slug:"agricultural-and-biological-sciences-plant-biology"},numberOfBooks:5,numberOfSeries:0,numberOfAuthorsAndEditors:108,numberOfWosCitations:43,numberOfCrossrefCitations:75,numberOfDimensionsCitations:142,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"367",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"10985",title:"Agro-Economic Risks of Phytophthora and an Effective Biocontrol Approach",subtitle:null,isOpenForSubmission:!1,hash:"5ce2fdab78f95851db363572e8e44e36",slug:"agro-economic-risks-of-phytophthora-and-an-effective-biocontrol-approach",bookSignature:"Waleed Mohamed Hussain Abdulkhair",coverURL:"https://cdn.intechopen.com/books/images_new/10985.jpg",editedByType:"Edited by",editors:[{id:"175713",title:"Dr.",name:"Waleed Mohamed Hussain",middleName:null,surname:"Abdulkhair",slug:"waleed-mohamed-hussain-abdulkhair",fullName:"Waleed Mohamed Hussain Abdulkhair"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10113",title:"Diagnostics of Plant Diseases",subtitle:null,isOpenForSubmission:!1,hash:"daef7c0ea5e568cfc5ae1613a74634b3",slug:"diagnostics-of-plant-diseases",bookSignature:"Dmitry Kurouski",coverURL:"https://cdn.intechopen.com/books/images_new/10113.jpg",editedByType:"Edited by",editors:[{id:"264297",title:"Dr.",name:"Dmitry",middleName:null,surname:"Kurouski",slug:"dmitry-kurouski",fullName:"Dmitry Kurouski"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8814",title:"Plant Diseases",subtitle:"Current Threats and Management Trends",isOpenForSubmission:!1,hash:"5a1f36b34b43d68f20c7caf3961dd18a",slug:"plant-diseases-current-threats-and-management-trends",bookSignature:"Snježana Topolovec-Pintarić",coverURL:"https://cdn.intechopen.com/books/images_new/8814.jpg",editedByType:"Edited by",editors:[{id:"66211",title:"Prof.",name:"Snježana",middleName:null,surname:"Topolovec-Pintaric",slug:"snjezana-topolovec-pintaric",fullName:"Snježana Topolovec-Pintaric"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6642",title:"Advances in Plant Pathology",subtitle:null,isOpenForSubmission:!1,hash:"99196a55714f4057fd77655b42e6855f",slug:"advances-in-plant-pathology",bookSignature:"Josphert Ngui Kimatu",coverURL:"https://cdn.intechopen.com/books/images_new/6642.jpg",editedByType:"Edited by",editors:[{id:"224171",title:"Prof.",name:"Josphert N.",middleName:null,surname:"Kimatu",slug:"josphert-n.-kimatu",fullName:"Josphert N. Kimatu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5606",title:"Citrus Pathology",subtitle:null,isOpenForSubmission:!1,hash:"99254ddaa61bea53d3c328233a4f6c15",slug:"citrus-pathology",bookSignature:"Harsimran Gill and Harsh Garg",coverURL:"https://cdn.intechopen.com/books/images_new/5606.jpg",editedByType:"Edited by",editors:[{id:"169846",title:"Dr.",name:"Harsimran",middleName:null,surname:"Gill",slug:"harsimran-gill",fullName:"Harsimran Gill"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:5,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"53286",doi:"10.5772/66518",title:"Advance in Citrus Postharvest Management: Diseases, Cold Storage and Quality Evaluation",slug:"advance-in-citrus-postharvest-management-diseases-cold-storage-and-quality-evaluation",totalDownloads:3181,totalCrossrefCites:10,totalDimensionsCites:18,abstract:"Citrus is a fruit crop grown in different Mediterranean countries. Generally, harvested fruits are used for fresh consumption or are processed (mainly to produce juices). In this chapter, the authors discuss the state of art on citrus postharvest with a scientific approach, evaluating the current knowledge about the physiology and pathology of citrus fruits and the main causes of deterioration. In addition, the authors explain the main facilities for the cold storage of citrus fruit with particular reference to the rapid-cooling techniques and treatments needed prior to shipment of citrus fruits (refer shipment). In the last part of the chapter, the non-destructive methods for the quality evaluation are presented.",book:{id:"5606",slug:"citrus-pathology",title:"Citrus Pathology",fullTitle:"Citrus Pathology"},signatures:"Maria C. Strano, Giuseppe Altieri, Naouel Admane, Francesco\nGenovese and Giovanni C. Di Renzo",authors:[{id:"193555",title:"Dr.",name:"Francesco",middleName:null,surname:"Genovese",slug:"francesco-genovese",fullName:"Francesco Genovese"},{id:"193583",title:"Prof.",name:"Giovanni Carlo",middleName:null,surname:"Di Renzo",slug:"giovanni-carlo-di-renzo",fullName:"Giovanni Carlo Di Renzo"},{id:"193584",title:"Prof.",name:"Giuseppe",middleName:null,surname:"Altieri",slug:"giuseppe-altieri",fullName:"Giuseppe Altieri"},{id:"193585",title:"Dr.",name:"Maria Concetta",middleName:null,surname:"Strano",slug:"maria-concetta-strano",fullName:"Maria Concetta Strano"},{id:"193789",title:"Dr.",name:"Naouel",middleName:null,surname:"Admane",slug:"naouel-admane",fullName:"Naouel Admane"}]},{id:"67782",doi:"10.5772/intechopen.87101",title:"Aspects in Tobamovirus Management in Intensive Agriculture",slug:"aspects-in-em-tobamovirus-em-management-in-intensive-agriculture",totalDownloads:992,totalCrossrefCites:10,totalDimensionsCites:17,abstract:"In the recent years, disease spread of old and newly evolved tobamoviruses has occurred worldwide, affecting production of various vegetable and ornamental crops. The tobamoviruses are highly stable plant viruses that could cause severe disease symptoms. The well-known tobamovirus Cucumber green mottle mosaic virus (CGMMV) has recently caused severe damages in the cucumber, melon, and watermelon cucurbitaceous crops, worldwide. Similarly, a recent widespread of the newly identified tobamoviruses, Tomato mottle mosaic virus (ToMMV) and Tomato brown rugose fruit virus (ToBRFV), has reduced the solanaceous crop production. The primary route of tobamoviral infection is through mechanical means. These viruses adhere to agricultural facilities, contaminate the soil, infect seeds, and spread via beneficial pollinators and irrigation water. Mechanical plant injury suffices to initiate viral infection. Practicing hygiene by plant growers and in nurseries is currently the main strategy for mitigation of tobamoviral infection. Promoting the production of solanaceous vegetable crops genetically resistant to ToMMV and ToBRFV infection is a promising approach. However, CGMMV-resistant sources of cucurbitaceous vegetable crops are scarce. Conferring resistance to rootstocks and cross-protection strategies are newly implemented approaches that could alleviate tobamovirus disease spread in both solanaceous and cucurbitaceous crops.",book:{id:"8814",slug:"plant-diseases-current-threats-and-management-trends",title:"Plant Diseases",fullTitle:"Plant Diseases - Current Threats and Management Trends"},signatures:"Elisheva Smith and Aviv Dombrovsky",authors:null},{id:"68107",doi:"10.5772/intechopen.87958",title:"Plant Metabolites in Plant Defense Against Pathogens",slug:"plant-metabolites-in-plant-defense-against-pathogens",totalDownloads:1404,totalCrossrefCites:4,totalDimensionsCites:11,abstract:"Medicinal plants are widely used worldwide to treat various diseases. Its widespread use is due in part to the cultural acceptance of traditional medicine in different regions of the world, as well as its effectiveness in treating various diseases. Many of its active substances or secondary metabolites are formed to a response of various situations that generate stress in their habitat, such as sudden changes in environmental temperature, humidity, rain, drought, and infections by phytopathogens (fungi, bacteria, viruses, nematodes, protozoa). The production of these secondary metabolites is a mechanism of defense of plants. In this context, the objective of this chapter is to study the secondary metabolites of medicinal plants that could have a promising application in the control of different phytopathogens in crops of agricultural and economic interest.",book:{id:"8814",slug:"plant-diseases-current-threats-and-management-trends",title:"Plant Diseases",fullTitle:"Plant Diseases - Current Threats and Management Trends"},signatures:"Xóchitl S. Ramírez-Gómez, Sandra N. Jiménez-García, Vicente Beltrán Campos and Ma. Lourdes García Campos",authors:null},{id:"67930",doi:"10.5772/intechopen.87055",title:"Impact of Climate Change on Plant Diseases and IPM Strategies",slug:"impact-of-climate-change-on-plant-diseases-and-ipm-strategies",totalDownloads:1991,totalCrossrefCites:7,totalDimensionsCites:10,abstract:"There has been a remarkable scientific output on the topic of how climate change is likely to affect plant diseases. Climate change influences the occurrence, prevalence, and severity of plant diseases. Projected atmospheric and climate change will thus affect the interaction between crops and pathogens in multiple ways. This will also affect disease management with regard to timing, preference, and efficacy of chemical, physical, and biological measures of control and their utilization within integrated pest management (IPM) strategies. Prediction of future requirements in disease management is of great interest for agro-industries, extension services, and practical farmers. A comprehensive analysis of potential climate change effects on disease control is difficult because current knowledge is limited and fragmented and due to the complexity of future risks for plant disease management, particularly if new crops are introduced in an area. Uncertainty in models of plant disease development under climate change calls for a diversity of management strategies, from more participatory approaches to interdisciplinary science. Involvement of stakeholders and scientists from outside plant pathology shows the importance of trade-offs. All these efforts and integrations will produce effective crop protection strategies using novel technologies as appropriate tools to adapt to altered climatic conditions.",book:{id:"8814",slug:"plant-diseases-current-threats-and-management-trends",title:"Plant Diseases",fullTitle:"Plant Diseases - Current Threats and Management Trends"},signatures:"Sahar Abdou Zayan",authors:null},{id:"62605",doi:"10.5772/intechopen.75837",title:"The Biology of Thecaphora frezii Smut and Its Effects on Argentine Peanut Production",slug:"the-biology-of-thecaphora-frezii-smut-and-its-effects-on-argentine-peanut-production",totalDownloads:1117,totalCrossrefCites:7,totalDimensionsCites:9,abstract:"Thecaphora frezii was first reported in 1962 in wild peanut from Aquidauana, Mato Grosso do Sul, Brazil. In Argentina, it was first detected in 1995 in commercial crops from the central-northern area of Córdoba province. The fungus can survive in the soil as teliospores. When peanut gynophore penetrates the soil, their exudates disrupt telial dormancy; T. frezii penetrates and colonizes the tissues and replaces the cells with teliospores. Since its first report, peanut smut prevalence has gradually increased in peanut areas to reach a 100% in 2012. Currently, it is the most important peanut disease in Argentina, not only for its destructive power on crop but also for its quick spread throughout the growing region of Córdoba and the lack of effective tools for its management. It is important for additional research to find effective agronomical practice that reaches high control efficiencies. The collaboration of all those involved in Argentinian peanut production systems is necessary for the management of peanut smut to be successful.",book:{id:"6642",slug:"advances-in-plant-pathology",title:"Advances in Plant Pathology",fullTitle:"Advances in Plant Pathology"},signatures:"Luis Ignacio Cazón, Juan Andrés Paredes and Alejandro Mario Rago",authors:[{id:"232647",title:"M.Sc.",name:"Luis Ignacio",middleName:null,surname:"Cazón",slug:"luis-ignacio-cazon",fullName:"Luis Ignacio Cazón"},{id:"240515",title:"MSc.",name:"Juan Andrés",middleName:null,surname:"Paredes",slug:"juan-andres-paredes",fullName:"Juan Andrés Paredes"},{id:"240517",title:"MSc.",name:"Alejandro Mario",middleName:null,surname:"Rago",slug:"alejandro-mario-rago",fullName:"Alejandro Mario Rago"}]}],mostDownloadedChaptersLast30Days:[{id:"53686",title:"Major and Emerging Fungal Diseases of Citrus in the Mediterranean Region",slug:"major-and-emerging-fungal-diseases-of-citrus-in-the-mediterranean-region",totalDownloads:3195,totalCrossrefCites:3,totalDimensionsCites:9,abstract:"This chapter deals with major endemic and emerging fungal diseases of citrus as well as with exotic fungal pathogens potentially harmful for citrus industry in the Mediterranean region, with particular emphasis on diseases reported in Italy and Maghreb countries. The aim is to provide an update of both the taxonomy of the causal agents and their ecology based on a molecular approach, as a preliminary step towards developing or upgrading integrated and sustainable disease management strategies. Potential or actual problems related to the intensification of new plantings, introduction of new citrus cultivars and substitution of sour orange with other rootstocks, globalization of commerce and climate changes are discussed. Fungal pathogens causing vascular, foliar, fruit, trunk and root diseases in commercial citrus orchards are reported, including Plenodomus tracheiphilus, Colletotrichum spp., Alternaria spp., Mycosphaerellaceae, Botryosphaeriaceae, Guignardia citricarpa and lignicolous basidiomycetes. Diseases caused by Phytophthora spp. (oomycetes) are also included as these pathogens have many biological, ecological and epidemiological features in common with the true fungi (eumycetes).",book:{id:"5606",slug:"citrus-pathology",title:"Citrus Pathology",fullTitle:"Citrus Pathology"},signatures:"Khaled Khanchouch, Antonella Pane, Ali Chriki and Santa Olga\nCacciola",authors:[{id:"193916",title:"M.Sc.",name:"Khaled",middleName:null,surname:"Khanchouch",slug:"khaled-khanchouch",fullName:"Khaled Khanchouch"},{id:"193918",title:"Dr.",name:"Santa Olga",middleName:null,surname:"Cacciola",slug:"santa-olga-cacciola",fullName:"Santa Olga Cacciola"},{id:"196942",title:"Dr.",name:"Antonella",middleName:null,surname:"Pane",slug:"antonella-pane",fullName:"Antonella Pane"},{id:"196943",title:"Prof.",name:"Ali",middleName:null,surname:"Chriki",slug:"ali-chriki",fullName:"Ali Chriki"}]},{id:"67930",title:"Impact of Climate Change on Plant Diseases and IPM Strategies",slug:"impact-of-climate-change-on-plant-diseases-and-ipm-strategies",totalDownloads:1988,totalCrossrefCites:7,totalDimensionsCites:10,abstract:"There has been a remarkable scientific output on the topic of how climate change is likely to affect plant diseases. Climate change influences the occurrence, prevalence, and severity of plant diseases. Projected atmospheric and climate change will thus affect the interaction between crops and pathogens in multiple ways. This will also affect disease management with regard to timing, preference, and efficacy of chemical, physical, and biological measures of control and their utilization within integrated pest management (IPM) strategies. Prediction of future requirements in disease management is of great interest for agro-industries, extension services, and practical farmers. A comprehensive analysis of potential climate change effects on disease control is difficult because current knowledge is limited and fragmented and due to the complexity of future risks for plant disease management, particularly if new crops are introduced in an area. Uncertainty in models of plant disease development under climate change calls for a diversity of management strategies, from more participatory approaches to interdisciplinary science. Involvement of stakeholders and scientists from outside plant pathology shows the importance of trade-offs. All these efforts and integrations will produce effective crop protection strategies using novel technologies as appropriate tools to adapt to altered climatic conditions.",book:{id:"8814",slug:"plant-diseases-current-threats-and-management-trends",title:"Plant Diseases",fullTitle:"Plant Diseases - Current Threats and Management Trends"},signatures:"Sahar Abdou Zayan",authors:null},{id:"74757",title:"The Trends in the Evaluation of Fusarium Wilt of Chickpea",slug:"the-trends-in-the-evaluation-of-fusarium-wilt-of-chickpea",totalDownloads:734,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"Chickpea (Cicer arietinum L.) is one of the important annual legume crops, cultivated throughout the India since ancient time. It is also grown in many countries of the world. The crop has been facing numerous biotic and abiotic constraints. Among biotic constraint crop affected adversely by diseases, caused by many pathogens. Ever since 1918 when for the first time wilt disease of chickpea was reported and Fusarium oxysporum f. sp. ciceri was the causal organism many strategies have been adopted to control the wilt disease. The controlling methods included conventional as well as modern one. However, more and more emphasis was given on biological control agents such as AM fungi and Trichoderma. The role of AM fungi have been evaluated for controlling the wilt disease similarly role of Trichoderma is thoroughly established biological control agent against Fusarium wilt. With the advent of modern tools and techniques developing markers, resistant varieties, all such sources enable us to reduce the effect of pathogens. Here an attempted has been made to acknowledge the trend of disease management and evaluation strategies of Fusarium wilt of chickpea for getting better yields of the crop.",book:{id:"10113",slug:"diagnostics-of-plant-diseases",title:"Diagnostics of Plant Diseases",fullTitle:"Diagnostics of Plant Diseases"},signatures:"Chandan Singh and Deepak Vyas",authors:[{id:"315463",title:"Mr.",name:"Chandan",middleName:null,surname:"Singh",slug:"chandan-singh",fullName:"Chandan Singh"},{id:"338974",title:"Prof.",name:"Deepak",middleName:null,surname:"Vyas",slug:"deepak-vyas",fullName:"Deepak Vyas"}]},{id:"60615",title:"Leaf Curl Disease: A Significant Constraint in the Production of Tomato in India",slug:"leaf-curl-disease-a-significant-constraint-in-the-production-of-tomato-in-india",totalDownloads:1457,totalCrossrefCites:3,totalDimensionsCites:5,abstract:"Tomato (Lycopersicon esculentum Mill.) is one of the most economically important vegetable crops in the world. Among the major biotic constraints, virus-associated Tomato leaf curl disease (ToLCD) is a major limiting factor affecting its cultivation and yield. Different symptoms associated with disease are reported such as leaf curling, puckering of leaves, vein yellowing, stunting, excessive branching, from pale yellowing to deep yellowing, and small leaves. The genus Begomovirus is a circular single-stranded DNA virus which is exclusively being transmitted by whitefly (Bemisia tabaci) in a persistent circulative manner. Most of the begomovirus species are monopartite (having DNA-A molecule only), except few species, which are bipartite (having DNA-A and DNA-B as the genomic component). No absolute effective control measures of the disease could be developed so far, except resistance, management of insect vectors, and altering the dates of sowing to avoid peaks of insect vector population. This chapter reports an account of history, symptoms, transmission, genome organization, distribution, and management of Tomato leaf curl disease.",book:{id:"6642",slug:"advances-in-plant-pathology",title:"Advances in Plant Pathology",fullTitle:"Advances in Plant Pathology"},signatures:"Pradeep Kumar and Manish Kumar",authors:[{id:"234558",title:"Dr.",name:"Manish",middleName:null,surname:"Kumar",slug:"manish-kumar",fullName:"Manish Kumar"},{id:"239750",title:"Ph.D. Student",name:"Pradeep",middleName:null,surname:"Kumar",slug:"pradeep-kumar",fullName:"Pradeep Kumar"}]},{id:"68015",title:"Sisal Bole Rot: An Important but Neglected Disease",slug:"sisal-bole-rot-an-important-but-neglected-disease",totalDownloads:988,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"Sisal (Agave sisalana) is one of the main sources of hard natural fibre and raw materials for the industry, medicine and handicrafts. Sisal yields a coarse and strong fibre that is increasingly being used in composite materials for automobiles, furniture, construction and plastic and paper products. Extracts of sisal contain substances with anti-inflammatory, antimicrobial and anthelmintic activities. Sisal is adapted to warm environments with low rainfall and is an excellent option for cultivation in semiarid conditions, where other crops cannot be grown. The world’s largest sisal producers are Brazil, Tanzania, China, Kenya and Madagascar. Sisal is a labour-intensive crop with great socio-economical importance as it is cultivated in poor areas employing familiar labour. Sisal bole rot is the main disease of sisal, responsible for substantial losses in producing countries. The disease is caused by certain species of the genus Aspergillus, especially the ones belonging in the section Nigri. The main symptoms are yellowing of the aerial parts and the red-coloured rot of the bole, which causes the plant to die. In this review we are going to address the taxonomy of the causal agents, disease diagnosis and epidemiology and disease management, with emphasis on biological control.",book:{id:"8814",slug:"plant-diseases-current-threats-and-management-trends",title:"Plant Diseases",fullTitle:"Plant Diseases - Current Threats and Management Trends"},signatures:"Valter Cruz-Magalhães, Jackeline Pereira Andrade, Yasmim Freitas Figueiredo, Phellippe Arthur Santos Marbach and Jorge Teodoro de Souza",authors:null}],onlineFirstChaptersFilter:{topicId:"367",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:8,limit:8,total:0},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:108,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:33,numberOfPublishedChapters:330,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:14,numberOfPublishedChapters:145,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:9,numberOfPublishedChapters:141,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:123,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:112,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:22,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:11,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:"2753-6580",doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}},{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}}]},series:{item:{id:"10",title:"Physiology",doi:"10.5772/intechopen.72796",issn:"2631-8261",scope:"Modern physiology requires a comprehensive understanding of the integration of tissues and organs throughout the mammalian body, including the cooperation between structure and function at the cellular and molecular levels governed by gene and protein expression. While a daunting task, learning is facilitated by identifying common and effective signaling pathways mediated by a variety of factors employed by nature to preserve and sustain homeostatic life. \r\nAs a leading example, the cellular interaction between intracellular concentration of Ca+2 increases, and changes in plasma membrane potential is integral for coordinating blood flow, governing the exocytosis of neurotransmitters, and modulating gene expression and cell effector secretory functions. Furthermore, in this manner, understanding the systemic interaction between the cardiovascular and nervous systems has become more important than ever as human populations' life prolongation, aging and mechanisms of cellular oxidative signaling are utilised for sustaining life. \r\nAltogether, physiological research enables our identification of distinct and precise points of transition from health to the development of multimorbidity throughout the inevitable aging disorders (e.g., diabetes, hypertension, chronic kidney disease, heart failure, peptic ulcer, inflammatory bowel disease, age-related macular degeneration, cancer). With consideration of all organ systems (e.g., brain, heart, lung, gut, skeletal and smooth muscle, liver, pancreas, kidney, eye) and the interactions thereof, this Physiology Series will address the goals of resolving (1) Aging physiology and chronic disease progression (2) Examination of key cellular pathways as they relate to calcium, oxidative stress, and electrical signaling, and (3) how changes in plasma membrane produced by lipid peroxidation products can affect aging physiology, covering new research in the area of cell, human, plant and animal physiology.",coverUrl:"https://cdn.intechopen.com/series/covers/10.jpg",latestPublicationDate:"July 20th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:14,editor:{id:"35854",title:"Prof.",name:"Tomasz",middleName:null,surname:"Brzozowski",slug:"tomasz-brzozowski",fullName:"Tomasz Brzozowski",profilePictureURL:"https://mts.intechopen.com/storage/users/35854/images/system/35854.jpg",biography:"Prof. Dr. Thomas Brzozowski works as a professor of Human Physiology and is currently Chairman at the Department of Physiology and is V-Dean of the Medical Faculty at Jagiellonian University Medical College, Cracow, Poland. His primary area of interest is physiology and pathophysiology of the gastrointestinal (GI) tract, with the major focus on the mechanism of GI mucosal defense, protection, and ulcer healing. He was a postdoctoral NIH fellow at the University of California and the Gastroenterology VA Medical Center, Irvine, Long Beach, CA, USA, and at the Gastroenterology Clinics Erlangen-Nuremberg and Munster in Germany. He has published 290 original articles in some of the most prestigious scientific journals and seven book chapters on the pathophysiology of the GI tract, gastroprotection, ulcer healing, drug therapy of peptic ulcers, hormonal regulation of the gut, and inflammatory bowel disease.",institutionString:null,institution:{name:"Jagiellonian University",institutionURL:null,country:{name:"Poland"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:4,paginationItems:[{id:"10",title:"Animal Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/10.jpg",isOpenForSubmission:!0,editor:{id:"202192",title:"Dr.",name:"Catrin",middleName:null,surname:"Rutland",slug:"catrin-rutland",fullName:"Catrin Rutland",profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",biography:"Catrin Rutland is an Associate Professor of Anatomy and Developmental Genetics at the University of Nottingham, UK. She obtained a BSc from the University of Derby, England, a master’s degree from Technische Universität München, Germany, and a Ph.D. from the University of Nottingham. She undertook a post-doctoral research fellowship in the School of Medicine before accepting tenure in Veterinary Medicine and Science. Dr. Rutland also obtained an MMedSci (Medical Education) and a Postgraduate Certificate in Higher Education (PGCHE). She is the author of more than sixty peer-reviewed journal articles, twelve books/book chapters, and more than 100 research abstracts in cardiovascular biology and oncology. She is a board member of the European Association of Veterinary Anatomists, Fellow of the Anatomical Society, and Senior Fellow of the Higher Education Academy. Dr. Rutland has also written popular science books for the public. https://orcid.org/0000-0002-2009-4898. www.nottingham.ac.uk/vet/people/catrin.rutland",institutionString:null,institution:{name:"University of Nottingham",institutionURL:null,country:{name:"United Kingdom"}}},editorTwo:null,editorThree:null},{id:"11",title:"Cell Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/11.jpg",isOpenForSubmission:!0,editor:{id:"133493",title:"Prof.",name:"Angel",middleName:null,surname:"Catala",slug:"angel-catala",fullName:"Angel Catala",profilePictureURL:"https://mts.intechopen.com/storage/users/133493/images/3091_n.jpg",biography:"Prof. Dr. Angel Catalá \r\nShort Biography Angel Catalá was born in Rodeo (San Juan, Argentina). He studied \r\nchemistry at the Universidad Nacional de La Plata, Argentina, where received aPh.D. degree in chemistry (Biological Branch) in 1965. From\r\n1964 to 1974, he worked as Assistant in Biochemistry at the School of MedicineUniversidad Nacional de La Plata, Argentina. From 1974 to 1976, he was a Fellowof the National Institutes of Health (NIH) at the University of Connecticut, Health Center, USA. From 1985 to 2004, he served as a Full Professor oBiochemistry at the Universidad Nacional de La Plata, Argentina. He is Member ofthe National Research Council (CONICET), Argentina, and Argentine Society foBiochemistry and Molecular Biology (SAIB). His laboratory has been interested for manyears in the lipid peroxidation of biological membranes from various tissues and different species. Professor Catalá has directed twelve doctoral theses, publishedover 100 papers in peer reviewed journals, several chapters in books andtwelve edited books. Angel Catalá received awards at the 40th InternationaConference Biochemistry of Lipids 1999: Dijon (France). W inner of the Bimbo PanAmerican Nutrition, Food Science and Technology Award 2006 and 2012, South AmericaHuman Nutrition, Professional Category. 2006 award in pharmacology, Bernardo\r\nHoussay, in recognition of his meritorious works of research. Angel Catalá belongto the Editorial Board of Journal of lipids, International Review of Biophysical ChemistryFrontiers in Membrane Physiology and Biophysics, World Journal oExperimental Medicine and Biochemistry Research International, W orld Journal oBiological Chemistry, Oxidative Medicine and Cellular Longevity, Diabetes and thePancreas, International Journal of Chronic Diseases & Therapy, International Journal oNutrition, Co-Editor of The Open Biology Journal.",institutionString:null,institution:{name:"National University of La Plata",institutionURL:null,country:{name:"Argentina"}}},editorTwo:null,editorThree:null},{id:"12",title:"Human Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/12.jpg",isOpenForSubmission:!0,editor:{id:"195829",title:"Prof.",name:"Kunihiro",middleName:null,surname:"Sakuma",slug:"kunihiro-sakuma",fullName:"Kunihiro Sakuma",profilePictureURL:"https://mts.intechopen.com/storage/users/195829/images/system/195829.jpg",biography:"Professor Kunihiro Sakuma, Ph.D., currently works in the Institute for Liberal Arts at the Tokyo Institute of Technology. He is a physiologist working in the field of skeletal muscle. He was awarded his sports science diploma in 1995 by the University of Tsukuba and began his scientific work at the Department of Physiology, Aichi Human Service Center, focusing on the molecular mechanism of congenital muscular dystrophy and normal muscle regeneration. His interest later turned to the molecular mechanism and attenuating strategy of sarcopenia (age-related muscle atrophy). His opinion is to attenuate sarcopenia by improving autophagic defects using nutrient- and pharmaceutical-based treatments.",institutionString:null,institution:{name:"Tokyo Institute of Technology",institutionURL:null,country:{name:"Japan"}}},editorTwo:{id:"331519",title:"Dr.",name:"Kotomi",middleName:null,surname:"Sakai",slug:"kotomi-sakai",fullName:"Kotomi Sakai",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000031QtFXQA0/Profile_Picture_1637053227318",biography:"Senior researcher Kotomi Sakai, Ph.D., MPH, works at the Research Organization of Science and Technology in Ritsumeikan University. She is a researcher in the geriatric rehabilitation and public health field. She received Ph.D. from Nihon University and MPH from St.Luke’s International University. Her main research interest is sarcopenia in older adults, especially its association with nutritional status. Additionally, to understand how to maintain and improve physical function in older adults, to conduct studies about the mechanism of sarcopenia and determine when possible interventions are needed.",institutionString:null,institution:{name:"Ritsumeikan University",institutionURL:null,country:{name:"Japan"}}},editorThree:null},{id:"13",title:"Plant Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/13.jpg",isOpenForSubmission:!0,editor:{id:"332229",title:"Prof.",name:"Jen-Tsung",middleName:null,surname:"Chen",slug:"jen-tsung-chen",fullName:"Jen-Tsung Chen",profilePictureURL:"https://mts.intechopen.com/storage/users/332229/images/system/332229.png",biography:"Dr. Jen-Tsung Chen is currently a professor at the National University of Kaohsiung, Taiwan. He teaches cell biology, genomics, proteomics, medicinal plant biotechnology, and plant tissue culture. Dr. Chen\\'s research interests include bioactive compounds, chromatography techniques, in vitro culture, medicinal plants, phytochemicals, and plant biotechnology. He has published more than ninety scientific papers and serves as an editorial board member for Plant Methods, Biomolecules, and International Journal of Molecular Sciences.",institutionString:"National University of Kaohsiung",institution:{name:"National University of Kaohsiung",institutionURL:null,country:{name:"Taiwan"}}},editorTwo:null,editorThree:null}]},overviewPageOFChapters:{paginationCount:16,paginationItems:[{id:"82135",title:"Carotenoids in Cassava (Manihot esculenta Crantz)",doi:"10.5772/intechopen.105210",signatures:"Lovina I. Udoh, Josephine U. Agogbua, Eberechi R. Keyagha and Itorobong I. Nkanga",slug:"carotenoids-in-cassava-manihot-esculenta-crantz",totalDownloads:15,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Carotenoids - New Perspectives and Application",coverURL:"https://cdn.intechopen.com/books/images_new/10836.jpg",subseries:{id:"13",title:"Plant Physiology"}}},{id:"82112",title:"Comparative Senescence and Lifespan",doi:"10.5772/intechopen.105137",signatures:"Hassan M. Heshmati",slug:"comparative-senescence-and-lifespan",totalDownloads:17,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Hassan M.",surname:"Heshmati"}],book:{title:"Mechanisms and Management of Senescence",coverURL:"https://cdn.intechopen.com/books/images_new/10935.jpg",subseries:{id:"11",title:"Cell Physiology"}}},{id:"81796",title:"Apoptosis-Related Diseases and Peroxisomes",doi:"10.5772/intechopen.105052",signatures:"Meimei Wang, Yakun Liu, Ni Chen, Juan Wang and Ye Zhao",slug:"apoptosis-related-diseases-and-peroxisomes",totalDownloads:11,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"The Metabolic Role of Peroxisome in Health and Disease",coverURL:"https://cdn.intechopen.com/books/images_new/10837.jpg",subseries:{id:"11",title:"Cell Physiology"}}},{id:"81723",title:"Peroxisomal Modulation as Therapeutic Alternative for Tackling Multiple Cancers",doi:"10.5772/intechopen.104873",signatures:"Shazia Usmani, Shadma Wahab, Abdul Hafeez, Shabana Khatoon and Syed Misbahul Hasan",slug:"peroxisomal-modulation-as-therapeutic-alternative-for-tackling-multiple-cancers",totalDownloads:12,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"The Metabolic Role of Peroxisome in Health and Disease",coverURL:"https://cdn.intechopen.com/books/images_new/10837.jpg",subseries:{id:"11",title:"Cell Physiology"}}}]},overviewPagePublishedBooks:{paginationCount:14,paginationItems:[{type:"book",id:"7264",title:"Calcium and Signal Transduction",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7264.jpg",slug:"calcium-and-signal-transduction",publishedDate:"October 24th 2018",editedByType:"Edited by",bookSignature:"John N. Buchholz and Erik J. Behringer",hash:"e373a3d1123dbd45fddf75d90e3e7c38",volumeInSeries:1,fullTitle:"Calcium and Signal Transduction",editors:[{id:"89438",title:"Dr.",name:"John N.",middleName:null,surname:"Buchholz",slug:"john-n.-buchholz",fullName:"John N. Buchholz",profilePictureURL:"https://mts.intechopen.com/storage/users/89438/images/6463_n.jpg",biography:"Full Professor and Vice Chair, Division of Pharmacology, Loma Linda University, School of Medicine. He received his B.S. Degree in Biology at La Sierra University, Riverside California (1980) and a PhD in Pharmacology from Loma Linda University School of Medicine (1988). Post-Doctoral Fellow at University of California, Irvine, College of Medicine 1989-1992 with a focus on autonomic nerve function in blood vessels and the impact of aging on the function of these nerves and overall blood vessel function. Twenty years of research funding and served on NIH R01 review panels, Editor-In-Chief of Edorium Journal of Aging Research. Serves as a peer reviewer for biomedical journals. Military Reserve Officer serving with the 100 Support Command, 100 Troop Command, 40 Infantry Division, CA National Guard.",institutionString:null,institution:{name:"Loma Linda University",institutionURL:null,country:{name:"United States of America"}}}]},{type:"book",id:"6925",title:"Endoplasmic Reticulum",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6925.jpg",slug:"endoplasmic-reticulum",publishedDate:"April 17th 2019",editedByType:"Edited by",bookSignature:"Angel Català",hash:"a9e90d2dbdbc46128dfe7dac9f87c6b4",volumeInSeries:2,fullTitle:"Endoplasmic Reticulum",editors:[{id:"196544",title:"Prof.",name:"Angel",middleName:null,surname:"Catala",slug:"angel-catala",fullName:"Angel Catala",profilePictureURL:"https://mts.intechopen.com/storage/users/196544/images/system/196544.jpg",biography:"Angel Catalá studied chemistry at Universidad Nacional de La Plata, Argentina, where he received a Ph.D. in Chemistry (Biological Branch) in 1965. From 1964 to 1974, he worked as an Assistant in Biochemistry at the School of Medicine at the same university. From 1974 to 1976, he was a fellow of the National Institutes of Health (NIH) at the University of Connecticut, Health Center, USA. From 1985 to 2004, he served as a Full Professor of Biochemistry at the Universidad Nacional de La Plata. He is a member of the National Research Council (CONICET), Argentina, and the Argentine Society for Biochemistry and Molecular Biology (SAIB). His laboratory has been interested for many years in the lipid peroxidation of biological membranes from various tissues and different species. Dr. Catalá has directed twelve doctoral theses, published more than 100 papers in peer-reviewed journals, several chapters in books, and edited twelve books. He received awards at the 40th International Conference Biochemistry of Lipids 1999 in Dijon, France. He is the winner of the Bimbo Pan-American Nutrition, Food Science and Technology Award 2006 and 2012, South America, Human Nutrition, Professional Category. In 2006, he won the Bernardo Houssay award in pharmacology, in recognition of his meritorious works of research. Dr. Catalá belongs to the editorial board of several journals including Journal of Lipids; International Review of Biophysical Chemistry; Frontiers in Membrane Physiology and Biophysics; World Journal of Experimental Medicine and Biochemistry Research International; World Journal of Biological Chemistry, Diabetes, and the Pancreas; International Journal of Chronic Diseases & Therapy; and International Journal of Nutrition. He is the co-editor of The Open Biology Journal and associate editor for Oxidative Medicine and Cellular Longevity.",institutionString:"Universidad Nacional de La Plata",institution:{name:"National University of La Plata",institutionURL:null,country:{name:"Argentina"}}}]},{type:"book",id:"6924",title:"Adenosine Triphosphate in Health and Disease",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6924.jpg",slug:"adenosine-triphosphate-in-health-and-disease",publishedDate:"April 24th 2019",editedByType:"Edited by",bookSignature:"Gyula Mozsik",hash:"04106c232a3c68fec07ba7cf00d2522d",volumeInSeries:3,fullTitle:"Adenosine Triphosphate in Health and Disease",editors:[{id:"58390",title:"Dr.",name:"Gyula",middleName:null,surname:"Mozsik",slug:"gyula-mozsik",fullName:"Gyula Mozsik",profilePictureURL:"https://mts.intechopen.com/storage/users/58390/images/system/58390.png",biography:"Gyula Mózsik MD, Ph.D., ScD (med), is an emeritus professor of Medicine at the First Department of Medicine, Univesity of Pécs, Hungary. He was head of this department from 1993 to 2003. His specializations are medicine, gastroenterology, clinical pharmacology, clinical nutrition, and dietetics. His research fields are biochemical pharmacological examinations in the human gastrointestinal (GI) mucosa, mechanisms of retinoids, drugs, capsaicin-sensitive afferent nerves, and innovative pharmacological, pharmaceutical, and nutritional (dietary) research in humans. He has published about 360 peer-reviewed papers, 197 book chapters, 692 abstracts, 19 monographs, and has edited 37 books. He has given about 1120 regular and review lectures. He has organized thirty-eight national and international congresses and symposia. He is the founder of the International Conference on Ulcer Research (ICUR); International Union of Pharmacology, Gastrointestinal Section (IUPHAR-GI); Brain-Gut Society symposiums, and gastrointestinal cytoprotective symposiums. He received the Andre Robert Award from IUPHAR-GI in 2014. Fifteen of his students have been appointed as full professors in Egypt, Cuba, and Hungary.",institutionString:"University of Pécs",institution:{name:"University of Pecs",institutionURL:null,country:{name:"Hungary"}}}]},{type:"book",id:"8008",title:"Antioxidants",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8008.jpg",slug:"antioxidants",publishedDate:"November 6th 2019",editedByType:"Edited by",bookSignature:"Emad Shalaby",hash:"76361b4061e830906267933c1c670027",volumeInSeries:5,fullTitle:"Antioxidants",editors:[{id:"63600",title:"Prof.",name:"Emad",middleName:null,surname:"Shalaby",slug:"emad-shalaby",fullName:"Emad Shalaby",profilePictureURL:"https://mts.intechopen.com/storage/users/63600/images/system/63600.png",biography:"Dr. Emad Shalaby is a professor of biochemistry on the Biochemistry Department Faculty of Agriculture, Cairo University. He\nreceived a short-term scholarship to carry out his post-doctoral\nstudies abroad, from Japan International Cooperation Agency\n(JICA), in coordination with the Egyptian government. Dr.\nShalaby speaks fluent English and his native Arabic. He has 77\ninternationally published research papers, has attended 15 international conferences, and has contributed to 18 international books and chapters.\nDr. Shalaby works as a reviewer on over one hundred international journals and is\non the editorial board of more than twenty-five international journals. He is a member of seven international specialized scientific societies, besides his local one, and\nhe has won seven prizes.",institutionString:"Cairo University",institution:{name:"Cairo University",institutionURL:null,country:{name:"Egypt"}}}]}]},openForSubmissionBooks:{paginationCount:0,paginationItems:[]},onlineFirstChapters:{paginationCount:27,paginationItems:[{id:"83092",title:"Novel Composites for Bone Tissue Engineering",doi:"10.5772/intechopen.106255",signatures:"Pugalanthipandian Sankaralingam, Poornimadevi Sakthivel and Vijayakumar Chinnaswamy Thangavel",slug:"novel-composites-for-bone-tissue-engineering",totalDownloads:0,totalCrossrefCites:null,totalDimensionsCites:0,authors:null,book:{title:"Biomimetics - Bridging the Gap",coverURL:"https://cdn.intechopen.com/books/images_new/11453.jpg",subseries:{id:"8",title:"Bioinspired Technology and Biomechanics"}}},{id:"82800",title:"Repurposing Drugs as Potential Therapeutics for the SARS-Cov-2 Viral Infection: Automatizing a Blind Molecular Docking High-throughput Pipeline",doi:"10.5772/intechopen.105792",signatures:"Aldo Herrera-Rodulfo, Mariana Andrade-Medina and Mauricio Carrillo-Tripp",slug:"repurposing-drugs-as-potential-therapeutics-for-the-sars-cov-2-viral-infection-automatizing-a-blind-",totalDownloads:7,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Molecular Docking - Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/11451.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"82582",title:"Protecting Bioelectric Signals from Electromagnetic Interference in a Wireless World",doi:"10.5772/intechopen.105951",signatures:"David Marcarian",slug:"protecting-bioelectric-signals-from-electromagnetic-interference-in-a-wireless-world",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"82586",title:"Fundamentals of Molecular Docking and Comparative Analysis of Protein–Small-Molecule Docking Approaches",doi:"10.5772/intechopen.105815",signatures:"Maden Sefika Feyza, Sezer Selin and Acuner Saliha Ece",slug:"fundamentals-of-molecular-docking-and-comparative-analysis-of-protein-small-molecule-docking-approac",totalDownloads:27,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Molecular Docking - Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/11451.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"82392",title:"Nanomaterials as Novel Biomarkers for Cancer Nanotheranostics: State of the Art",doi:"10.5772/intechopen.105700",signatures:"Hao Yu, Zhihai Han, Cunrong Chen and Leisheng Zhang",slug:"nanomaterials-as-novel-biomarkers-for-cancer-nanotheranostics-state-of-the-art",totalDownloads:23,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biotechnology - Biosensors, Biomaterials and Tissue Engineering - Annual Volume 2022",coverURL:"https://cdn.intechopen.com/books/images_new/11405.jpg",subseries:{id:"9",title:"Biotechnology - Biosensors, Biomaterials and Tissue Engineering"}}},{id:"82184",title:"Biological Sensing Using Infrared SPR Devices Based on ZnO",doi:"10.5772/intechopen.104562",signatures:"Hiroaki Matsui",slug:"biological-sensing-using-infrared-spr-devices-based-on-zno",totalDownloads:10,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Hiroaki",surname:"Matsui"}],book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"82122",title:"Recent Advances in Biosensing in Tissue Engineering and Regenerative Medicine",doi:"10.5772/intechopen.104922",signatures:"Alma T. Banigo, Chigozie A. Nnadiekwe and Emmanuel M. Beasi",slug:"recent-advances-in-biosensing-in-tissue-engineering-and-regenerative-medicine",totalDownloads:22,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"82080",title:"The Clinical Usefulness of Prostate Cancer Biomarkers: Current and Future Directions",doi:"10.5772/intechopen.103172",signatures:"Donovan McGrowder, Lennox Anderson-Jackson, Lowell Dilworth, Shada Mohansingh, Melisa Anderson Cross, Sophia Bryan, Fabian Miller, Cameil Wilson-Clarke, Chukwuemeka Nwokocha, Ruby Alexander-Lindo and Shelly McFarlane",slug:"the-clinical-usefulness-of-prostate-cancer-biomarkers-current-and-future-directions",totalDownloads:16,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Cancer Bioinformatics",coverURL:"https://cdn.intechopen.com/books/images_new/10661.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"82005",title:"Non-Invasive Approach for Glucose Detection in Urine Quality using Its Image Analysis",doi:"10.5772/intechopen.104791",signatures:"Anton Yudhana, Liya Yusrina Sabila, Arsyad Cahya Subrata, Hendriana Helda Pratama and Muhammad Syahrul Akbar",slug:"non-invasive-approach-for-glucose-detection-in-urine-quality-using-its-image-analysis",totalDownloads:8,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"81778",title:"Influence of Mechanical Properties of Biomaterials on the Reconstruction of Biomedical Parts via Additive Manufacturing Techniques: An Overview",doi:"10.5772/intechopen.104465",signatures:"Babatunde Olamide Omiyale, Akeem Abiodun Rasheed, Robinson Omoboyode Akinnusi and Temitope Olumide Olugbade",slug:"influence-of-mechanical-properties-of-biomaterials-on-the-reconstruction-of-biomedical-parts-via-add",totalDownloads:11,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biotechnology - Biosensors, Biomaterials and Tissue Engineering - Annual Volume 2022",coverURL:"https://cdn.intechopen.com/books/images_new/11405.jpg",subseries:{id:"9",title:"Biotechnology - Biosensors, Biomaterials and Tissue Engineering"}}}]},subseriesFiltersForOFChapters:[{caption:"Bioinspired Technology and Biomechanics",value:8,count:1,group:"subseries"},{caption:"Biotechnology - Biosensors, Biomaterials and Tissue Engineering",value:9,count:2,group:"subseries"},{caption:"Bioinformatics and Medical Informatics",value:7,count:20,group:"subseries"}],publishedBooks:{paginationCount:9,paginationItems:[{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",publishedDate:"July 27th 2022",editedByType:"Edited by",bookSignature:"Dragana Gabrić and Marko Vuletić",hash:"4af8830e463f89c57515c2da2b9777b0",volumeInSeries:11,fullTitle:"Current Concepts in Dental Implantology - From Science to Clinical Research",editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić",profilePictureURL:"https://mts.intechopen.com/storage/users/26946/images/system/26946.png",institutionString:"University of Zagreb",institution:{name:"University of Zagreb",institutionURL:null,country:{name:"Croatia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9493",title:"Periodontology",subtitle:"Fundamentals and Clinical Features",coverURL:"https://cdn.intechopen.com/books/images_new/9493.jpg",slug:"periodontology-fundamentals-and-clinical-features",publishedDate:"February 16th 2022",editedByType:"Edited by",bookSignature:"Petra Surlin",hash:"dfe986c764d6c82ae820c2df5843a866",volumeInSeries:8,fullTitle:"Periodontology - Fundamentals and Clinical Features",editors:[{id:"171921",title:"Prof.",name:"Petra",middleName:null,surname:"Surlin",slug:"petra-surlin",fullName:"Petra Surlin",profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institutionString:"University of Medicine and Pharmacy of Craiova",institution:{name:"University of Medicine and Pharmacy of Craiova",institutionURL:null,country:{name:"Romania"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9588",title:"Clinical Concepts and Practical Management Techniques in Dentistry",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9588.jpg",slug:"clinical-concepts-and-practical-management-techniques-in-dentistry",publishedDate:"February 9th 2022",editedByType:"Edited by",bookSignature:"Aneesa Moolla",hash:"42deab8d3bcf3edf64d1d9028d42efd1",volumeInSeries:7,fullTitle:"Clinical Concepts and Practical Management Techniques in Dentistry",editors:[{id:"318170",title:"Dr.",name:"Aneesa",middleName:null,surname:"Moolla",slug:"aneesa-moolla",fullName:"Aneesa Moolla",profilePictureURL:"https://mts.intechopen.com/storage/users/318170/images/system/318170.png",institutionString:"University of the Witwatersrand",institution:{name:"University of the Witwatersrand",institutionURL:null,country:{name:"South Africa"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8202",title:"Periodontal Disease",subtitle:"Diagnostic and Adjunctive Non-surgical Considerations",coverURL:"https://cdn.intechopen.com/books/images_new/8202.jpg",slug:"periodontal-disease-diagnostic-and-adjunctive-non-surgical-considerations",publishedDate:"February 5th 2020",editedByType:"Edited by",bookSignature:"Nermin Mohammed Ahmed Yussif",hash:"0aee9799da7db2c732be44dd8fed16d8",volumeInSeries:6,fullTitle:"Periodontal Disease - Diagnostic and Adjunctive Non-surgical Considerations",editors:[{id:"210472",title:"Dr.",name:"Nermin",middleName:"Mohammed Ahmed",surname:"Yussif",slug:"nermin-yussif",fullName:"Nermin Yussif",profilePictureURL:"https://mts.intechopen.com/storage/users/210472/images/system/210472.jpg",institutionString:"MSA University",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8837",title:"Human Teeth",subtitle:"Key Skills and Clinical Illustrations",coverURL:"https://cdn.intechopen.com/books/images_new/8837.jpg",slug:"human-teeth-key-skills-and-clinical-illustrations",publishedDate:"January 22nd 2020",editedByType:"Edited by",bookSignature:"Zühre Akarslan and Farid Bourzgui",hash:"ac055c5801032970123e0a196c2e1d32",volumeInSeries:5,fullTitle:"Human Teeth - Key Skills and Clinical Illustrations",editors:[{id:"171887",title:"Prof.",name:"Zühre",middleName:null,surname:"Akarslan",slug:"zuhre-akarslan",fullName:"Zühre Akarslan",profilePictureURL:"https://mts.intechopen.com/storage/users/171887/images/system/171887.jpg",institutionString:"Gazi University",institution:{name:"Gazi University",institutionURL:null,country:{name:"Turkey"}}}],equalEditorOne:{id:"52177",title:"Prof.",name:"Farid",middleName:null,surname:"Bourzgui",slug:"farid-bourzgui",fullName:"Farid Bourzgui",profilePictureURL:"https://mts.intechopen.com/storage/users/52177/images/system/52177.png",biography:"Prof. Farid Bourzgui obtained his DMD and his DNSO option in Orthodontics at the School of Dental Medicine, Casablanca Hassan II University, Morocco, in 1995 and 2000, respectively. Currently, he is a professor of Orthodontics. He holds a Certificate of Advanced Study type A in Technology of Biomaterials used in Dentistry (1995); Certificate of Advanced Study type B in Dento-Facial Orthopaedics (1997) from the Faculty of Dental Surgery, University Denis Diderot-Paris VII, France; Diploma of Advanced Study (DESA) in Biocompatibility of Biomaterials from the Faculty of Medicine and Pharmacy of Casablanca (2002); Certificate of Clinical Occlusodontics from the Faculty of Dentistry of Casablanca (2004); University Diploma of Biostatistics and Perceptual Health Measurement from the Faculty of Medicine and Pharmacy of Casablanca (2011); and a University Diploma of Pedagogy of Odontological Sciences from the Faculty of Dentistry of Casablanca (2013). He is the author of several scientific articles, book chapters, and books.",institutionString:"University of Hassan II Casablanca",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"7",totalChapterViews:"0",totalEditedBooks:"2",institution:{name:"University of Hassan II Casablanca",institutionURL:null,country:{name:"Morocco"}}},equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7060",title:"Gingival Disease",subtitle:"A Professional Approach for Treatment and Prevention",coverURL:"https://cdn.intechopen.com/books/images_new/7060.jpg",slug:"gingival-disease-a-professional-approach-for-treatment-and-prevention",publishedDate:"October 23rd 2019",editedByType:"Edited by",bookSignature:"Alaa Eddin Omar Al Ostwani",hash:"b81d39988cba3a3cf746c1616912cf41",volumeInSeries:4,fullTitle:"Gingival Disease - A Professional Approach for Treatment and Prevention",editors:[{id:"240870",title:"Ph.D.",name:"Alaa Eddin Omar",middleName:null,surname:"Al Ostwani",slug:"alaa-eddin-omar-al-ostwani",fullName:"Alaa Eddin Omar Al Ostwani",profilePictureURL:"https://mts.intechopen.com/storage/users/240870/images/system/240870.jpeg",institutionString:"International University for Science and Technology.",institution:{name:"Islamic University of Science and Technology",institutionURL:null,country:{name:"India"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7572",title:"Trauma in Dentistry",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7572.jpg",slug:"trauma-in-dentistry",publishedDate:"July 3rd 2019",editedByType:"Edited by",bookSignature:"Serdar Gözler",hash:"7cb94732cfb315f8d1e70ebf500eb8a9",volumeInSeries:3,fullTitle:"Trauma in Dentistry",editors:[{id:"204606",title:"Dr.",name:"Serdar",middleName:null,surname:"Gözler",slug:"serdar-gozler",fullName:"Serdar Gözler",profilePictureURL:"https://mts.intechopen.com/storage/users/204606/images/system/204606.jpeg",institutionString:"Istanbul Aydin University",institution:{name:"Istanbul Aydın University",institutionURL:null,country:{name:"Turkey"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7139",title:"Current Approaches in Orthodontics",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7139.jpg",slug:"current-approaches-in-orthodontics",publishedDate:"April 10th 2019",editedByType:"Edited by",bookSignature:"Belma Işık Aslan and Fatma Deniz Uzuner",hash:"2c77384eeb748cf05a898d65b9dcb48a",volumeInSeries:2,fullTitle:"Current Approaches in Orthodontics",editors:[{id:"42847",title:"Dr.",name:"Belma",middleName:null,surname:"Işik Aslan",slug:"belma-isik-aslan",fullName:"Belma Işik Aslan",profilePictureURL:"https://mts.intechopen.com/storage/users/42847/images/system/42847.jpg",institutionString:"Gazi University Dentistry Faculty Department of Orthodontics",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"6668",title:"Dental Caries",subtitle:"Diagnosis, Prevention and Management",coverURL:"https://cdn.intechopen.com/books/images_new/6668.jpg",slug:"dental-caries-diagnosis-prevention-and-management",publishedDate:"September 19th 2018",editedByType:"Edited by",bookSignature:"Zühre Akarslan",hash:"b0f7667770a391f772726c3013c1b9ba",volumeInSeries:1,fullTitle:"Dental Caries - Diagnosis, Prevention and Management",editors:[{id:"171887",title:"Prof.",name:"Zühre",middleName:null,surname:"Akarslan",slug:"zuhre-akarslan",fullName:"Zühre Akarslan",profilePictureURL:"https://mts.intechopen.com/storage/users/171887/images/system/171887.jpg",institutionString:"Gazi University",institution:{name:"Gazi University",institutionURL:null,country:{name:"Turkey"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},subseriesFiltersForPublishedBooks:[{group:"subseries",caption:"Prosthodontics and Implant Dentistry",value:2,count:3},{group:"subseries",caption:"Oral Health",value:1,count:6}],publicationYearFilters:[{group:"publicationYear",caption:"2022",value:2022,count:3},{group:"publicationYear",caption:"2020",value:2020,count:2},{group:"publicationYear",caption:"2019",value:2019,count:3},{group:"publicationYear",caption:"2018",value:2018,count:1}],authors:{paginationCount:148,paginationItems:[{id:"165328",title:"Dr.",name:"Vahid",middleName:null,surname:"Asadpour",slug:"vahid-asadpour",fullName:"Vahid Asadpour",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/165328/images/system/165328.jpg",biography:"Vahid Asadpour, MS, Ph.D., is currently with the Department of Research and Evaluation, Kaiser Permanente Southern California. He has both an MS and Ph.D. in Biomedical Engineering. He was previously a research scientist at the University of California Los Angeles (UCLA) and visiting professor and researcher at the University of North Dakota. He is currently working in artificial intelligence and its applications in medical signal processing. In addition, he is using digital signal processing in medical imaging and speech processing. Dr. Asadpour has developed brain-computer interfacing algorithms and has published books, book chapters, and several journal and conference papers in this field and other areas of intelligent signal processing. He has also designed medical devices, including a laser Doppler monitoring system.",institutionString:"Kaiser Permanente Southern California",institution:null},{id:"169608",title:"Prof.",name:"Marian",middleName:null,surname:"Găiceanu",slug:"marian-gaiceanu",fullName:"Marian Găiceanu",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/169608/images/system/169608.png",biography:"Prof. Dr. Marian Gaiceanu graduated from the Naval and Electrical Engineering Faculty, Dunarea de Jos University of Galati, Romania, in 1997. He received a Ph.D. (Magna Cum Laude) in Electrical Engineering in 2002. Since 2017, Dr. Gaiceanu has been a Ph.D. supervisor for students in Electrical Engineering. He has been employed at Dunarea de Jos University of Galati since 1996, where he is currently a professor. Dr. Gaiceanu is a member of the National Council for Attesting Titles, Diplomas and Certificates, an expert of the Executive Agency for Higher Education, Research Funding, and a member of the Senate of the Dunarea de Jos University of Galati. He has been the head of the Integrated Energy Conversion Systems and Advanced Control of Complex Processes Research Center, Romania, since 2016. He has conducted several projects in power converter systems for electrical drives, power quality, PEM and SOFC fuel cell power converters for utilities, electric vehicles, and marine applications with the Department of Regulation and Control, SIEI S.pA. (2002–2004) and the Polytechnic University of Turin, Italy (2002–2004, 2006–2007). He is a member of the Institute of Electrical and Electronics Engineers (IEEE) and cofounder-member of the IEEE Power Electronics Romanian Chapter. He is a guest editor at Energies and an academic book editor for IntechOpen. He is also a member of the editorial boards of the Journal of Electrical Engineering, Electronics, Control and Computer Science and Sustainability. Dr. Gaiceanu has been General Chairman of the IEEE International Symposium on Electrical and Electronics Engineering in the last six editions.",institutionString:'"Dunarea de Jos" University of Galati',institution:{name:'"Dunarea de Jos" University of Galati',country:{name:"Romania"}}},{id:"4519",title:"Prof.",name:"Jaydip",middleName:null,surname:"Sen",slug:"jaydip-sen",fullName:"Jaydip Sen",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/4519/images/system/4519.jpeg",biography:"Jaydip Sen is associated with Praxis Business School, Kolkata, India, as a professor in the Department of Data Science. His research areas include security and privacy issues in computing and communication, intrusion detection systems, machine learning, deep learning, and artificial intelligence in the financial domain. He has more than 200 publications in reputed international journals, refereed conference proceedings, and 20 book chapters in books published by internationally renowned publishing houses, such as Springer, CRC press, IGI Global, etc. Currently, he is serving on the editorial board of the prestigious journal Frontiers in Communications and Networks and in the technical program committees of a number of high-ranked international conferences organized by the IEEE, USA, and the ACM, USA. He has been listed among the top 2% of scientists in the world for the last three consecutive years, 2019 to 2021 as per studies conducted by the Stanford University, USA.",institutionString:"Praxis Business School",institution:null},{id:"320071",title:"Dr.",name:"Sidra",middleName:null,surname:"Mehtab",slug:"sidra-mehtab",fullName:"Sidra Mehtab",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00002v6KHoQAM/Profile_Picture_1584512086360",biography:"Sidra Mehtab has completed her BS with honors in Physics from Calcutta University, India in 2018. She has done MS in Data Science and Analytics from Maulana Abul Kalam Azad University of Technology (MAKAUT), Kolkata, India in 2020. Her research areas include Econometrics, Time Series Analysis, Machine Learning, Deep Learning, Artificial Intelligence, and Computer and Network Security with a particular focus on Cyber Security Analytics. Ms. Mehtab has published seven papers in international conferences and one of her papers has been accepted for publication in a reputable international journal. She has won the best paper awards in two prestigious international conferences – BAICONF 2019, and ICADCML 2021, organized in the Indian Institute of Management, Bangalore, India in December 2019, and SOA University, Bhubaneswar, India in January 2021. Besides, Ms. Mehtab has also published two book chapters in two books. Seven of her book chapters will be published in a volume shortly in 2021 by Cambridge Scholars’ Press, UK. Currently, she is working as the joint editor of two edited volumes on Time Series Analysis and Forecasting to be published in the first half of 2021 by an international house. Currently, she is working as a Data Scientist with an MNC in Delhi, India.",institutionString:"NSHM College of Management and Technology",institution:{name:"Association for Computing Machinery",country:{name:"United States of America"}}},{id:"226240",title:"Dr.",name:"Andri Irfan",middleName:null,surname:"Rifai",slug:"andri-irfan-rifai",fullName:"Andri Irfan Rifai",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/226240/images/7412_n.jpg",biography:"Andri IRFAN is a Senior Lecturer of Civil Engineering and Planning. He completed the PhD at the Universitas Indonesia & Universidade do Minho with Sandwich Program Scholarship from the Directorate General of Higher Education and LPDP scholarship. He has been teaching for more than 19 years and much active to applied his knowledge in the project construction in Indonesia. His research interest ranges from pavement management system to advanced data mining techniques for transportation engineering. He has published more than 50 papers in journals and 2 books.",institutionString:null,institution:{name:"Universitas Internasional Batam",country:{name:"Indonesia"}}},{id:"314576",title:"Dr.",name:"Ibai",middleName:null,surname:"Laña",slug:"ibai-lana",fullName:"Ibai Laña",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/314576/images/system/314576.jpg",biography:"Dr. Ibai Laña works at TECNALIA as a data analyst. He received his Ph.D. in Artificial Intelligence from the University of the Basque Country (UPV/EHU), Spain, in 2018. He is currently a senior researcher at TECNALIA. His research interests fall within the intersection of intelligent transportation systems, machine learning, traffic data analysis, and data science. He has dealt with urban traffic forecasting problems, applying machine learning models and evolutionary algorithms. He has experience in origin-destination matrix estimation or point of interest and trajectory detection. Working with large volumes of data has given him a good command of big data processing tools and NoSQL databases. He has also been a visiting scholar at the Knowledge Engineering and Discovery Research Institute, Auckland University of Technology.",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",country:{name:"Spain"}}},{id:"314575",title:"Dr.",name:"Jesus",middleName:null,surname:"L. Lobo",slug:"jesus-l.-lobo",fullName:"Jesus L. Lobo",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/314575/images/system/314575.png",biography:"Dr. Jesús López is currently based in Bilbao (Spain) working at TECNALIA as Artificial Intelligence Research Scientist. In most cases, a project idea or a new research line needs to be investigated to see if it is good enough to take into production or to focus on it. That is exactly what he does, diving into Machine Learning algorithms and technologies to help TECNALIA to decide whether something is great in theory or will actually impact on the product or processes of its projects. So, he is expert at framing experiments, developing hypotheses, and proving whether they’re true or not, in order to investigate fundamental problems with a longer time horizon. He is also able to design and develop PoCs and system prototypes in simulation. He has participated in several national and internacional R&D projects.\n\nAs another relevant part of his everyday research work, he usually publishes his findings in reputed scientific refereed journals and international conferences, occasionally acting as reviewer and Programme Commitee member. Concretely, since 2018 he has published 9 JCR (8 Q1) journal papers, 9 conference papers (e.g. ECML PKDD 2021), and he has co-edited a book. He is also active in popular science writing data science stories for reputed blogs (KDNuggets, TowardsDataScience, Naukas). Besides, he has recently embarked on mentoring programmes as mentor, and has also worked as data science trainer.",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",country:{name:"Spain"}}},{id:"103779",title:"Prof.",name:"Yalcin",middleName:null,surname:"Isler",slug:"yalcin-isler",fullName:"Yalcin Isler",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRyQ8QAK/Profile_Picture_1628834958734",biography:"Yalcin Isler (1971 - Burdur / Turkey) received the B.Sc. degree in the Department of Electrical and Electronics Engineering from Anadolu University, Eskisehir, Turkey, in 1993, the M.Sc. degree from the Department of Electronics and Communication Engineering, Suleyman Demirel University, Isparta, Turkey, in 1996, the Ph.D. degree from the Department of Electrical and Electronics Engineering, Dokuz Eylul University, Izmir, Turkey, in 2009, and the Competence of Associate Professorship from the Turkish Interuniversity Council in 2019.\n\nHe was Lecturer at Burdur Vocational School in Suleyman Demirel University (1993-2000, Burdur / Turkey), Software Engineer (2000-2002, Izmir / Turkey), Research Assistant in Bulent Ecevit University (2002-2003, Zonguldak / Turkey), Research Assistant in Dokuz Eylul University (2003-2010, Izmir / Turkey), Assistant Professor at the Department of Electrical and Electronics Engineering in Bulent Ecevit University (2010-2012, Zonguldak / Turkey), Assistant Professor at the Department of Biomedical Engineering in Izmir Katip Celebi University (2012-2019, Izmir / Turkey). He is an Associate Professor at the Department of Biomedical Engineering at Izmir Katip Celebi University, Izmir / Turkey, since 2019. In addition to academics, he has also founded Islerya Medical and Information Technologies Company, Izmir / Turkey, since 2017.\n\nHis main research interests cover biomedical signal processing, pattern recognition, medical device design, programming, and embedded systems. He has many scientific papers and participated in several projects in these study fields. He was an IEEE Student Member (2009-2011) and IEEE Member (2011-2014) and has been IEEE Senior Member since 2014.",institutionString:null,institution:{name:"Izmir Kâtip Çelebi University",country:{name:"Turkey"}}},{id:"339677",title:"Dr.",name:"Mrinmoy",middleName:null,surname:"Roy",slug:"mrinmoy-roy",fullName:"Mrinmoy Roy",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/339677/images/16768_n.jpg",biography:"An accomplished Sales & Marketing professional with 12 years of cross-functional experience in well-known organisations such as CIPLA, LUPIN, GLENMARK, ASTRAZENECA across different segment of Sales & Marketing, International Business, Institutional Business, Product Management, Strategic Marketing of HIV, Oncology, Derma, Respiratory, Anti-Diabetic, Nutraceutical & Stomatological Product Portfolio and Generic as well as Chronic Critical Care Portfolio. A First Class MBA in International Business & Strategic Marketing, B.Pharm, D.Pharm, Google Certified Digital Marketing Professional. Qualified PhD Candidate in Operations and Management with special focus on Artificial Intelligence and Machine Learning adoption, analysis and use in Healthcare, Hospital & Pharma Domain. Seasoned with diverse therapy area of Pharmaceutical Sales & Marketing ranging from generating revenue through generating prescriptions, launching new products, and making them big brands with continuous strategy execution at the Physician and Patients level. Moved from Sales to Marketing and Business Development for 3.5 years in South East Asian Market operating from Manila, Philippines. Came back to India and handled and developed Brands such as Gluconorm, Lupisulin, Supracal, Absolut Woman, Hemozink, Fabiflu (For COVID 19), and many more. In my previous assignment I used to develop and execute strategies on Sales & Marketing, Commercialization & Business Development for Institution and Corporate Hospital Business portfolio of Oncology Therapy Area for AstraZeneca Pharma India Ltd. Being a Research Scholar and Student of ‘Operations Research & Management: Artificial Intelligence’ I published several pioneer research papers and book chapters on the same in Internationally reputed journals and Books indexed in Scopus, Springer and Ei Compendex, Google Scholar etc. Currently, I am launching PGDM Pharmaceutical Management Program in IIHMR Bangalore and spearheading the course curriculum and structure of the same. I am interested in Collaboration for Healthcare Innovation, Pharma AI Innovation, Future trend in Marketing and Management with incubation on Healthcare, Healthcare IT startups, AI-ML Modelling and Healthcare Algorithm based training module development. I am also an affiliated member of the Institute of Management Consultant of India, looking forward to Healthcare, Healthcare IT and Innovation, Pharma and Hospital Management Consulting works.",institutionString:null,institution:{name:"Lovely Professional University",country:{name:"India"}}},{id:"310576",title:"Prof.",name:"Erick Giovani",middleName:null,surname:"Sperandio Nascimento",slug:"erick-giovani-sperandio-nascimento",fullName:"Erick Giovani Sperandio Nascimento",position:null,profilePictureURL:"https://intech-files.s3.amazonaws.com/0033Y00002pDKxDQAW/ProfilePicture%202022-06-20%2019%3A57%3A24.788",biography:"Prof. Erick Sperandio is the Lead Researcher and professor of Artificial Intelligence (AI) at SENAI CIMATEC, Bahia, Brazil, also working with Computational Modeling (CM) and HPC. He holds a PhD in Environmental Engineering in the area of Atmospheric Computational Modeling, a Master in Informatics in the field of Computational Intelligence and Graduated in Computer Science from UFES. He currently coordinates, leads and participates in R&D projects in the areas of AI, computational modeling and supercomputing applied to different areas such as Oil and Gas, Health, Advanced Manufacturing, Renewable Energies and Atmospheric Sciences, advising undergraduate, master's and doctoral students. He is the Lead Researcher at SENAI CIMATEC's Reference Center on Artificial Intelligence. In addition, he is a Certified Instructor and University Ambassador of the NVIDIA Deep Learning Institute (DLI) in the areas of Deep Learning, Computer Vision, Natural Language Processing and Recommender Systems, and Principal Investigator of the NVIDIA/CIMATEC AI Joint Lab, the first in Latin America within the NVIDIA AI Technology Center (NVAITC) worldwide program. He also works as a researcher at the Supercomputing Center for Industrial Innovation (CS2i) and at the SENAI Institute of Innovation for Automation (ISI Automação), both from SENAI CIMATEC. He is a member and vice-coordinator of the Basic Board of Scientific-Technological Advice and Evaluation, in the area of Innovation, of the Foundation for Research Support of the State of Bahia (FAPESB). He serves as Technology Transfer Coordinator and one of the Principal Investigators at the National Applied Research Center in Artificial Intelligence (CPA-IA) of SENAI CIMATEC, focusing on Industry, being one of the six CPA-IA in Brazil approved by MCTI / FAPESP / CGI.br. He also participates as one of the representatives of Brazil in the BRICS Innovation Collaboration Working Group on HPC, ICT and AI. He is the coordinator of the Work Group of the Axis 5 - Workforce and Training - of the Brazilian Strategy for Artificial Intelligence (EBIA), and member of the MCTI/EMBRAPII AI Innovation Network Training Committee. He is the coordinator, by SENAI CIMATEC, of the Artificial Intelligence Reference Network of the State of Bahia (REDE BAH.IA). He leads the working group of experts representing Brazil in the Global Partnership on Artificial Intelligence (GPAI), on the theme \"AI and the Pandemic Response\".",institutionString:"Manufacturing and Technology Integrated Campus – SENAI CIMATEC",institution:null},{id:"1063",title:"Prof.",name:"Constantin",middleName:null,surname:"Volosencu",slug:"constantin-volosencu",fullName:"Constantin Volosencu",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/1063/images/system/1063.png",biography:"Prof. Dr. Constantin Voloşencu graduated as an engineer from\nPolitehnica University of Timișoara, Romania, where he also\nobtained a doctorate degree. He is currently a full professor in\nthe Department of Automation and Applied Informatics at the\nsame university. Dr. Voloşencu is the author of ten books, seven\nbook chapters, and more than 160 papers published in journals\nand conference proceedings. He has also edited twelve books and\nhas twenty-seven patents to his name. He is a manager of research grants, editor in\nchief and member of international journal editorial boards, a former plenary speaker, a member of scientific committees, and chair at international conferences. His\nresearch is in the fields of control systems, control of electric drives, fuzzy control\nsystems, neural network applications, fault detection and diagnosis, sensor network\napplications, monitoring of distributed parameter systems, and power ultrasound\napplications. He has developed automation equipment for machine tools, spooling\nmachines, high-power ultrasound processes, and more.",institutionString:'"Politechnica" University Timişoara',institution:null},{id:"221364",title:"Dr.",name:"Eneko",middleName:null,surname:"Osaba",slug:"eneko-osaba",fullName:"Eneko Osaba",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/221364/images/system/221364.jpg",biography:"Dr. Eneko Osaba works at TECNALIA as a senior researcher. He obtained his Ph.D. in Artificial Intelligence in 2015. He has participated in more than twenty-five local and European research projects, and in the publication of more than 130 papers. He has performed several stays at universities in the United Kingdom, Italy, and Malta. Dr. Osaba has served as a program committee member in more than forty international conferences and participated in organizing activities in more than ten international conferences. He is a member of the editorial board of the International Journal of Artificial Intelligence, Data in Brief, and Journal of Advanced Transportation. He is also a guest editor for the Journal of Computational Science, Neurocomputing, Swarm, and Evolutionary Computation and IEEE ITS Magazine.",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",country:{name:"Spain"}}},{id:"275829",title:"Dr.",name:"Esther",middleName:null,surname:"Villar-Rodriguez",slug:"esther-villar-rodriguez",fullName:"Esther Villar-Rodriguez",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/275829/images/system/275829.jpg",biography:"Dr. Esther Villar obtained a Ph.D. in Information and Communication Technologies from the University of Alcalá, Spain, in 2015. She obtained a degree in Computer Science from the University of Deusto, Spain, in 2010, and an MSc in Computer Languages and Systems from the National University of Distance Education, Spain, in 2012. Her areas of interest and knowledge include natural language processing (NLP), detection of impersonation in social networks, semantic web, and machine learning. Dr. Esther Villar made several contributions at conferences and publishing in various journals in those fields. Currently, she is working within the OPTIMA (Optimization Modeling & Analytics) business of TECNALIA’s ICT Division as a data scientist in projects related to the prediction and optimization of management and industrial processes (resource planning, energy efficiency, etc).",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",country:{name:"Spain"}}},{id:"49813",title:"Dr.",name:"Javier",middleName:null,surname:"Del Ser",slug:"javier-del-ser",fullName:"Javier Del Ser",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/49813/images/system/49813.png",biography:"Prof. Dr. Javier Del Ser received his first PhD in Telecommunication Engineering (Cum Laude) from the University of Navarra, Spain, in 2006, and a second PhD in Computational Intelligence (Summa Cum Laude) from the University of Alcala, Spain, in 2013. He is currently a principal researcher in data analytics and optimisation at TECNALIA (Spain), a visiting fellow at the Basque Center for Applied Mathematics (BCAM) and a part-time lecturer at the University of the Basque Country (UPV/EHU). His research interests gravitate on the use of descriptive, prescriptive and predictive algorithms for data mining and optimization in a diverse range of application fields such as Energy, Transport, Telecommunications, Health and Industry, among others. In these fields he has published more than 240 articles, co-supervised 8 Ph.D. theses, edited 6 books, coauthored 7 patents and participated/led more than 40 research projects. He is a Senior Member of the IEEE, and a recipient of the Biscay Talent prize for his academic career.",institutionString:"Tecnalia Research & Innovation",institution:{name:"Tecnalia",country:{name:"Spain"}}},{id:"278948",title:"Dr.",name:"Carlos Pedro",middleName:null,surname:"Gonçalves",slug:"carlos-pedro-goncalves",fullName:"Carlos Pedro Gonçalves",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRcmyQAC/Profile_Picture_1564224512145",biography:'Carlos Pedro Gonçalves (PhD) is an Associate Professor at Lusophone University of Humanities and Technologies and a researcher on Complexity Sciences, Quantum Technologies, Artificial Intelligence, Strategic Studies, Studies in Intelligence and Security, FinTech and Financial Risk Modeling. He is also a progammer with programming experience in:\n\nA) Quantum Computing using Qiskit Python module and IBM Quantum Experience Platform, with software developed on the simulation of Quantum Artificial Neural Networks and Quantum Cybersecurity;\n\nB) Artificial Intelligence and Machine learning programming in Python;\n\nC) Artificial Intelligence, Multiagent Systems Modeling and System Dynamics Modeling in Netlogo, with models developed in the areas of Chaos Theory, Econophysics, Artificial Intelligence, Classical and Quantum Complex Systems Science, with the Econophysics models having been cited worldwide and incorporated in PhD programs by different Universities.\n\nReceived an Arctic Code Vault Contributor status by GitHub, due to having developed open source software preserved in the \\"Arctic Code Vault\\" for future generations (https://archiveprogram.github.com/arctic-vault/), with the Strategy Analyzer A.I. module for decision making support (based on his PhD thesis, used in his Classes on Decision Making and in Strategic Intelligence Consulting Activities) and QNeural Python Quantum Neural Network simulator also preserved in the \\"Arctic Code Vault\\", for access to these software modules see: https://github.com/cpgoncalves. He is also a peer reviewer with outsanding review status from Elsevier journals, including Physica A, Neurocomputing and Engineering Applications of Artificial Intelligence. Science CV available at: https://www.cienciavitae.pt//pt/8E1C-A8B3-78C5 and ORCID: https://orcid.org/0000-0002-0298-3974',institutionString:"University of Lisbon",institution:{name:"Universidade Lusófona",country:{name:"Portugal"}}},{id:"241400",title:"Prof.",name:"Mohammed",middleName:null,surname:"Bsiss",slug:"mohammed-bsiss",fullName:"Mohammed Bsiss",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/241400/images/8062_n.jpg",biography:null,institutionString:null,institution:null},{id:"276128",title:"Dr.",name:"Hira",middleName:null,surname:"Fatima",slug:"hira-fatima",fullName:"Hira Fatima",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/276128/images/14420_n.jpg",biography:"Dr. Hira Fatima\nAssistant Professor\nDepartment of Mathematics\nInstitute of Applied Science\nMangalayatan University, Aligarh\nMobile: no : 8532041179\nhirafatima2014@gmal.com\n\nDr. Hira Fatima has received his Ph.D. degree in pure Mathematics from Aligarh Muslim University, Aligarh India. Currently working as an Assistant Professor in the Department of Mathematics, Institute of Applied Science, Mangalayatan University, Aligarh. She taught so many courses of Mathematics of UG and PG level. Her research Area of Expertise is Functional Analysis & Sequence Spaces. She has been working on Ideal Convergence of double sequence. She has published 17 research papers in National and International Journals including Cogent Mathematics, Filomat, Journal of Intelligent and Fuzzy Systems, Advances in Difference Equations, Journal of Mathematical Analysis, Journal of Mathematical & Computer Science etc. She has also reviewed few research papers for the and international journals. She is a member of Indian Mathematical Society.",institutionString:null,institution:null},{id:"414880",title:"Dr.",name:"Maryam",middleName:null,surname:"Vatankhah",slug:"maryam-vatankhah",fullName:"Maryam Vatankhah",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Borough of Manhattan Community College",country:{name:"United States of America"}}},{id:"414879",title:"Prof.",name:"Mohammad-Reza",middleName:null,surname:"Akbarzadeh-Totonchi",slug:"mohammad-reza-akbarzadeh-totonchi",fullName:"Mohammad-Reza Akbarzadeh-Totonchi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Ferdowsi University of Mashhad",country:{name:"Iran"}}},{id:"414878",title:"Prof.",name:"Reza",middleName:null,surname:"Fazel-Rezai",slug:"reza-fazel-rezai",fullName:"Reza Fazel-Rezai",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"American Public University System",country:{name:"United States of America"}}},{id:"426586",title:"Dr.",name:"Oladunni A.",middleName:null,surname:"Daramola",slug:"oladunni-a.-daramola",fullName:"Oladunni A. Daramola",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Federal University of Technology",country:{name:"Nigeria"}}},{id:"357014",title:"Prof.",name:"Leon",middleName:null,surname:"Bobrowski",slug:"leon-bobrowski",fullName:"Leon Bobrowski",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Bialystok University of Technology",country:{name:"Poland"}}},{id:"302698",title:"Dr.",name:"Yao",middleName:null,surname:"Shan",slug:"yao-shan",fullName:"Yao Shan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Dalian University of Technology",country:{name:"China"}}},{id:"354126",title:"Dr.",name:"Setiawan",middleName:null,surname:"Hadi",slug:"setiawan-hadi",fullName:"Setiawan Hadi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Padjadjaran University",country:{name:"Indonesia"}}},{id:"125911",title:"Prof.",name:"Jia-Ching",middleName:null,surname:"Wang",slug:"jia-ching-wang",fullName:"Jia-Ching Wang",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"National Central University",country:{name:"Taiwan"}}},{id:"332603",title:"Prof.",name:"Kumar S.",middleName:null,surname:"Ray",slug:"kumar-s.-ray",fullName:"Kumar S. Ray",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Indian Statistical Institute",country:{name:"India"}}},{id:"415409",title:"Prof.",name:"Maghsoud",middleName:null,surname:"Amiri",slug:"maghsoud-amiri",fullName:"Maghsoud Amiri",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Allameh Tabataba'i University",country:{name:"Iran"}}},{id:"357085",title:"Mr.",name:"P. Mohan",middleName:null,surname:"Anand",slug:"p.-mohan-anand",fullName:"P. Mohan Anand",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Indian Institute of Technology Kanpur",country:{name:"India"}}},{id:"356696",title:"Ph.D. Student",name:"P.V.",middleName:null,surname:"Sai Charan",slug:"p.v.-sai-charan",fullName:"P.V. Sai Charan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Indian Institute of Technology Kanpur",country:{name:"India"}}},{id:"357086",title:"Prof.",name:"Sandeep K.",middleName:null,surname:"Shukla",slug:"sandeep-k.-shukla",fullName:"Sandeep K. Shukla",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Indian Institute of Technology Kanpur",country:{name:"India"}}}]}},subseries:{item:{id:"4",type:"subseries",title:"Fungal Infectious Diseases",keywords:"Emerging Fungal Pathogens, Invasive Infections, Epidemiology, Cell Membrane, Fungal Virulence, Diagnosis, Treatment",scope:"Fungi are ubiquitous and there are almost no non-pathogenic fungi. Fungal infectious illness prevalence and prognosis are determined by the exposure between fungi and host, host immunological state, fungal virulence, and early and accurate diagnosis and treatment. \r\nPatients with both congenital and acquired immunodeficiency are more likely to be infected with opportunistic mycosis. Fungal infectious disease outbreaks are common during the post- disaster rebuilding era, which is characterised by high population density, migration, and poor health and medical conditions.\r\nSystemic or local fungal infection is mainly associated with the fungi directly inhaled or inoculated in the environment during the disaster. The most common fungal infection pathways are human to human (anthropophilic), animal to human (zoophilic), and environment to human (soilophile). Diseases are common as a result of widespread exposure to pathogenic fungus dispersed into the environment. \r\nFungi that are both common and emerging are intertwined. In Southeast Asia, for example, Talaromyces marneffei is an important pathogenic thermally dimorphic fungus that causes systemic mycosis. Widespread fungal infections with complicated and variable clinical manifestations, such as Candida auris infection resistant to several antifungal medicines, Covid-19 associated with Trichoderma, and terbinafine resistant dermatophytosis in India, are among the most serious disorders. \r\nInappropriate local or systemic use of glucocorticoids, as well as their immunosuppressive effects, may lead to changes in fungal infection spectrum and clinical characteristics. Hematogenous candidiasis is a worrisome issue that affects people all over the world, particularly ICU patients. CARD9 deficiency and fungal infection have been major issues in recent years. Invasive aspergillosis is associated with a significant death rate. Special attention should be given to endemic fungal infections, identification of important clinical fungal infections advanced in yeasts, filamentous fungal infections, skin mycobiome and fungal genomes, and immunity to fungal infections.\r\nIn addition, endemic fungal diseases or uncommon fungal infections caused by Mucor irregularis, dermatophytosis, Malassezia, cryptococcosis, chromoblastomycosis, coccidiosis, blastomycosis, histoplasmosis, sporotrichosis, and other fungi, should be monitored. \r\nThis topic includes the research progress on the etiology and pathogenesis of fungal infections, new methods of isolation and identification, rapid detection, drug sensitivity testing, new antifungal drugs, schemes and case series reports. It will provide significant opportunities and support for scientists, clinical doctors, mycologists, antifungal drug researchers, public health practitioners, and epidemiologists from all over the world to share new research, ideas and solutions to promote the development and progress of medical mycology.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/4.jpg",hasOnlineFirst:!0,hasPublishedBooks:!1,annualVolume:11400,editor:{id:"174134",title:"Dr.",name:"Yuping",middleName:null,surname:"Ran",slug:"yuping-ran",fullName:"Yuping Ran",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bS9d6QAC/Profile_Picture_1630330675373",biography:"Dr. Yuping Ran, Professor, Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China. Completed the Course Medical Mycology, the Centraalbureau voor Schimmelcultures (CBS), Fungal Biodiversity Centre, Netherlands (2006). International Union of Microbiological Societies (IUMS) Fellow, and International Emerging Infectious Diseases (IEID) Fellow, Centers for Diseases Control and Prevention (CDC), Atlanta, USA. Diploma of Dermatological Scientist, Japanese Society for Investigative Dermatology. Ph.D. of Juntendo University, Japan. Bachelor’s and Master’s degree, Medicine, West China University of Medical Sciences. Chair of Sichuan Medical Association Dermatology Committee. General Secretary of The 19th Annual Meeting of Chinese Society of Dermatology and the Asia Pacific Society for Medical Mycology (2013). In charge of the Annual Medical Mycology Course over 20-years authorized by National Continue Medical Education Committee of China. Member of the board of directors of the Asia-Pacific Society for Medical Mycology (APSMM). Associate editor of Mycopathologia. Vice-chief of the editorial board of Chinses Journal of Mycology, China. Board Member and Chair of Mycology Group of Chinese Society of Dermatology.",institutionString:null,institution:{name:"Sichuan University",institutionURL:null,country:{name:"China"}}},editorTwo:null,editorThree:null,series:{id:"6",title:"Infectious Diseases",doi:"10.5772/intechopen.71852",issn:"2631-6188"},editorialBoard:[{id:"302145",title:"Dr.",name:"Felix",middleName:null,surname:"Bongomin",slug:"felix-bongomin",fullName:"Felix Bongomin",profilePictureURL:"https://mts.intechopen.com/storage/users/302145/images/system/302145.jpg",institutionString:null,institution:{name:"Gulu University",institutionURL:null,country:{name:"Uganda"}}},{id:"45803",title:"Ph.D.",name:"Payam",middleName:null,surname:"Behzadi",slug:"payam-behzadi",fullName:"Payam Behzadi",profilePictureURL:"https://mts.intechopen.com/storage/users/45803/images/system/45803.jpg",institutionString:"Islamic Azad University, Tehran",institution:{name:"Islamic Azad University, Tehran",institutionURL:null,country:{name:"Iran"}}}]},onlineFirstChapters:{paginationCount:5,paginationItems:[{id:"82701",title:"Pathology of Streptococcal Infections",doi:"10.5772/intechopen.105814",signatures:"Yutaka Tsutsumi",slug:"pathology-of-streptococcal-infections",totalDownloads:8,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Yutaka",surname:"Tsutsumi"}],book:{title:"Streptococcal Infections",coverURL:"https://cdn.intechopen.com/books/images_new/10828.jpg",subseries:{id:"3",title:"Bacterial Infectious Diseases"}}},{id:"82634",title:"Bacterial Sexually Transmitted Disease",doi:"10.5772/intechopen.105747",signatures:"Lebeza Alemu Tenaw",slug:"bacterial-sexually-transmitted-disease",totalDownloads:12,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Bacterial Sexually Transmitted Infections - New Findings, Diagnosis, Treatment, and Prevention",coverURL:"https://cdn.intechopen.com/books/images_new/11569.jpg",subseries:{id:"3",title:"Bacterial Infectious Diseases"}}},{id:"82193",title:"Enterococcal Infections: Recent Nomenclature and emerging trends",doi:"10.5772/intechopen.104792",signatures:"Kavita Raja",slug:"enterococcal-infections-recent-nomenclature-and-emerging-trends",totalDownloads:14,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Streptococcal Infections",coverURL:"https://cdn.intechopen.com/books/images_new/10828.jpg",subseries:{id:"3",title:"Bacterial Infectious Diseases"}}},{id:"81821",title:"Pneumococcal Carriage in Jordanian Children and the Importance of Vaccination",doi:"10.5772/intechopen.104999",signatures:"Adnan Al-Lahham",slug:"pneumococcal-carriage-in-jordanian-children-and-the-importance-of-vaccination",totalDownloads:8,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Streptococcal Infections",coverURL:"https://cdn.intechopen.com/books/images_new/10828.jpg",subseries:{id:"3",title:"Bacterial Infectious Diseases"}}},{id:"80546",title:"Streptococcal Skin and Skin-Structure Infections",doi:"10.5772/intechopen.102894",signatures:"Alwyn Rapose",slug:"streptococcal-skin-and-skin-structure-infections",totalDownloads:77,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Streptococcal Infections",coverURL:"https://cdn.intechopen.com/books/images_new/10828.jpg",subseries:{id:"3",title:"Bacterial Infectious Diseases"}}}]},publishedBooks:{paginationCount:1,paginationItems:[{type:"book",id:"10795",title:"Plant Stress Physiology",subtitle:"Perspectives in Agriculture",coverURL:"https://cdn.intechopen.com/books/images_new/10795.jpg",slug:"plant-stress-physiology-perspectives-in-agriculture",publishedDate:"April 28th 2022",editedByType:"Edited by",bookSignature:"Mirza Hasanuzzaman and Kamran Nahar",hash:"c5a7932b74fe612b256bf95d0709756e",volumeInSeries:11,fullTitle:"Plant Stress Physiology - Perspectives in Agriculture",editors:[{id:"76477",title:"Prof.",name:"Mirza",middleName:null,surname:"Hasanuzzaman",slug:"mirza-hasanuzzaman",fullName:"Mirza Hasanuzzaman",profilePictureURL:"https://mts.intechopen.com/storage/users/76477/images/system/76477.png",institutionString:"Sher-e-Bangla Agricultural University",institution:{name:"Sher-e-Bangla Agricultural University",institutionURL:null,country:{name:"Bangladesh"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},testimonialsList:[{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}},{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.png",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}}]},submityourwork:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:108,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:33,numberOfPublishedChapters:330,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:14,numberOfPublishedChapters:145,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:9,numberOfPublishedChapters:140,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:123,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:112,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:22,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:11,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:"2753-6580",doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],subseriesList:[{id:"7",title:"Bioinformatics and Medical Informatics",scope:"Bioinformatics aims to help understand the functioning of the mechanisms of living organisms through the construction and use of quantitative tools. The applications of this research cover many related fields, such as biotechnology and medicine, where, for example, Bioinformatics contributes to faster drug design, DNA analysis in forensics, and DNA sequence analysis in the field of personalized medicine. Personalized medicine is a type of medical care in which treatment is customized individually for each patient. Personalized medicine enables more effective therapy, reduces the costs of therapy and clinical trials, and also minimizes the risk of side effects. Nevertheless, advances in personalized medicine would not have been possible without bioinformatics, which can analyze the human genome and other vast amounts of biomedical data, especially in genetics. The rapid growth of information technology enabled the development of new tools to decode human genomes, large-scale studies of genetic variations and medical informatics. The considerable development of technology, including the computing power of computers, is also conducive to the development of bioinformatics, including personalized medicine. In an era of rapidly growing data volumes and ever lower costs of generating, storing and computing data, personalized medicine holds great promises. Modern computational methods used as bioinformatics tools can integrate multi-scale, multi-modal and longitudinal patient data to create even more effective and safer therapy and disease prevention methods. Main aspects of the topic are: Applying bioinformatics in drug discovery and development; Bioinformatics in clinical diagnostics (genetic variants that act as markers for a condition or a disease); Blockchain and Artificial Intelligence/Machine Learning in personalized medicine; Customize disease-prevention strategies in personalized medicine; Big data analysis in personalized medicine; Translating stratification algorithms into clinical practice of personalized medicine.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/7.jpg",keywords:"Biomedical Data, Drug Discovery, Clinical Diagnostics, Decoding Human Genome, AI in Personalized Medicine, Disease-prevention Strategies, Big Data Analysis in Medicine"},{id:"8",title:"Bioinspired Technology and Biomechanics",scope:'Bioinspired technologies take advantage of understanding the actual biological system to provide solutions to problems in several areas. Recently, bioinspired systems have been successfully employing biomechanics to develop and improve assistive technology and rehabilitation devices. The research topic "Bioinspired Technology and Biomechanics" welcomes studies reporting recent advances in bioinspired technologies that contribute to individuals\' health, inclusion, and rehabilitation. Possible contributions can address (but are not limited to) the following research topics: Bioinspired design and control of exoskeletons, orthoses, and prostheses; Experimental evaluation of the effect of assistive devices (e.g., influence on gait, balance, and neuromuscular system); Bioinspired technologies for rehabilitation, including clinical studies reporting evaluations; Application of neuromuscular and biomechanical models to the development of bioinspired technology.',coverUrl:"https://cdn.intechopen.com/series_topics/covers/8.jpg",keywords:"Bioinspired Systems, Biomechanics, Assistive Technology, Rehabilitation"},{id:"9",title:"Biotechnology - Biosensors, Biomaterials and Tissue Engineering",scope:"The Biotechnology - Biosensors, Biomaterials and Tissue Engineering topic within the Biomedical Engineering Series aims to rapidly publish contributions on all aspects of biotechnology, biosensors, biomaterial and tissue engineering. We encourage the submission of manuscripts that provide novel and mechanistic insights that report significant advances in the fields. Topics can include but are not limited to: Biotechnology such as biotechnological products and process engineering; Biotechnologically relevant enzymes and proteins; Bioenergy and biofuels; Applied genetics and molecular biotechnology; Genomics, transcriptomics, proteomics; Applied microbial and cell physiology; Environmental biotechnology; Methods and protocols. Moreover, topics in biosensor technology, like sensors that incorporate enzymes, antibodies, nucleic acids, whole cells, tissues and organelles, and other biological or biologically inspired components will be considered, and topics exploring transducers, including those based on electrochemical and optical piezoelectric, thermal, magnetic, and micromechanical elements. Chapters exploring biomaterial approaches such as polymer synthesis and characterization, drug and gene vector design, biocompatibility, immunology and toxicology, and self-assembly at the nanoscale, are welcome. Finally, the tissue engineering subcategory will support topics such as the fundamentals of stem cells and progenitor cells and their proliferation, differentiation, bioreactors for three-dimensional culture and studies of phenotypic changes, stem and progenitor cells, both short and long term, ex vivo and in vivo implantation both in preclinical models and also in clinical trials.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/9.jpg",keywords:"Biotechnology, Biosensors, Biomaterials, Tissue Engineering"}],annualVolumeBook:{},thematicCollection:[],selectedSeries:null,selectedSubseries:null},seriesLanding:{item:{id:"7",title:"Biomedical Engineering",doi:"10.5772/intechopen.71985",issn:"2631-5343",scope:"Biomedical Engineering is one of the fastest-growing interdisciplinary branches of science and industry. The combination of electronics and computer science with biology and medicine has improved patient diagnosis, reduced rehabilitation time, and helped to facilitate a better quality of life. Nowadays, all medical imaging devices, medical instruments, or new laboratory techniques result from the cooperation of specialists in various fields. The series of Biomedical Engineering books covers such areas of knowledge as chemistry, physics, electronics, medicine, and biology. This series is intended for doctors, engineers, and scientists involved in biomedical engineering or those wanting to start working in this field.",coverUrl:"https://cdn.intechopen.com/series/covers/7.jpg",latestPublicationDate:"August 3rd, 2022",hasOnlineFirst:!0,numberOfOpenTopics:3,numberOfPublishedChapters:107,numberOfPublishedBooks:12,editor:{id:"50150",title:"Prof.",name:"Robert",middleName:null,surname:"Koprowski",fullName:"Robert Koprowski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYTYNQA4/Profile_Picture_1630478535317",biography:"Robert Koprowski, MD (1997), PhD (2003), Habilitation (2015), is an employee of the University of Silesia, Poland, Institute of Computer Science, Department of Biomedical Computer Systems. For 20 years, he has studied the analysis and processing of biomedical images, emphasizing the full automation of measurement for a large inter-individual variability of patients. Dr. Koprowski has authored more than a hundred research papers with dozens in impact factor (IF) journals and has authored or co-authored six books. Additionally, he is the author of several national and international patents in the field of biomedical devices and imaging. Since 2011, he has been a reviewer of grants and projects (including EU projects) in biomedical engineering.",institutionString:null,institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}},subseries:[{id:"7",title:"Bioinformatics and Medical Informatics",keywords:"Biomedical Data, Drug Discovery, Clinical Diagnostics, Decoding Human Genome, AI in Personalized Medicine, Disease-prevention Strategies, Big Data Analysis in Medicine",scope:"Bioinformatics aims to help understand the functioning of the mechanisms of living organisms through the construction and use of quantitative tools. The applications of this research cover many related fields, such as biotechnology and medicine, where, for example, Bioinformatics contributes to faster drug design, DNA analysis in forensics, and DNA sequence analysis in the field of personalized medicine. Personalized medicine is a type of medical care in which treatment is customized individually for each patient. Personalized medicine enables more effective therapy, reduces the costs of therapy and clinical trials, and also minimizes the risk of side effects. Nevertheless, advances in personalized medicine would not have been possible without bioinformatics, which can analyze the human genome and other vast amounts of biomedical data, especially in genetics. The rapid growth of information technology enabled the development of new tools to decode human genomes, large-scale studies of genetic variations and medical informatics. The considerable development of technology, including the computing power of computers, is also conducive to the development of bioinformatics, including personalized medicine. In an era of rapidly growing data volumes and ever lower costs of generating, storing and computing data, personalized medicine holds great promises. Modern computational methods used as bioinformatics tools can integrate multi-scale, multi-modal and longitudinal patient data to create even more effective and safer therapy and disease prevention methods. Main aspects of the topic are: Applying bioinformatics in drug discovery and development; Bioinformatics in clinical diagnostics (genetic variants that act as markers for a condition or a disease); Blockchain and Artificial Intelligence/Machine Learning in personalized medicine; Customize disease-prevention strategies in personalized medicine; Big data analysis in personalized medicine; Translating stratification algorithms into clinical practice of personalized medicine.",annualVolume:11403,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/7.jpg",editor:{id:"351533",title:"Dr.",name:"Slawomir",middleName:null,surname:"Wilczynski",fullName:"Slawomir Wilczynski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000035U1loQAC/Profile_Picture_1630074514792",institutionString:null,institution:{name:"Medical University of Silesia",institutionURL:null,country:{name:"Poland"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"5886",title:"Dr.",name:"Alexandros",middleName:"T.",surname:"Tzallas",fullName:"Alexandros Tzallas",profilePictureURL:"https://mts.intechopen.com/storage/users/5886/images/system/5886.png",institutionString:"University of Ioannina, Greece & Imperial College London",institution:{name:"University of Ioannina",institutionURL:null,country:{name:"Greece"}}},{id:"257388",title:"Distinguished Prof.",name:"Lulu",middleName:null,surname:"Wang",fullName:"Lulu Wang",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRX6kQAG/Profile_Picture_1630329584194",institutionString:"Shenzhen Technology University",institution:{name:"Shenzhen Technology University",institutionURL:null,country:{name:"China"}}},{id:"225387",title:"Prof.",name:"Reda R.",middleName:"R.",surname:"Gharieb",fullName:"Reda R. Gharieb",profilePictureURL:"https://mts.intechopen.com/storage/users/225387/images/system/225387.jpg",institutionString:"Assiut University",institution:{name:"Assiut University",institutionURL:null,country:{name:"Egypt"}}}]},{id:"8",title:"Bioinspired Technology and Biomechanics",keywords:"Bioinspired Systems, Biomechanics, Assistive Technology, Rehabilitation",scope:'Bioinspired technologies take advantage of understanding the actual biological system to provide solutions to problems in several areas. Recently, bioinspired systems have been successfully employing biomechanics to develop and improve assistive technology and rehabilitation devices. The research topic "Bioinspired Technology and Biomechanics" welcomes studies reporting recent advances in bioinspired technologies that contribute to individuals\' health, inclusion, and rehabilitation. Possible contributions can address (but are not limited to) the following research topics: Bioinspired design and control of exoskeletons, orthoses, and prostheses; Experimental evaluation of the effect of assistive devices (e.g., influence on gait, balance, and neuromuscular system); Bioinspired technologies for rehabilitation, including clinical studies reporting evaluations; Application of neuromuscular and biomechanical models to the development of bioinspired technology.',annualVolume:11404,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/8.jpg",editor:{id:"144937",title:"Prof.",name:"Adriano",middleName:"De Oliveira",surname:"Andrade",fullName:"Adriano Andrade",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRC8QQAW/Profile_Picture_1625219101815",institutionString:null,institution:{name:"Federal University of Uberlândia",institutionURL:null,country:{name:"Brazil"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"49517",title:"Prof.",name:"Hitoshi",middleName:null,surname:"Tsunashima",fullName:"Hitoshi Tsunashima",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYTP4QAO/Profile_Picture_1625819726528",institutionString:null,institution:{name:"Nihon University",institutionURL:null,country:{name:"Japan"}}},{id:"425354",title:"Dr.",name:"Marcus",middleName:"Fraga",surname:"Vieira",fullName:"Marcus Vieira",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00003BJSgIQAX/Profile_Picture_1627904687309",institutionString:null,institution:{name:"Universidade Federal de Goiás",institutionURL:null,country:{name:"Brazil"}}},{id:"196746",title:"Dr.",name:"Ramana",middleName:null,surname:"Vinjamuri",fullName:"Ramana Vinjamuri",profilePictureURL:"https://mts.intechopen.com/storage/users/196746/images/system/196746.jpeg",institutionString:"University of Maryland, Baltimore County",institution:{name:"University of Maryland, Baltimore County",institutionURL:null,country:{name:"United States of America"}}}]},{id:"9",title:"Biotechnology - Biosensors, Biomaterials and Tissue Engineering",keywords:"Biotechnology, Biosensors, Biomaterials, Tissue Engineering",scope:"The Biotechnology - Biosensors, Biomaterials and Tissue Engineering topic within the Biomedical Engineering Series aims to rapidly publish contributions on all aspects of biotechnology, biosensors, biomaterial and tissue engineering. We encourage the submission of manuscripts that provide novel and mechanistic insights that report significant advances in the fields. Topics can include but are not limited to: Biotechnology such as biotechnological products and process engineering; Biotechnologically relevant enzymes and proteins; Bioenergy and biofuels; Applied genetics and molecular biotechnology; Genomics, transcriptomics, proteomics; Applied microbial and cell physiology; Environmental biotechnology; Methods and protocols. Moreover, topics in biosensor technology, like sensors that incorporate enzymes, antibodies, nucleic acids, whole cells, tissues and organelles, and other biological or biologically inspired components will be considered, and topics exploring transducers, including those based on electrochemical and optical piezoelectric, thermal, magnetic, and micromechanical elements. Chapters exploring biomaterial approaches such as polymer synthesis and characterization, drug and gene vector design, biocompatibility, immunology and toxicology, and self-assembly at the nanoscale, are welcome. Finally, the tissue engineering subcategory will support topics such as the fundamentals of stem cells and progenitor cells and their proliferation, differentiation, bioreactors for three-dimensional culture and studies of phenotypic changes, stem and progenitor cells, both short and long term, ex vivo and in vivo implantation both in preclinical models and also in clinical trials.",annualVolume:11405,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/9.jpg",editor:{id:"126286",title:"Dr.",name:"Luis",middleName:"Jesús",surname:"Villarreal-Gómez",fullName:"Luis Villarreal-Gómez",profilePictureURL:"https://mts.intechopen.com/storage/users/126286/images/system/126286.jpg",institutionString:null,institution:{name:"Autonomous University of Baja California",institutionURL:null,country:{name:"Mexico"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"35539",title:"Dr.",name:"Cecilia",middleName:null,surname:"Cristea",fullName:"Cecilia Cristea",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYQ65QAG/Profile_Picture_1621007741527",institutionString:null,institution:{name:"Iuliu Hațieganu University of Medicine and Pharmacy",institutionURL:null,country:{name:"Romania"}}},{id:"40735",title:"Dr.",name:"Gil",middleName:"Alberto Batista",surname:"Gonçalves",fullName:"Gil Gonçalves",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYRLGQA4/Profile_Picture_1628492612759",institutionString:null,institution:{name:"University of Aveiro",institutionURL:null,country:{name:"Portugal"}}},{id:"211725",title:"Associate Prof.",name:"Johann F.",middleName:null,surname:"Osma",fullName:"Johann F. Osma",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSDv7QAG/Profile_Picture_1626602531691",institutionString:null,institution:{name:"Universidad de Los Andes",institutionURL:null,country:{name:"Colombia"}}},{id:"69697",title:"Dr.",name:"Mani T.",middleName:null,surname:"Valarmathi",fullName:"Mani T. Valarmathi",profilePictureURL:"https://mts.intechopen.com/storage/users/69697/images/system/69697.jpg",institutionString:"Religen Inc. | A Life Science Company, United States of America",institution:null},{id:"205081",title:"Dr.",name:"Marco",middleName:"Vinícius",surname:"Chaud",fullName:"Marco Chaud",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSDGeQAO/Profile_Picture_1622624307737",institutionString:null,institution:{name:"Universidade de Sorocaba",institutionURL:null,country:{name:"Brazil"}}}]}]}},libraryRecommendation:{success:null,errors:{},institutions:[]},route:{name:"chapter.detail",path:"/chapters/68908",hash:"",query:{},params:{id:"68908"},fullPath:"/chapters/68908",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()